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Abstract  
 
Radiological and histopathological studies have established that in 
addition to the classical white matter (WM) demyelinating lesions, cortical grey 
matter  (CGM) lesions are also a significant part of the pathology in multiple 
sclerosis (MS), and contribute to the clinical and cognitive deficits seen in MS 
patients. Double inversion recovery (DIR) has been identified as a good 
sequence for the radiological detection of cortical grey matter lesions.  
In this project I investigated the role of phase sensitive inversion 
recovery (PSIR), a T1-weighted MRI sequence, using a 3T MRI scanner, for 
the detection of CGM lesions in multiple sclerosis. Detection of CGM lesions 
on a standard DIR sequence (1x1x3mm resolution) was compared with a 
higher resolution PSIR sequence (0.5x0.5x2mm), to explore if it can help 
improve the study of CGM lesions. A representative cohort, including patients 
with relapsing remitting (RR), primary progressive (PP) and secondary 
progressive (SP)MS, was recruited in this project, together with controls in 
order to allow a comparison of findings with those of healthy subjects who do 
not have MS. 
 I systematically investigated if the use of high resolution PSIR scans 
can improve CGM lesion detection and classification, when compared to DIR. 
Using the PSIR sequence, I studied the hypothesis that the distribution of 
lesions impacts the pattern of cognitive impairment seen in patients. CGM 
lesion volumes were estimated for frontal, temporal , parietal  and occipital 
lobes and cognitive tests were conducted (Hayling, Stroop, immediate and 
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delayed story and figure recall, PASAT (Paced auditory serial addition test) 
and SDMT (Symbol digit modality test)). Differences between phenotypes and 
associations with cognitive measures were explored using a multiple 
regression model.  A follow up study was undertaken to understand how CGM 
lesions evolve with time and in order to explore potential specificity of PSIR-
detected CGM lesions, I compared the findings of CGM lesion detection in MS 
patients, with patients diagnosed with Fabry’s disease. 
Compared with DIR, high resolution PSIR was found to detect a 
significantly greater number of CGM lesions and also improved the 
classification of CGM lesions. A fronto-temporal dominance of CGM lesions 
was noted in my study. Different CGM and JC lesion subtypes were found to 
be associated with cognitive function; the relationship being influenced by the 
lobar location and the cognitive function being assessed. In the follow-up 
study I found that people with SPMS have a grater accrual of CGM lesions 
than RRMS and the process appeared to be independent of WM lesion 
accrual. CGM lesions were also seen in patients with Fabry’s disease though 
the frequency was less that in MS.  
The data presented in my study suggests that PSIR has the potential 
to improve the quantitative and qualitative study of CGM lesions. CGM lesions 
were noted across all disease phenotypes, though more common in 
progressive disease. The distribution, accrual and evolution of CGM lesions 
provides insights into the pathogenesis of MS and helps understand the 
contribution of CGM lesions to neurological and cognitive impairment. 
Detection of CGM lesions has a potential role to help with a diagnosis of MS 
when it suspected but not confirmed. 
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1 Introduction 
1.1 Background 
Multiple sclerosis (MS) is a chronic neuro-inflammatory condition that 
causes demyelination and neuronal loss in the central nervous system (CNS). 
The pathological hallmark, focal CNS white matter (WM) lesions, were first 
depicted in 1838 by Carswell (Leary et al. 2009) and the condition was 
studied further by Charcot who called it sclerose en plaques (Frohman 2006; 
Polman et al. 2005; Rinaldi et al. 2011; Compston 1999). The understanding 
of the clinical features, natural history and pathogenesis of MS has improved 
over the years, and this is reflected in the improved sensitivity and specificity 
of the diagnostic criteria for MS, most recently revised in 2010 (Polman et al.  
2011). 
Based on the natural history of disease and the duration and 
progression of clinical symptoms, four phenotypes of MS are recognised. 
These are relapsing remitting, primary progressive, and secondary 
progressive and progressive relapsing MS (Leary et al. 2009; Lublin & 
Reingold 1996). In relapsing remitting MS, the clinical course consists of 
relapses (episodes of neurological dysfunction with partial or complete 
recovery) that are caused by focal inflammatory events; neurodegenerative 
mechanisms are likely the main cause of progressive disability that accrues in 
later stages of relapse onset disease (secondary progressive MS)(Trapp et al.  
1999). 
The pathological features of MS, consist of white matter lesions that 
represent areas of demyelination with relative sparing of axons and varying 
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degrees of inflammation.  The common sites of dymyelination include optic 
nerves, corpus callosum, periventricular regions, brainstem, cerebellum and 
the spinal cord. The normal appearing white matter (NAWM) is also seen to 
show abnormalities (Mistry et al. 2011; Kutzelnigg et al. 2005a; Zeis et al 
2008; Graumann et al. 2003).  
Though traditionally thought to be limited to the white matter (WM), 
Charcot  (as early as 1868) had pointed out that in addition to cerebral and 
cerebellar WM, deep grey matter (DGM), and spinal cord white and grey 
matter, cortical demyelination was also present in MS (Popescu et al. 2012a). 
Histopathological observations in 1898 (Sander) and 1916 (Dawson 1916) 
also reported involvement of grey matter (GM) in regions in MS. In routine 
bipotic and autoptic pathology, the conventional lipid stains that were used to 
study demyelinated lesions were unable to prove useful in regions of low 
myelin density, as in the cortex and deep grey matter (Stadelmann et al. 
2008). 
 In addition, cortical pathology was also underestimated due to the 
scarcity of obvious tissue damage, gliosis and minimal perivascular 
inflammatory infiltrate. Immunohistochemistry of MBP (Myelin basic protein) 
(Brownell & Hughes 1962; Lumsden 1970; Bø et al. 2003b; Bø et al. 2009; 
Geurts et al.  2008) and more superior microscopy methods have facilitated 
the identification of cortical lesions and allows characteristics such as their 
size and extent to be further explored across all stages and phenotypes of 
disease. (Stadelmann et al. 2008; Peterson et al. 2001, Bø, 2006a; Vercellino 
2005,Kampman et al. 2012, Bø & Bø 2009; Runia et al. 2012; Disanto et al. 
2012) It is now established that extensive cortical demyelination is present in 
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people with MS, and is at least partially (Geurts & Barkhof 2008) independent 
of white matter pathology (Kutzelnigg et al. 2005a).  
In addition to demyelination of axons, grey matter damage consists of 
neuroaxonal degeneration(Geurts & Barkhof 2008). Focal WM lesions are 
unable to completely explain the patterns of clinical and cognitive impairment 
in people with MS. Furthermore, cognitively preserved people with MS have 
less damage to the cerebral cortex(Amato et al. 2004), suggesting that 
pathological processes in the grey matter may be the missing piece of the 
puzzle (Calabrese, Rinaldi, Poretto, et al.  2011b) of the clinical-radiological 
paradox (Barkhof 2002a). 
Histopathological studies of grey matter pathology are possibly 
significantly skewed by lack of the availability of tissue samples from people 
across different stages of disease; most samples are either from patients with 
atypical clinical presentations or post mortem (from people with progressive 
and long duration of disease). There are practical limits on the amount of 
tissue that can be assessed and examination of the whole brain is 
prohibitively time consuming. Longitudinal studies are also not practical using 
histopathological specimens. Radiological observations on the other hand 
allow an in vivo study of cortical pathology non-invasively. Scans can be 
repeated over time, across all subtypes and duration of MS.  
Conventional magnetic resonance imaging (MRI) in MS has focused 
on white matter lesions (Ceccarelli et al. 2012a; Poser et al. 1983; Tintoré et 
al. 2003). T1-weighted, T2-weighted and fluid attenuated inversion recovery 
(FLAIR) are the main sequences used. Radiological demonstration of white 
matter lesions plays an important role in the diagnosis of MS, which requires 
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the demonstration of disease activity to be disseminated in space and time. 
This is based on clinical history, together with laboratory and imaging 
evidence of demyelination, in the form of white matter lesions (Lezak et al.  
2012; Griffin et al.  2002; Lucchinetti et al. 1996; Pirko et al. 2007; Allen et al.  
2001; Polman et al. 2005; McDonald et al.  2001; Poser et al. 1983; Tintoré et 
al. 2003). WM lesions appear as hypointense lesions, the so called “black 
holes” in T1w scans and as hyperintensities in T2w and FLAIR images. There 
is evidence that T1-weighted black hole lesions are biased towards more 
destructive lesions and when persistent, represents areas of permanent 
axonal loss (Haller et al. 2009; van Waesberghe et al. 1999); however 
findings on these conventional scans cannot be regarded as pathologically 
specific. Black holes that enhance following contrast injections are young 
lesions, associated with inflammation and breakdown of the blood-brain 
barrier, and the hypointensity may reverse with follow up. MS lesions are seen 
as hyperintense regions with a high signal foci on T2 weighted imaging (Trip & 
Miller 2005). Oedema, demyelination, axonal loss, oligodendrocyte loss and 
remyelination (Barkhof et al.2003) are thought to contribute to the 
hyperintensities seen on T2w imaging. Proton density(PD) weighted images 
are specially helpful in appreciating periventricular lesions as the adjacent 
CSF has a lower signal on this sequence (Trip & Miller 2005). These scans 
are limited in the ability to detect abnormalities in the normal appearing white 
matter.  
Detection of cortical grey matter (CGM) lesions has, however, 
remained limited using conventional MRI sequences (Geurts et al. 2008; Kidd 
et al.  1999). Visibility of these lesions is limited by their location, size and 
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intrinsic properties of the lesions (minimal inflammation, lack of a blood brain 
barrier disruption (van Horssen et al. 2007) and a lesser degree of contrast 
between the lesional /non-lesional cortex) (Geurts et al. 2011; Geurts, Bø, et 
al.  2005a). The proximity of the lesions to the CSF also causes susceptibility 
artefacts. (Schmierer et al.  2010)  
Due to the challenges in detecting cortical lesions, various techniques 
aimed at global GM assessment have been used (Geurts & Barkhof 
2008).These include quantitative measures such as magnetisation transfer 
ratio (MTR) (Griffin et al.  2002), T1 relaxation time measures (Geurts & 
Barkhof 2008; Barkhof 2002b; Vrenken, Geurts, et al.  2006a), diffusion tensor 
imaging (Vrenken, Pouwels, et al.  2006b) and quantification of metabolites 
such as N acetyl-aspartate using spectroscopy (Chard et al.  2002).  
To improve the study of cortical lesions different methodologies have 
been investigated in an attempt to non-invasively reproduce information 
derived from histopathological studies, and study the clinical relevance of 
cortical pathology. The use of MRI with high and ultra-high field strengths, 
imaging using 3D protocols and using sequences with improved contrast and 
signal to noise ratio (SNR) are some of these approaches. Ultra-high field 
strengths beyond 3T (Wattjes et al. 2009) e.g.7T (Nielsen et al.  2013; Absinta 
et al.  2013; Tallantyre et al.  2009) and 9.4 T (Schmierer et al.  2010; Filippi 
et al.  2013) provide a higher SNR and thus a greater resolution(Geurts et al.  
2008a). Improved contrast between lesion and non-lesional tissue are other 
advantages. Nevertheless these are not without disadvantages such as 
problems difficulties of narrow bore and incomplete coverage with some 
sequences and limited clinical availability. Subpial demyelination (Bø, 
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Vedeler, Nyland, Trapp & Mørk 2003b) is well recognized in MS but is 
challenging to detect using MRI. Using imaging at ultra-high field strengths of 
9.4 Tesla, it has been possible to visualise subpial cortical demyelination. 
Schmierer et al. found a total of 36 CGM lesions in the 21 tissue blocks 
studied, and 18/36 were reported to be Type III (supbial) lesioins. (Schmierer 
et al.  2010).  
An alternative strategy to improve SNR is to use 3D imaging. While in 
2D imaging, each radiofrequency (RF) pulse is seen to excite a narrow slice, 
in 3D imaging, the entire imaging volume is excited by the RF pulse. (Johnson 
et al.  1999) Using 3D sequences an improved SNR can be achieved in 
shorter time spans. However in some conditions 2D sequences may in fact be 
better and more sensitive (Johnson et al.  1999) and various factors such as 
the slab thickness, the coil used and the sequence parameters need to be 
considered. 
MRI sequences that have been used for the study of cortical lesions 
include 2D DIR, multi-slab 3D DIR (Geurts, Pouwels, et al.  2005b), single 
slab isotropic 3D DIR (Geurts & Barkhof 2008)MPRAGE (Nelson et al.  2008), 
3D FLAIR (Kilsdonk et al. 2013) and Flash T2* (Nielsen et al.  2011). Double 
inversion recovery, which suppresses signal from both CSF and white matter, 
has greatly improved the visualisation of grey matter lesions.(Q. Li et al. 2011; 
Wattjes et al. 2007; Bender & Klose 2010; Geurts, Pouwels, et al. 2005b; 
Calabrese et al.  2007). Consensus recommendations for detecting CGM 
lesions have recently been published (Geurts et al.  2011). Using DIR, it has 
been possible to detect cortical lesions even in patients with clinically isolated 
syndrome and radiologically isolated syndrome (Filippi et al. 2010b; 
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Papadopoulou et al. 2013). It has been possible to separate CGM lesions as 
being intracortical (IC – limited to the substance of the cortex) and 
leucocortical (LC – mixed GM/WM lesions) (Geurts et al. 2005a; Geurts & 
Barkhof 2008; Geurts et al. 2011). However subpial lesions have not been 
identified using DIR at clinically used field strengths (Geurts et al. 2011; 
Schmierer et al. 2010). It has also not been possible to accurately separate 
juxtacortical (JC – white matter lesions that abut but do not enter the cortex ) 
lesions from LC lesions. (Giorgio et al. 2011; Kidd et al. 1999; Geurts, Bø, et 
al.  2005a). DIR has improved the radiological detection of cortical lesions as 
compared to FLAIR. The improvement of DIR vs. FLAIR for LC lesions was a 
sensitivity of 83% (vs. 65%) and on retrospective scoring this was 96% (vs. 
91%). However, postmortem correlations indicate that only about 18% of the 
pathologically visible lesions are visualised (Seewann et al. 2012) 
Phase sensitive inversion recovery (PSIR) (Hou et al.  2005),(Nelson 
et al.  2007a) is a T1-weighted sequence, with a high SNR and good grey - 
white contrast; it has the potential to improve the quantitative and qualitative 
detection of cortical lesions. DIR and PSIR, individually and together, have the 
potential of enhancing the understanding of cortical pathology in MS, across 
all stages of disease (Nelson et al. 2007a). 
Given the differences and limitations of DIR and PSIR, it is important 
to determine if these two sequences identify similar or different pathological 
processes and determine if they preferentially identify lesions at a particular 
location or region of the cerebral cortex. Inflammatory cortical demyelination is 
common in early MS but in long standing progressive patients, the 
inflammatory component is not seen typically (Lucchinetti et al. 2011). DIR 
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does not detect all cortical lesions (Geurts et al. 2005a) and it has been 
suggested that only the relatively new, oedematous lesions might be visible 
on DIR (Calabrese et al. 2007b). It remains to be investigated if similar 
findings are seen with PSIR or whether the latter is more sensitive to 
detecting lesions even in the absence of inflammation.  
The differential specificity to pathological processes has been noted 
with the use of conventional scanning of WM lesions (van Waesberghe et al.  
1998; Guttmann et al. 2006). No MRI sequence on its own is able to provide 
perfect contrast specific for a particular pathological substrate. The overlap in 
histopathological specificity is largely due to the distribution of water in the 
diseased parenchyma (Guttmann et al. 2006). T2 weighted MRI is sensitive to 
inflammation, oedema, demyelination, loss of axons and to remyelination 
(Guttmann et al. 1995). The hypointensities on T1w MRI represent axonal 
loss but this cannot be differentiated from the transient oedematous changes 
in acute lesions (van walderveen et al. 2001). Diffusion MRI is sensitive to 
WM damage and magnetisation transfer imaging has an enhanced specificity 
towards demyelination (Guttmann et al 2006). A systematic combination of 
different sequences can  be used to provide a better understanding of MS 
pathogenesis. DIR is sensitive to cortical demyelination (Seewann et al. 
2012); combined radiological and histopathological studies will help ascertain 
the pathological substrate of PSIR lesions. If DIR and PSIR are in fact 
differentially sensitive for different pathological processes, it would suggest a 
multimodal approach (Ceccarelli et al. 2012a; Tallantyre et al. 2010; Mike et 
al. 2011; Nelson et al.  2011) combining both DIR and PSIR (Nelson et al. 
2007a) would help identify different stages of cortical pathology.  
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Recently published consensus recommendations (Geurts et al. 2011) 
(See Table 1.1) advise caution while marking regions high signal in the 
archicortex and paleocortex e.g. insula. Are there similar or different artefact 
prone regions on PSIR , and if so, can these scans be used together ? 
Alternatively can either provide as much information as the other? With 
respect to the location of lesions, juxtacortical lesions have not been reported 
separate from LC using DIR. Given that JC lesions have independently been 
used for diagnosis and to predict cognitive impairment, it will be interesting to 
see if PSIR improves identification of JC lesions and advance the 
understanding of cognitive problems in MS. 
 
 
Table 1.1 Recommendations for marking cortical lesions on DIR 
Mandatory 
features 
Cortical lesions are hyperintense on DIR images and should 
occupy at least 3 pixels ( at 1mm2 isotropic in-plane resolution) 
Supportive 
points 
To be aware of regions prone to artefacts - including the 
archicortex and paleocortex e.g. insula 
Maintain near constant image contrast setting 
Multiple slices of the scan should be seen to ascertain if a 
hyperintensity is a cortical lesions; this helps differentiate it from 
artefacts such as vessels 
Use other T1 based and T2 / FLAIR images to confirm doubtful 
lesions 
   
(Based on Geurts et al. 2011) 
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 The detection and study of CGM lesions has a potential role in (i) 
diagnosing and differentiating MS from other conditions (ii) understanding the 
pathogenesis and (iii) correlation between CGM lesions and disability in 
people with MS. White matter lesion load and distribution does not correlate 
well with disease phenotype, stage of disease or extent of disability seen in 
patients. Associations between WM lesion load and presentations such as 
fatigue (Bakshi 2003) and cognitive impairment (Hulst et al. 2013; Giorgio & 
De Stefano 2010)are modest. Cortical lesion loads have also been 
demonstrated to correlate with tests of cognitive impairment. (Calabrese et al. 
2009; Calabrese et al.  2011a). If the numbers and distribution of  CGM 
lesions has a better correlation with markers of disability, this will help to 
bridge the clinical radiological paradox. (Leary et al. 2009; Frohman 2006; 
Chard et al.  2010; Crawford et al.  2004; Bobholz & Rao 2003; Zang et al. 
2004; Giorgio & De Stefano 2010; Trapp & Nave 2008; Jongen et al. 2012).  
Cortical lesions, if specific for MS, may have a diagnostic role (Filippi 
et al. 2010b). However, to be able to establish this, it is important to 
investigate for evidence of grey matter lesions in healthy controls (to 
understand whether aging is associated with cortical lesions in the way that it 
is with white matter lesions) and also in other neurological conditions, such as 
small vessel disease and migraine, which are also known to cause white 
matter lesions.  
Cortical lesions have been reported in healthy controls with DIR 
(Geurts et al.  2005b) albeit few. Further studies are needed to determine if 
these observations in controls are true or represent a misinterpretation of 
artefacts. If intracortical lesions are found to be specific to MS, they could be 
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incorporated in the diagnostic criteria for MS (Filippi et al.  2010b)and help 
improve the specificity of these criteria. While consensus recommendations 
have been recently outlined for the detection of grey matter lesions on DIR 
(See Table 1.1) (Geurts et al.  2011), there are no available guidelines for 
lesion detection using PSIR. 
The pathogenesis of grey matter lesions may differ from that of white 
matter lesions. While there are similarities e.g. both grey and white matter 
lesions are seen in early stages of disease (e.g. in CIS), (Simon et al. 2012); 
the relative lack of inflammation and greater extent of demyelination in cortical 
lesions (vs. WM) are some important differences. Longitudinal MRI studies of 
CGM lesion evolution may help understand the pathogenesis of GM and WM 
lesions, and further define new treatment endpoints for clinical trials. A better 
method to in vivo detect grey matter lesions will likely improve the ability to 
correlate and predict disease progression in patients.  
The sections below describe the etiology, clinical features and 
pathogenesis of Multiples sclerosis. A background of basic MRI physics and 
the sequences that have evolved for the detection of grey matter pathology 
are described. In this project I have also studied the association of cortical 
lesion load with the performance on cognitive tasks; thus the cognitive tests 
are described. A brief overview of the cognitive impairment seen in MS is 
detailed in the subsequent sections.  
1.2 Etiology 
No definite cause for MS has been found, however a variety of 
environmental factors may predispose a person with genetic susceptibility, to 
develop MS (Ceccarelli, Bakshi, et al.  2012a; Gandhi & Weiner 2012). MS is 
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relatively common in the young population of temperate regions such as 
northern Europe, North America and Australasia, and less common in Asia 
and the Middle East (Compston et al. 2006). In the UK, it is estimated that the 
prevalence of MS is 203.4 cases per 100000 population, (Mackenzie et al. 
2014) and the incidence is 9.64 cases per 100000/year. It commonly presents 
at 20-40 years of age and is more common in females than males; males > 
females 2:1. (Leary et al. 2009). 
Genetic susceptibility for MS has been studied and the major risk 
factor for MS is a haplotype within the major histocompatibility region; more 
than a hundred additional loci with genome-wide significance have now been 
identified but the variants and their effects at molecular and cellular levels are 
still being understood. (IMSGC et al.  2007; Kemppinen et al.  2011). 
Ethnicity, gender, and familial risk also influence the chances of developing 
MS (Nelson et al. 2012).First degree relatives have a 10 to 25 times greater 
risk of developing MS. (Griffin et al.  2002; Filippi et al. 2010b; Trapp & Nave 
2008; Nelson et al.  2007b; Gandhi & Weiner 2012). In comparison to African-
American population, the white population is more susceptible and so are 
women in comparison to men (2F:M). Differences in gender distribution are, 
however, noted depending on specific phenotype and also based on age at 
onset and seem to be changing with time. (Compston et al.  2006) 
Environmental factors including climate, infections, vaccinations, 
smoking and diet have all been found to be risk factors for the development of 
disease (Lauer 1995; Steiner 1952, Martinelli et al 2014; Fernandes de Abreu 
et al 2011; Runia et al 2012). Infections associated with the development of 
MS include EBV (Sundström et al.  2004), retroviruses, human herpes virus 6. 
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Environmental factors like growing up in a temperate climate, being born in 
summer (and thereby spending in-utero period largely in winter), lack of 
sunlight exposure and low vitamin D levels (Fernandes de Abreu et al.  2011; 
Kampman et al.  2012; Runia et al.  2012; Disanto et al.  2012) have all been 
studied as risks in the context of MS.  
1.3 Clinical Aspects 
Clinical Features 
The clinical hallmark of MS presentation is clinical features 
disseminated in space (site of localization) and time and the condition was 
thus formerly known as Disseminated Sclerosis.  
Four distinct phenotypes have been described based on the onset and 
progression of disease.(Leary et al.  2009) These are Relapsing-remitting, 
Primary progressive, Secondary progressive and Progressive relapsing 
MS.(Leary et al.  2009; Lublin & Reingold 1996) (See Figure 1.1). The course 
of disease is very individual and variable between patients. While some 
patients have a very aggressive course, others run a very mild course e.g. 
benign MS, wherein patients do not enter the progressive form of disease.  
The onset of disease is seen to be relapsing remitting in about 85% 
patients (Leary et al.  2009) (Nelson et al.  2008; Geurts et al.  2011; Trapp & 
Nave 2008). An episode of acute or subacute new neurological deficit or 
worsening of old symptoms, which lasts for a minimum of 24 hours, is defined 
as a relapse. Symptoms evolve over days and recovery can take up to many 
weeks. The is very variable; annual relapse rates of 0.1 to more than 1 a year 
have been reported in different studies (Confavreux et al. 2014; Myhr et al. 
2001). Pathologically these clinical events represent focal inflammation and 
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demyelination in the central nervous system white matter. (Seewann et al.  
2012; Gandhi & Weiner 2012; Patzold & Pocklington 1982)  
In the early years of disease, the incidence of a relapse is estimated to 
be 1.1 times / year and this decreases with increasing duration of disease and 
advance to progressive disease.  
When recovery following relapses is followed by a gradually 
increasing, accumulating deficit and disability, the disease is said to enter a 
secondary progressive phase. About 60% patients progress to SPMS in about 
10-15 years after the onset of disease. (Geurts et al.  2011; Weinshenker et 
al.  1989; Schmierer et al.  2010) 
PPMS, on the other hand, has a progressive course from the onset of 
disease, and about 15% patients present with this pattern. About 25% of 
patients initially diagnosed to have PPMS, are seen to have superimposed 
relapses together with the progressive phase of disease and are referred to 
as progressive relapsing MS. 
Figure 1.1 Phenotypes of Multiple Sclerosis 
 
(Adapted from Leary et al. 2009) 
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Diagnosis of MS 
MS (MS) is a neuro-inflammatory condition that has until recently, 
been thought to be a white-matter disease. The diagnosis of MS is based on a 
combination of clinical and radiological or laboratory evidence of 
demyelination; white matter ‘lesions’ being the radiological hallmark. 
Over the years, the diagnostic criteria for MS have evolved from the 
initial Schumacher criteria (Schumacher et al.  1965) followed by Poser 
criteria (Poser et al.  1983), McDonald with revisions in (2005)(Polman et al.  
2005) and most recently, the 2010 McDonald criteria arose following revisions 
made by the International Panel for Diagnosis of MS when it met in Dublin in 
May 2010 (Kilsdonk et al.  2011; Polman et al.  2011); with each iteration 
showing an increasing trend to gravitate towards the use of laboratory (e.g. 
CSF analysis ) and radiological evidence to aid in the diagnosis 
The revised criteria have aimed to maintain the diagnostic specificity 
and sensitivity while allowing for a simplification – a single scan after a single 
clinical episode can now at times suffice to establish a diagnosis of MS. 
(Polman et al.  2011) The use of these criteria allows diagnosis to be 
established early and thus prompt initiation of treatment, where indicated. 
Dissemination of disease in space and time remains the essential requirement 
in establishing a diagnosis. (Popescu & Lucchinetti 2012a; Schumacher et al.  
1965; Poser et al.  1983; Schumacher et al. 1965)The use of visual evoked 
potentials (indicating optic nerve damage), demonstration of unmatched 
oligoclonal bands, IgG index in CSF (evidence of immunoglobulin generation 
in the central nervous system), and investigations that help exclude 
differentials (e.g. Aquaporin 4 antibodies in NMO; Serum and CSF ACE levels 
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in neurosarcoid; Anti Rho and Anti La antibodies in SLE etc.) may all aid the 
diagnosis of MS. (Charil et al. 2006) 
Radiological criteria are based on demonstration of white matter 
‘plaques’ or ‘lesions’ in regions and patterns that are typical of MS: these 
include the periventricular and juxtacortical white matter, infratentorial (brain 
stem and cerebellum) and spinal cord.  
The use of contrast (gadolinium chelate (GAD)-based) enhanced 
images helps to (i) exclude other conditions e.g. sarcoidosis which could have 
accompanying meningeal enhancement and tend to have a persistence of 
enhancement and (ii) determine the ‘age’ of a lesion; new MS lesions show 
GAD enhancement, indicating the active, inflammatory state, for about 4 
weeks.  
It needs to be remembered however, that the diagnostic criteria 
outlined above should be used only in presentations suggestive of MS / a 
demyelinating event involving the CNS, the first such being referred to as a 
clinically isolated syndrome (CIS) i.e. a single isolated demyelinating event. 
These presentations can remain localized to one neuroanatomical location 
(monofocal) or involve multiple sites (multifocal), at the same time. Some 
common presentations of CIS include optic neuritis, partial myelitis or 
involvement of the brainstem/ cerebellum/ cerebral hemispheres. (Polman et 
al.  2011; Miller et al.  2012; Miller et al.  2005).  
The 2010 McDonald MRI Criteria for dissemination in time and space 
are outlined in Table 1. (Montalban et al.  2010; Polman et al.  2011). To 
demonstrate dissemination in space (DIS), one or more T2 lesions are 
required to be seen in at least two regions amongst the periventricular, 
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juxtacortical, infratentorial and spinal cord regions. A follow up MRI 
demonstrating a new T2 and/or GAD enhancing lesion (in comparison to a 
baseline scan, with no specific time lag) or a single scan demonstrating 
asymptomatic GAD enhancing and non-enhancing lesions, are taken to be 
evidence of dissemination in time (DIT). 
A diagnosis of primary progressive MS can be established if there is 
evidence of : (i) disease progression for at least one year and (ii) at least two 
of the following: (a) DIS (Brain) based on one or more T2 lesions in at least 
two characteristic regions i.e. periventricular/juxtacortical /infratentorial (b) DIS 
(Spinal Cord) based on two or more T2 lesions and (c) evidence of 
unmatched oligoclonal bands / elevated IgG index in CSF. 
For both relapse onset and progressive onset disease, in the scenario 
of a brainstem/spinal cord presentation, the symptomatic lesions are not 
included in determining the fulfillment of criteria. Further, for purposes of 
demonstrating DIS, GAD enhancement of lesions is not included as it used to 
be in the earlier 2001 and 2005 McDonald criteria. 
Cortical lesions are not part of the criteria for MS until now. With the 
use of higher field strength scanning (Pitt et al. 2010; Wattjes et al. 2009) and 
utilization of sequences that improve CGM lesion detection (DIR, PSIR, 
MPRAGE) and study (MTR), inclusion of cortical  abnormalities has potential 
to further improve the sensitivity and specificity of the criteria.CGM lesions 
occur very early in disease and this suggests that an early diagnosis can 
possibly be established based on detection and distribution of intracortical 
lesions, as has been reported using DIR (Filippi et al 2010b). 
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1.4 Anatomy of the cerebral cortex 
Grey matter is the portion of the central nervous system that is 
composed of the nerve cell bodies, proximal portion of the processes and the 
surrounding neuroglia. It is so called due to the grey colour. White matter, in 
contrast, consists of the nerve fibres in neuroglia, and is white in colour, the 
colour being attributed to the presence of high lipid content in the myelin 
covering the myelinated nerves (Ceccarelli et al. 2012a; Snell 1997.; Gandhi 
& Weiner 2012). 
Grey matter covering the cerebral hemispheres forms the cerebral 
cortex and number of neocortical neurons has been reported as 21.4 billion in 
females and 26.3 billion in males (Pelvig et al 2008). The organisation into 
folds or convolutions (gyri) and fissures (sulci) significantly increases the 
surface area of the cerebral cortex. The thickness of the cerebral cortex 
ranges from about 1.5 mm to 4.5 mm – being thin in the sulcal pit (fissure) 
and thick over the crown / crest of each gyrus. It is composed of grey matter 
(nerve cells, proximal fibres, neuroglia) and blood vessels.(Compston et al.  
2006; Snell 1997a.) 
The main types of cells that make up the cerebral cortex include 
pyramidal cells, stellate cells, fusiform cells, horizontal cells of Cajal and cells 
of Martinotti. ( Snell 1997a) The distribution of fibres within the cortex is in two 
directions, perpendicular to each other. This could either be radial or 
tangential. The tangential fibres, includes fibres that run along the cortical 
ribbon, parallel to the cortical surface. The radial fibres, make an angle of 90 
degrees (perpendicular) to the cortical surface. 
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• Table 1.2 Revised McDonald Criteria (2010) (Polman et al. 2011) 
Clinical Features Additional requirements to establish a diagnosis 
Attacks Clinical Evidence DIS DIT 
>= 2 
e/o >=2 lesions 
OR 
e/o 1 lesion with 
historical 
evidence of a 
previous attack 
 
None 
>= 2 1 lesion 
>=1 T2 lesion in 
at least 2/4 MS-
typical regions of 
the CNS* 
OR 
Await further 
clinical attack 
implicating a 
different CNS site 
 
1 >=2 lesions  
Simultaneous presence of 
asymptomatic GAD+ and 
GAD- lesions at anytime 
OR 
A new T2 and/or GAD+ 
lesion on follow-up MRI 
irrespective of its timing with 
reference to a baseline scan 
OR 
Await a second clinical 
attack 
1 1 
>=1 T2 lesion in 
at least 2 of 4 MS-
typical regions of 
the CNS* 
OR 
Await a second 
clinical attack 
implicating a 
different CNS site 
 
Simultaneous presence of 
asymptomatic GAD+ and 
GAD- lesions at anytime 
OR 
A new T2 and/or GAD+ 
lesion(s) on follow-up MRI, 
irrespective of its timing with 
reference to a baseline scan 
OR 
Await a 2nd clinical attack 
(e/o – objective clinical evidence of ; GAD + :GAD enhancing and GAD – is 
non-enhancing,*periventricular, juxtacortical, infratentorial and spinal cord) 
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The cerebral cortex is divided into layers depending on the types of 
cells and the density and arrangement of cells within the cortex. The subpial 
surface (adjacent to CSF) is the superficial plexiform layer. The layers from 
outwards to inwards are the plexiform layer , external granular layer, external 
pyramidal layer, internal granular layer, ganglionic layer (internal pyramidal 
layer) and the multiform layer (layer of polymorphic cells) (Figure 1.2) 
While most of the cortical surfaces are comprised of the these six 
layers, some regions where this clear arrangement cannot be demarcated are 
referred to as heterotypical regions. Examples of such regions include the 
post central gyrus, superior temporal gyrus and parts of hippocampal gyrus 
(all granular type) and other regions such as the precentral gyrus, other parts 
of the temporal lobe (agranular type).  
It is important to appreciate this heterogeneity in the cortical structure 
to understand variations in imaging of the cortex – in health and in disease 
The functional specialisation of different regions has been extensively studied. 
However, given the complexity of the architecture of the cerebral cortex, the 
anatomical location is used to divide the cortex into lobes – the four main 
lobes being Frontal, Temporal, Parietal and Occipital. In addition some 
scientists further qualify the Insula and the limbic lobes as separate cortical 
regions.  
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Figure 1.2 : Layers of the cerebral cortex (Based on Snell 1997a) 
 
I Molecular Layer 
II External Granular Layer 
III External Pyramidal Layer 
IV Internal Granular Layer 
V Ganglionic layer (Internal Pyramidal layer) 
VI Multiform layer (Layer of polymorphic cells) 
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Figure 1.3 Types of cells in the grey matter (Adapted from Snell 1997a) 
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1.5 Current understanding of the pathophysiology of MS  
In the section below I describe the current understanding of the 
pathophysiology of MS describing (i) pathological features of MS in grey and 
white matter and (ii) mechanisms thought to be responsible for these 
changes. 
The ‘lesion’ or ‘plaque’ is the histological hallmark of the disease 
(Popescu & Lucchinetti 2012b) and represents multiple regions characterized 
by the loss of myelin. Demyelination is accompanied by inflammation, varying 
degrees of gliosis and preservation of axons(Popescu et al. 2013). 
Astrogliosis, injury to oligodendrocytes, degeneration of axons and 
simultaneous remyelination are other changes seen in lesions. Though initially 
thought to be limited to white matter, recent studies have established that 
demyelinating lesions are seen in the CGM as well. (Calabrese, Filippi, et al.  
2010b; Geurts & Barkhof 2008; Peterson et al. 2001; Pirko et al. 2007) . 
Pathological features  
White matter lesions 
White matter lesions continue to develop in patients with MS, even as 
older lesions evolve into chronic lesions, with no associated active 
inflammation. Acute, chronic and remyelinating lesions often co-exist in a 
patient. Different types of focal white matter lesions have been reported – 
these include classically active lesions, slowly expanding lesions and inactive 
lesions (See Figure 1.4)(Lassmann 2008b). 
Acute active lesions are frequently seen in patients with relapsing 
remitting MS in the context of clinical attacks (Filippi et al. 2012). In acute 
lesions, there is a loss of the normal lamellar pattern of myelin, possibly as a 
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result of antibody related processes. Macroscopically acute white matter 
lesions are pink, soft and usually round or oval in shape. Microscopically the 
‘lesion’ has distinct margins and a very cellular infiltrate consisting of 
lymphocytes, plasma cells, astrocytes and macrophages; myelin laden 
macrophages are the hallmark of an active lesion(Calabresi 2011). 
Preferential destruction of oligodendrocytes is seen in acute lesions (Sobel et 
al. 2008). There is significant oedema and minimal scarring noted in these 
lesions. Lesions are also noted to be distributed in the proximity of blood 
vessels i.e. perivascular.  
Luchinetti et al. have demonstrated that acute lesions can be 
classified into four distinct patterns based on the heterogeneity of the 
immunopatterns. (Lucchinetti et al.  2000; Popescu et al. 2013).  
Pattern I lesions are perivascular with sharp boundaries. Active 
demyelination is characteristically noted and there is no immunoglobulin 
deposition or complement activation. Pattern II lesions are also sharply 
demarcated lesions and in addition to evidence of active demyelination, are 
characterized by immunoglobulin and complement deposition and 
phagocytosis. In both Pattern I and II a variable loss of oligodendrocytes is 
noted at the lesion border. Remyelinating lesions show evidence of 
oligodendrocytes in the inactive centre of the lesions. Pattern III lesions show 
ill defined margins, oligodendrocyte apoptosis and demyelination with 
preferential loss of periaxonal myelin components. Immunoglobin deposition, 
complement activation and remyelinated lesions are not seen. The fourth 
immunopattern, Patter IV, is extremely rare and is characterised by a 
profound non-apoptotic death of oligodendrocytes in the perilesional WM.  
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This classification of immunopatterns has been challenged in some 
studies (Barnett and Prineas et al. 2004). In a small series, Barnett and 
Prineas noted  an overlap in the stages of complement containing 
macrophages and oligodendendrocyte apoptosis ( an overlap between 
patterns II and III), and interpreted this to imply that the pathogenic 
heterogeneity of lesions depends on the age of individual lesions and not on 
the patient. 
 
Variable axonal injury is seen as irregularly swollen axons, 
accumulation of amyloid B precursor protein and some degree of axonal loss. 
This is commonly seen in the context of acute lesions and is a factor 
responsible for the relapse related disability seen in patients. (Popescu & 
Lucchinetti 2012b; Filippi et al. 2012; Popescu et al. 2013). Retrograde 
degeneration has also been reported in the vicinity of the destructive JC WM 
lesions (Lassmann 2008b) 
 
Slowly expanding lesions (SEL) differ from the classically active 
lesions. Macrophages containing all stages of myelin degradation products 
are rare and maybe even absent in SEL (Lassmann et al. 2007); a rim of 
activated microglia is characteristically seen in these lesions, and some of 
these microglia contain myelin degradation products. Perivascular infiltration 
of T cells is noted, but scarce. These smoldering plaques are thought to be 
responsible for progression (Popescu et al. 2013). 
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Figure 1.4 Different types of focal white matter lesions 
(Adapted from Lassmann 2008b) 
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Chronic lesions on the other hand are firm and grey in their 
macroscopic appearance. The absence of inflammatory changes, and a 
greater extent of demyelination and axonal loss differentiates these from 
acute lesions. (Leary et al. 2009). Chronic lesions are more common in 
progressive disease. (Popescu et al. 2013) Chronic active lesions have a 
sharp edge and in addition to the macrophages and astrocytes, degenerating 
axons are noted in this phase, even as demyelination and remyelination 
continue to occur in parallel. Myelin in the form of droplets and a deposition of 
immunoglobulins differentiates these from acute lesions. In contrast to the 
increased cellularity in acute lesions, the centre of chronic lesions consists of 
demyelinated axons, with few lymphocytes and macrophages; no 
oligodendrocytes are seen. These chronic lesions also show increased 
astroglial scar tissue, thick vessels with hyalinised walls. (Lucchinetti et al.  
1996; Allen et al.  2001) 
Chronic inactive plaques are completely demyelinated, hypocellular 
lesions. They have sharp edges and are characterised by astrogliosis, loss of 
axons, absence of oligodendrocytes, minimal infiltration with macrophages, 
microglia and lymphocytes. As a lesion evolves from chronic active to chronic 
inactive, oedema and inflammation resolve and there is disappearance of 
macrophages and microglia. The demyelinated plaque then typically contains 
many glial fibres which are produced by astrocytes. 
Remyelination of lesions, by cells of oligodendrocyte lineage (Bramow 
et al. 2010), can be seen in active MS patients. The degree and efficiency of 
remyelination is however less in patients with progressive disease (Bramow et 
al.2010; Lucchinetti et al. 2000). In these lesions thin myelinated axons with 
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short distances between nodes of Ranvier, are characteristically seen. They 
have a sharp margin and a reduced myelin density. When a lesion is 
completely remyelinated it is referred to as a “shadow plaque” These lesions 
are more vulnerable than the surrounding normal appearing white matter, to 
subsequent “attacks” (Prineas et al. 1993). 
The normal appearing white matter (NAWM) shows diffuse 
inflammatory changes. Inflammatory infiltrates largely consisting of T 
lymphocytes , activated microglia and diffuse axonal injury are noted 
throughout the NAWM (Lassmann et al. 2007).  
Grey matter lesions 
Grey matter demyelinating lesions in MS have been reported in the 
cerebral CGM (Bo et al 2003; Vercellino et al 2005; Kutzelnigg et al 2005b). In 
addition the  cerebellar cortex (Kutzelnigg et al 2007) and deep grey matter 
(Gilmore et al 2009; Vercellino et al. 2009) is also affected (Haider et al. 
2014). Atrophy of deep grey matter nuclei, thalamus (Cifelli et al 2002) and 
caudate has been linked with the progression of clinical disease (Neema et al 
2009). The changes observed in imaging studies are due to a combination of 
focal demyelinated lesions and diffuse changes in the normal appearing grey 
matter (Haider et al. 2014). Increased oxidative injury and anterograde or 
retrograde degeneration in iron rich regions of the brain have been postulated 
as a possible mechanism of these changes, and the association with clinical 
disability.  
In the cerebellum, the extent of cortical demyelination is similar or 
even more than reported in regions of the forebrain in patients with MS 
(Kutzelnigg et al.2007). Demyelination with relative preservation of neurons, 
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axons and synapses, is seen in the context of cerebellar cortical lesions.  In 
addition, scattered axonal swellings and end bulbs has also been reported 
(Kutzelnigg et al. 2007). The cerebellum also has an important role in 
cognitive functions and Cerasa et al (Cerasa et al. 2012) demonstrated that 
affection of neurofunctional  networks responsible for communication between 
the cerebellum and cerebral cortex, impacts cognitive functions such as 
working memory. 
 In this project we focus on the study of grey matter lesions in the 
cerebral cortex and these are referred to as CGM. lesions. In comparison to 
WM lesions, CGM lesions have a smaller number of macrophages and 
lymphocytes and lesser amount of inflammation, microglial activation and 
astrogliosis. Cortical demyelination, neuronal loss and atrophy are seen in 
patients with MS (Bo et al. 2006a, Bo et al. 2003b). 
Based on their location within the cortex, demyelinating lesions have 
been classified into four types. (See Figure 1.5) (Bø et al. 2006a, Bø et al.  
2003b, Wegner et al. 2009; Rudick et al. 2009). Type I lesions are at the 
border of the cortex and white matter, and involve both grey and white matter. 
Lesions limited to the substance of the CGM have been described as Type II 
lesions (Intracortical) and are noted to be perivascular in distribution. Type III 
lesions are seen in proximity to the meningeal surface, below the pia mater. 
They extend from the pial surface to cortical layer three / four or through the 
entire width of the cortex, becoming Type IV full thickness lesions.  
Subpial lesions (Type III) dominate the histopathological findings in 
MS (Bø et al. 2003b; Albert et al. 2007b) and have been reported to constitute 
about 50 to 65% of the total cortical demyelination (Lucchinetti et al. 2011, Bø 
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et al. 2003b; Albert et al. 2007b). These are mainly seen in the sulcal folds, 
particularly in the insula, cingulate, frontal and temporal cortices, the 
hippocampus and the cerebellum (Lassmann et al. 2007, Lassmann 2008b).  
Subpial lesions are seen as large band like lesions affecting the 
superficial layers of the cortex and can extend inwards from the outer surface 
of the cortex, and are oriented towards inflammatory infiltrates that are located 
in the leptomeninges. (Kutzelnigg et al. 2005a).  
 
 
 
Figure 1.5 Classification of cortical grey matter lesions  
 
(Types I – IV) and their corresponding radiological categories 
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The current view is that the neuropathological affection of the grey 
matter consists of (i) cortical demyelination with neuronal loss (diffuse) (ii) 
cortical atrophy(Lassmann 2008b) and (iii) synaptic changes including a 
change a loss of synapse and an impaired capacity of existing synapses 
(Wegner et al. 2006). The neuronal and axonal loss, in the early stages of 
disease, is seen on a backdrop of inflammation (Popescu et al.  2013). 
Pathophysiology of cortical MS lesions in general, is noted to have features 
that are quite different in comparison to white matter pathology. These include 
a scarcity of T and B cell infiltration, microgolial activation and astrogliosis. 
Remyelination is often seen in the CGM lesions and is more prominent than in 
the WM lesions (Albert et al. 2007b; Stadelmann et al.  2008).Blood brain 
barrier damage and edema is minimal / absent in the context of CGM lesions 
(Bø et al. 2003a). However, in meninges adjacent to CGM lesions extensive 
infiltration of T and B cells is seen. Meningeal inflammation (focal perivascular 
and diffuse) is prominent in early MS (Lucchinetti et al. 2011) and in some 
patients lymph follicle like inflammatory infiltrates are seen, specially in the 
patients with a more aggressive disease course. (Magliozzi et al.  2006). 
Reduced density of neurons in the region of the CGM lesion and 
adjacent normal appearing cortex has also been reported. (Vercellino et al. 
2005). In various studies, 10-36% neuronal and glial loss has also been seen 
in the cortex (Lassmann 2008b; Wegner et al. 2006; Vercellino et al. 2005) 
and is thought to be contributory to the reduction of cortical thickness seen in 
patients(Stadelmann et al. 2008); this is seen in both the demyelinated and 
the normal cortex (Wegner et al. 2006). Other features noted in CGM lesions 
include neuronal apoptosis, dystrophic axons and synaptic loss (Lassmann 
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2008b). 
In early MS, most cortical lesions have myelin laden macrophages, 
indicating active demyelination. Inflammatory infiltrates of T cells, fewer B 
cells and minimal breakdown of the blood brain barrier (BBB) is present. In 
the more chronic cortical lesions, there is no breakdown of BBB and no 
evidence of inflammatory infiltrates or complement deposition. Microglia, 
apoptosis of neurons and damage to oligodendrocytes are also seen. In 
association with subpial lesions, profound inflammatory infiltrates of T cells, B 
cells and macrophages, have been described in late stages of disease. 
(Magliozzi et al. 2006). The degree of meningeal inflammation correlates with 
the degree of microglial activation, and in turn with the extent of 
demyelination, neurodegeneration and severity of clinical course. (Popescu et 
al. 2013) 
Pathogenic mechanisms 
Multiple sclerosis is considered to be an immune mediated disease 
with inflammation (Gandhi & Weiner 2012) against myelin, that is precipitated 
by environmental agents in predisposed individuals (Tsunoda & Fujinami 
2002 , Frohman 2006) Demyelination with gliosis, inflammation and relative 
preservation of the axons is the traditional understanding of this pathology 
(Popescu & Lucchinetti 2012b). The variability and individual differences seen 
in the pathological features imply that there is probably no single or simple 
mechanism that can explain the pathogenesis of multiple sclerosis. 
(Lucchinetti et al. 1996; Lassmann & Lucchinetti 2008) The important features 
of pathogenesis in MS include (i) inflammation (ii) demyelination and (iii) injury 
of axons and neurons (Ellwardt et al. 2014; Gandhi & Weiner 2012; Bø et al. 
 
 
48 
2003b; Ceccarelli et al. 2012a; Compston 1999; Albert et al. 2007a; Dawson 
1916) 
The different mechanisms of tissue injury in multiple sclerosis lesions 
include (i) initial inflammatory tissue injury (ii) amplification of oxidative tissue 
injury (mitochondrial damage, iron liberation, retrograde degeneration) and (iii) 
astrocyte injury leading to an amplification of demyelination and 
neurodegeneration. (Lassmann 2008b)These mechanisms may all be seen in 
a lesion at the same time; however, their relative contribution is determined 
based on differences in lesion subtype, stage of disease and inter-individual 
differences. (Lassmann 2008a). 
The inflammatory injury (related to active tissue injury) is seen across 
all stages of disease and involves both, the adaptive and innate 
immunity(Lassmann 2014) The degree of inflammation is more extensive in 
the early RRMS phase and reduces with the duration of disease (Frischer et 
al.  2009). Immune mediated mechanisms (Lassmann 2014) cause an active 
demyelination in relation to damage to the blood brain barrier (BBB), in the 
early stages of disease. Dendritic cells, monocytes, microglia, natural killer 
(NK) cells and mast cells are constituents of the innate immune system and 
they play a major role in the immune-pathogenesis of MS. Infections such as 
EBV affect the interplay between the T cells, cerebrovascular endothelium 
and adhesion molecules that recruit immune cells into the central nervous 
system. 
A cascade of immunological events leads to demyelination (Frohman 
2006; Geurts, Bø, et al. 2005a; Raine 1994). Different mechanisms including 
cytotoxic T cells, antibodies and production of reactive oxygen / NO 
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intermediates by activated microglia, contribute to this inflammatory injury. T- 
and B-cell immune mediated mechanisms represent adaptive immunity. 
(Frohman 2006; Trapp et al. 1998; Gandhi & Weiner 2012) and the response 
of the microglia is a manifestation of the innate immunity.  
Following appropriate antigenic stimulation, CD4+ T cells differentiate 
into pathogenic myelin reactive CD4+ T cells. While the interaction with the 
antigen occurs in the periphery, a disruption in the blood-brain barrier allows 
these cells to enter the central nervous system and interact with the brain 
parenchyma and spinal cord, causing demyelination and as a result, acute 
MS lesions ( Popescu et al. 2013). Regulatory CD24+ and CD25+ are 
deficient in MS patients; this is the principle to use one of the first line disease 
modifying drugs, glatiramer acetate which helps restore their numbers and 
build an immunological tolerance to self/auto antigens. (Viglietta et al. 2004; 
Frohman 2006) 
Immune response in MS also involves the B Cell mediated immunity. 
B cells produce antigen specific antibodies, become the substrate for antigen 
presenting cells which are required for differentiation of T Cells and also 
produce a variety of cytokines. Patients with MS have an increase in the local, 
intra-thecal production of immunoglobulin’s as demonstrated by an increased 
IgG index (Frohman 2006)and presence of oligoclonal bands in CSF (and not 
serum).  
The use of newer techniques like microarray, has helped identify 
additional targets involved in the pathogenesis of a lesion e.g. alpha 4 integrin 
(alpha 4 beta1 and alpha4beta7) (Kleinschmidt-Demasters et al. 2012), a 
receptor expressed on T-cells aids with adhesion and transport pathways. A 
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specific monoclonal antibody against this receptor, natalizumab, (Frohman 
2006; Rinaldi et al. 2011; Pucci et al. 2011) is an agent that has helped 
reduce the frequency of clinical relapses. It has also been shown to reduce 
the progression of disability and reduces the number of new T2 weighted and 
GAD enhancing T1-weighted lesions. Another similar target is osteopontin, 
which has been found to have an increased expression in MS lesions. 
Antibody and complement associated mechanisms are responsible for 
demyelination and injury in the Pattern II lesions, the prime antigen target 
being the myelin oligodendrocyte glycoprotein. In pattern III lesions, the early 
changes are see in the sites most distal from the oligodendrocyte cell body, 
suggesting a dying back oligodendrogliopathy. The disturbance responsible 
for the appearance in pattern IV lesions is thought to be a primary metabolic 
and involves toxic action of the various inflammatory mediators. 
In the later stages, there is an amplification of the oxidative tissue 
injury. Liberation of iron from oligodendrocytes (causing iron accumulation) 
and progressive mitochondrial damage lead to an expansion of WM lesions 
(pre-existing) (Lassmann 2014) and widespread diffuse injury to both the GM 
and WM. The accumulating damage to interconnected regions leads to 
retrograde degeneration of neurons. As a result, there is pre-activation of 
microglia, which on exposure to pro-inflammatory cytokines, differentiate into 
cytotoxic effector cells. As lesions progress, astrocytes within the lesions also 
become activated and transform into protoplasmatic astrocytes. This leads to 
a loss of molecules expressed by the distal astrocyte processes (aquaporin 4, 
excitatory amino acid transporter 2 and connexins). Excitotoxins thus 
accumulate in the extracellular space and there is loss of trophic support of 
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the oliogdendrocytes, axons and neurons. Under the effect of oxidative stress, 
the astrocytes become senescent and cause an increased production of pro-
inflammatory cytokines. This results in increased demyelination and 
neurodegeneration. 
Neuroinflammation and neurodegeneration are both recognized in 
MS(Ellwardt & Zipp 2014); however their temporal association is still not 
clearly understood. In the initial stages of RRMS, exacerbations are 
responsive to treatment with steroids, however in later stages of SPMS this is 
not seen, suggesting that neuroinflammation is not primarily responsible for 
the disability at this stage, which may in turn be due to a neurodegenerative 
process. Evidence of a degenerative process has however been seen even at 
disease onset(Ellwardt & Zipp 2014; Trapp & Stys 2009). Both innate and 
adaptive immunity contribute to the neurodegenerative process via effector 
molecules such as cytokines, glutamate or reactive species. The 
neurodegeneration in turn can be both primary and secondary. This is 
attributed to increased loss of axons, which maybe due to mechanisms that 
are related to demyelination or maybe demyelination independent (DeLuca et 
al. 2006). The axonal density reduces up to about 80% loss within the MS 
plaques, in patients with chronic disease. Until the point that up to 40% of 
axons are lost, no obvious physical disability may sometimes be apparent. 
Inflammation continues to be a parallel process, reaching minimal levels in 
chronic inactive lesions of long duration.(Popescu et al. 2013) As the disease 
progresses, the neurodegenerative mechanisms perhaps become 
independent of the inflammatory processes. (Deshmukh et al.  2013) 
The primary target in the pathogenesis of MS, is thought to be myelin 
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(myelinopathy) or the myelin producing cell (oligodendrogliopathy)(Tsunoda & 
Fujinami 2002). Damage to the axons is thought to be secondary to the 
damage to myelin and the pathology moves from out (myelin) to in (axons) 
(Outside to In theory) (See Figure 1.6). The damage to the myelin be due to 
cytotoxic T cells and macrophages or toxic substances (cytokines, proteases).  
This however fails to explain the axonal damage seen in normal appearing 
white matter (Bjartmar et al. 2001)and the grey matter damage in the normal 
appearing grey matter(Sharma et al. 2001).  
A contrary theory is the Inside (axon) to Out (myelin) model. This 
suggests that primary injury maybe axonal damage which in turn leads to 
demyelination. Mechanisms proposed include (i) disruption of crosstalk 
between the axon and oligodendrocyte (ii) induction of oligodendrocyte 
apoptosis by activated microglia and macrophages and (iii) triggering of 
autoimmunity by causing injury to the central nervous system. It is suggested 
that (Tsunoda & Fujinami 2002) both these models are not mutually exclusive 
and may act synergistically. In the region of the NAWM, secondary Wallerian 
degeneration contributes to the diffuse changes, however this alone cannot 
explain extent of injury seen (Lassmann et al. 2007). Diffuse axonal injury is at 
least partially independent of the changes in focal white matter lesions.   
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  Figure 1.6 (a)Outside In and (b)Inside Out models of injury  
(From Tsunoda & Fujinami 2002) 
 
  
 
 
54 
The pathogenesis of grey and white matter lesions may differ 
significantly and is still not clearly understood. Unlike white matter lesions, 
CGM lesions have minimal inflammatory changes and occur even in the 
absence of evidence for significant immune mediated damage. (Calabrese et 
al. 2011c; Nelson et al. 2007b; Geurts et al. 2011; Albert et al. 2007a; 
Traboulsee 2006; Calabrese 2007a; Bø et al. 2006b; Popescu et al.  
2011,Vercellino et al. 2005)  
Grey matter lesions 
The mechanisms responsible for grey matter damage are broadly 
categorised as primary (developing inside the grey matter regions) or 
secondary (as a consequence of ongoing damage in the cerebral white 
matter)(Geurts & Barkhof 2008). It is suggested that both primary and 
secondary mechanisms are simultaneously responsible for the demyelination 
and axonal degeneration seen in the grey matter. 
Secondary mechanisms of grey matter damage occur as a 
consequence of inflammatory demyelinating injury to the white matter. An 
abnormal and extensive distribution of sodium channels is noted in acute MS 
lesion following demyelination. These changes in expression of axonal 
sodium channels lead to an  increased ATP demand. In addition, 
mitochondrial abnormalities are present due to being exposed to nitric oxide. 
This results in the mismatch of energy supply and demand, resulting in ‘virtual 
hypoxia’ (Stys 2004; Geurts and Barkhof 2008).  
An increased concentration of metabotropic and ionotropic glutamate 
receptors and transporters is also found in the demyelinated and injured 
axons of the white matter and this glutamate dyshomeostasis has been 
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suggested as another secondary mechanism of grey matter damage. 
Upregulation of anti-apoptotic molecule bcl2 and ciliary neurotrophic growth 
factor signaling pathways is seen in the cortical neurons in MS patients and 
reflects a compensatory reaction to the demyelinating damage in the white 
matter; this can further lead to retrograde degeneration of the axons (Geurts 
and Barkhof 2008).  
Primary mechanisms include (i) meningeal inflammation (ii) antibody 
mediated pathological mechanisms, which can be seen even in a complement 
independent manner (See Figure 1.7). 
Meningeal inflammation (Magliozzi et al.  2007; Magliozzi et al.  2010) 
is noted from early stages of disease and can be both focal (perivascular) or 
diffuse, and is thought to contribute to the cortical demyelination and 
consequently even to the subcortical inflammation and demyelination in the 
white matter (Andersson et al. 1994, Popescu & Lucchinetti 2012a).  
Ectopic B cell follicles have been noted in the leptomeninges of 
patients with MS. These changes follow a gradient in the superficial layers of 
the cortex, suggesting that cytotoxic or myelinotoxic factors from the CSF 
might play a role in the development of CGM lesions. In a cohort of 36 post 
mortem brain samples from progressive patients (29 SPMS; 7PPMS) studied 
by Magliozzi et al. (Magliozzi et al.  2007) ectopic follicles were found in 
41.4% of the SPMS cases but not in PPMS. These follicles were mainly in the 
frontal, temporal and parietal lobes and in the cingulate gyrus and usually 
found in or at the entrance (rarely) of the cerebral sulci. Even in the follicle 
negative SPMS group, subpial demyelination was found to be more localized 
to the depth of the cerebral sulci. (Kutzelnigg & Lassmann 2006). The 
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preferential affection of subpial layers in the sulci led to the hypothesis that 
stagnant CSF mediators play a role in the development of CGM lesions 
(Stadelmann et al. 2008). By studying the distribution of lesions in vivo in 
regions in proximity to the meninges (sulcal pits; subpial lesions) (Serafini et 
al.  2004; Magliozzi et al.  2007; Magliozzi et al.  2010) this hypothesis can be 
tested. 
Figure 1.7 Primary and secondary pathogenic mechanisms of GM 
damage (Adapted from Geurts & Barkhof 2008) 
 
Complement deposition has not been observed in grey matter lesions 
(in contrast to white matter lesions). (Geurts and Barkhof 2008); the only 
exception being complement factor C4d seen in some MS cases. However 
antibody related pathological mechanisms leading to demyelination of cortical 
axons cannot be excluded. It is possible that (i) complement and auto-
antibodies are present but their levels are below the threshold of detection by 
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current immunohistochemical techniques and (ii) antibody related damage is 
possibly even independent of complement (via Fc receptors on microglia, 
monocyte derived macrophages and natural killer cells (Brink BP et al. 2005).  
Cortical regions that consistently show a high degree of metabolic 
activity, are believed to show a preferential degeneration in the context of 
ageing and Alzheimer’s disease (Buckner et al 2005; Geurts et al. 2008). In 
MS a vulnerability of specific cortical regions (Sailer et al. 2003; Wegner et al 
2003) such as the superior temporal gyrus, superior and middle fontal gyri  
has been noted; however factors contributing to this vulnerability remain to be 
clearly understood. Geurts et al (Geurts et al. 2008) suggest that further 
studies should explore if similar to neurodegenerative conditions like 
Alzheimer’s, even in MS, regions of high metabolic activity are selectively 
vulnerable to damage – suggesting a ‘use it and lose it’ principle. 
1.6 MR Physics  
Magnetic resonance imaging (MRI), earlier referred to as nuclear 
magnetic resonance imaging, is a technique that allows in vivo study of the 
human anatomy. It uses the magnetic properties of hydrogen, when subjected 
to an external field and radiofrequency radiation. As part of water and lipids, 
hydrogen ions make up about 75-80% of the human body. A hydrogen 
nucleus contains a single proton. A proton is a charged particle which 
constantly spins around its own axis. As a proton has a mass, a positive 
charge and a spin, it produces a small magnetic field. The directional 
magnetic field in association with charged particles in motion is called 
moment. In the absence of an external magnetic field these spins are 
orientated randomly such that the net magnetic field within a subject or tissue 
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is near zero (McRobbie et al.  2003). 
When subjected to the external magnetic field of the scanner (B0), the 
spins of the hydrogen nuclei align themselves in the direction of B0 so that 
there is a net longitudinal magnetisation vector parallel with B0. When another 
external field is then applied(RF pulse; B1) there is a shift from this 
equilibrium, resulting in a change in the net longitudinal magnetisation, which 
depends on the length and amplitude of B1. The net effect of the RF pulse is 
a flip of the net magnetisation vector, from being parallel to B0, to being 
shifted some angle away from it, creating a transverse component to the 
magenetisation.  
Although the effect of B0 is to align the net magnetisation with it, the 
individual spins precess around B0. This precession causes the magnetic 
moments to follow a circular path, called the precession path, around B0 and 
the frequency of the precession is referred to as the precession frequency 
(Westbrook et al. 2011). The precessional frequency (w0) is determined using 
the Larmor equation and thus also called the Larmor frequency. As per the 
Larmor equation, the Larmor frequency is the product of strength of B0 and 
they gyromagnetic ratio.  The gryomagnetic ratio is an intrinsic property of the 
spin species; for protons, this is ~ 42.6 MHz/T @1T so at 3T would be 
approximately 128MHz. The protons gyrating around the axis (precession) at 
the larmor frequency, in phase with each other, generate a rotating transverse 
magnetic vector.  
Perturbing the magnetisation means that there will be a component of 
it perpendicular to B0. This perpendicular component of the magnetisation is 
measured and the changes as it returns to alignment with B0 is studied. The 
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pattern / nature of the perpendicular component can be changed by changing 
the B1. By altering the change to the net magnetisation that will be generated, 
the imaging sequences can be used to provide information such as the 
contrast between tissues. 
 When the external field is removed, the hydrogen nuclei release 
energy into the surrounding lattice (spin–lattice integration) and the net 
longitudinal magnetisation returns to being parallel with B0; this process is 
referred to as T1 relaxation or recovery. The spins also dephases and this 
depends on i) spin-spin interactions and ii) inhomogeneities in the external 
magnetic field; this process is referred to as T2 decay. The T2 of NAWM and 
a WM lesion at 1.5 T field strength, are ~61 and ~107 respectively; at 7T the 
T2 is ~25 for NAWM and ~55 for white matter lesions. The T1 relaxation and 
T2 decay times depend upon the properties of the individual tissues. When 
the effect of inhomogeneities in the external field are not accounted for, a 
shorter T2 decay is obtained, referred to as T2* decay. To adjust for these 
inhomogeneities spin echo methods are used which use 180 degree pulses 
which reverse the dephasing due to inhomogeneities. For any given tissue, T2 
is always shorter than T1. Another important property of tissues that is utilised 
for generating images, is the PD of a tissue; this refers to the number of 
hydrogen atoms in a particular volume.  
Pulse sequences are of two main types – spin and gradient echo. A 
spin echo uses two RF pulses to create an echo; following the administration 
of the excitatory RF pulse, the signal is refocused by a further RF pulse. The 
time between administration of the excitatory pulse and acquisition of the 
echo (peak of echo) is referred to as the echo time (TE). After the initial 
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excitatory RF pulse, it can be repeated; the time between the two excitatory 
pulses is referred to as the repetition time (TR). While good quality images 
can be created using SE, they are time consuming.  
A gradient echo sequence consists of a pair of bipolar gradient pulses. 
There is no refocusing 180 degree pulse. Data are sampled during a gradient 
echo; this gradient echo is achieved by dephasing the spins with a negatively 
pulsed gradient before they are rephrased by an opposite gradient with 
opposite polarity. 
In order to produce images with predictable contrast between tissues, 
the images are ‘weighted’ preferentially towards T1 / T2 or PD. This is 
achieved by altering the TE, TR and the initial flip angle caused by the 
excitatory pulse (for gradient echo sequences) (McRobbie et al. 2003).When 
both TR and TE are short (TR <750ms and TE < 40ms), a T1w image is 
generated (i.e. the image contrast is governed by differences in the T1 of the 
tissues) and when both are long (TR> 1000ms TE>75ms) a T2w image is 
generated. For PD-weighted image, the TE has to be short and the TR has to 
be long.  
Phase sensitive inversion recovery  
An Inversion recovery (IR) sequence  is a T1w MRI sequence that is 
able to generate a contrast between different tissues based on the differences 
in the T1 relaxation times of various tissues. It  is a variation of the spin echo 
sequence (McRobbie et al. 2003) in which a 180 degree RF pulse is used to 
invert the longitudinal magnetisation prior to the 90 degree excitation pulse. 
The parameters that specify a particular IR sequence are the inversion time 
(TI), repetition time (TR) and the echo time (TE).  
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  IR sequences are often used to suppress fluid and fat.  Variants of 
this sequence are created by either adjusting the imaging parameters or 
adding additional pulses. These include short tau inversion recovery (STIR), 
fluid attenuated inversion recovery (FLAIR), spectral presaturation inversion 
recovery (SPIR) and phase sensitive inversion recovery (PSIR). Inversion 
recovery sequences have also been used for cardiac imaging to detect 
myocardial infarctions; estimation of pulmonary blood flow and perfusion; 
detection of hemorrhage in atherosclerotic plaques etc. 
 
Figure 1.8 Generation of PSIR sequence (From Garach et al.  2004) 
 
 
 The IR image can have values ranging from –M0 to +M0; where M0 is 
the tissue magnetisation at thermal equilibrium. As the image contains 
negative values, the real part of the complex image needs to be reconstructed 
so as to benefit from the complete contrast range. The IR image has 
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information pertaining to both magnitude and polarity, which are stored in the 
magnitude and phase component of the complex image respectively.  
The phase component that stores information regarding polarity is 
referred to as the intrinsic phase. An additional component of phase is the 
background phase, which is due to factors such as errors in acquisition, field 
inhomogeneities and off-resonance phenomenon (McVeigh et al. 1986; 
Garach et al 2004).   
In conventional IR reconstruction, only the magnitude images is used, 
so as to overcome the undesirable effects due to the background phase 
(Garach et al. 2004). In PSIR, in addition to the magnitude, the intrinsic phase 
information is also used, giving the full dynamic range ( -M0 to M0), providing 
a greater T1 contrast (Zhou et al. 2004).  
For purposes of PSIR reconstruction, polarities (intrinsic phase) 
associated with each image pixel needs to be determined. The intrinsic phase 
can be estimated by subtracting the background phase from the total phase. 
To estimate the background phase, multiple acquisitions (with different TI) can 
be used, however this increases chances of errors due to problems with 
registration, motion artefacts etc. An alternative approach is using algorithms 
based on the differing characteristics of intrinsic and background phase 
(Borrello et al. 1990; Garach et al. 2004; Ma et al. 2005).  
A Markov Random field (MRF) model has been successfully used for 
estimating the background phase (Garach et al. 2004). The background 
phase of two neighboring pixels can be determined by comparing the phase 
difference between two adjacent pixels, with and without adding 180 degrees 
to the phase of one of the pixels. A combination that provides the minimum 
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phase difference is selected to be the background phase and the optimum 
combination can be determined by analyzing all possibilities between adjacent 
pixels.  To do so for the whole image is not computationally practical. To 
overcome this two different  approaches are used (i) block merging and (ii) 
region growing. (Garach et al. 2004). 
In block merging ( also called “divide-and-conquer” method), the 
phase map is divided into many 2x2 blocks and each such block is optimized. 
The next step involves combining neighboring blocks into 4x4 blocks, 8 x 8 
blocks, 16x16 blocks etc. until the entire field of view is combined into a single 
block. Each sub-block then differs in phase from the adjacent blocks. Flipping 
the phase within sub-blocks and creation of representative pixels (mean of 
pixels along the row) along each row are additional steps to achieve the best 
possible optimization and background phase can then be estimated. Using 
this information, the PSIR image can the be reconstructed on a pixel by pixel 
basis. This multiple resolution procedure is helpful given the slow varying 
nature of background phase. 
An alternative approach to achieve optimization is the region growing 
method which is helpful in conditions of high variations in the background 
phase (Garach et al. 2004).  This starts from a single point and then 
ascertains the optimal set of parameters along a spiral path; thus starting from 
a small number of pixels and expanding till the entire field of view is covered. 
The four centre pixels of the image are the first to be optimized; following this, 
the ‘region growing’ starts along the top left corner. Following a circular 
trajectory, moving from the top left to the top right corner, and then to the 
bottom right and bottom left corner, returning back to the top left corner. At 
 
 
64 
this point, the process would then move to the top left corner of the next larger 
loop. This method of optimization is specially useful for situations with a low 
SNR image in the presence of high variations in background phase.  
 Over the past few years, another new sequence, double inversion 
recovery (DIR) has been extensively used (Figure 1.9) and has improved 
detection of cortical lesions. In this sequence, the CSF and white matter 
signals are suppressed, leading to improved visualization of the grey matter 
and CGM lesions. 
Figure 1.9: Generation of the Double inversion recovery sequence 
 
       (Adapted from Boulby et al 2004) 
1.7 MRI of MS lesions 
Magnetic resonance imaging (MRI) is a non-invasive method to 
achieve high-resolution images of the brain and spinal cord. It has significantly 
changed the study and management of MS since first being used in the 1970s 
(Compston et al. 2006). 
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Imaging of White Matter in MS 
The ability to readily detect focal white matter abnormalities in patients 
with MS, enabled magnetic resonance imaging to become an important aid in 
the diagnosis and management of this condition. (Filippi et al. 2011).T2-
weighted, Post-contrast T1 weighted and Fluid Attenuated Inversion Recovery 
sequences are the most established conventionally used protocols for 
studying MS. A ‘lesion’ appears hyper-intense on a T2w/FLAIR sequence, the 
histopathological correlate being inflammation or edema/ abnormal 
myelination/ gliosis or axonal loss. (Filippi et al.  2011). On T1w spin echo 
sequences, 20-30% lesions appear hypointense, and are commonly referred 
to as ‘black holes’. The intensity can however be variable, tending towards 
either the lighter GM or the darker CSF; reflecting different degrees of 
pathological severity. While most acute black holes are seen to resolve / 
disappear over a duration of about six months, about 36% persist; these 
persistent black holes represent regions of low myelination (Schmierer et al. 
2004). Acute inflammatory lesions (up to 4 weeks), show enhancement on 
T1w sequences, when contrast agents like GAD are administered. This is 
because of the breakdown of the blood-brain barrier seen in acute lesions. 
Some of these GAD enhancing lesions evolve into being persistent black 
holes. (Filippi et al.  2011; van Waesberghe et al.  1998) 
White matter lesions in MS have been described to have characteristic 
shapes and distributions. Lesions in the brain may be ovoid in shape, and 
commonly seen in the periventricular (including corpus callosum), juxtacortical 
and infratentorial regions. The periventricular lesions tend to be perpendicular 
to the surface of the ventricles commonly referred to as ‘Dawson’s fingers’. 
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Distribution is often variable and asymmetric and the lesion load does not 
correlate with the stage/ severity of disease (Fisniku et al. 2008). Patients with 
PPMS have been noted to have a generally smaller number of brain lesions 
when compared with relapse onset MS. (Lucchinetti et al. 2004). 
 In the spinal cord, lesions may appear cigar shaped on sagittal scans. 
Their width usually encompasses less than half of the diameter of the cord, 
and the length is limited to less than 2 vertebral bodies. A predilection for the 
cervical cord, and for the posterior and lateral columns has been noted across 
phenotypes. Typically, these lesions do not show any mass effect, however 
may do in the acute phase. 
In addition to the lesion load, brain atrophy, quantified using T1w 
images has been another frequently used measure of disease and is found to 
be a better indicator of prognosis (Miller et al. 2002). The atrophy noted in MS 
can be due to destructive processes like demyelination and axonal loss and 
can also be the result of resolution of oedema in acute lesions. The onset of 
neurodegenerative processes may also contribute to this in the later / 
progressive forms of disease. Brain atrophy is increasingly used as an 
endpoint / measure in clinical trials focused on neuroprotection (Barkhof et al. 
2009b).  
Imaging of Grey matter in MS 
 The goals of grey matter imaging research are to quantify the disease 
burden, help in diagnosis, predict disability and guide treatment; together with 
being able to understand the kinetics of disease progression. In addition to 
CGM lesions, grey matter atrophy, diffuse grey matter damage and 
abnormalities in deep grey matter have been reported using MRI (Ceccarelli 
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et al. 2012).  Grey matter atrophy is a sensitive marker for neurodegeneration 
and can be detected even in early disease. MS phenotypes have been 
differentiated based on the distribution of regional grey matter atrophy, which 
has also helped predict the extent of cognitive impairment and symptoms of 
fatigue (Ceccarelli et al. 2008).  
Diffuse abnormalities in grey matter have been shown in studies using 
Diffusion tensor imaging (DTI) (Calabrese et al. 2011c) and Magnetisation 
Transfer Ratio (MTR) (Tur et al.  2011; Davies et al.  2004; Fox et al.  2005). 
Techniques such as susceptibility weighted imaging (SWI) (X. Chen et al. 
2012; Hagemeier et al.  2012; Ropele et al. 2011) have also helped to 
understand the role of iron deposition in MS.  These show changes in early 
phases of disease and can be monitored over time or provide evidence to 
support /refute effects of iron deposition (SWI) and explore whether it might 
be a cause / effect of grey matter lesions. (Stankiewicz et al. 2007; X. Chen et 
al. 2012). Abnormalities in the deep grey matter (Geurts et al. 2008) including 
abnormal metabolite concentrations, T2 hypointensities in the basal ganglia 
and thalamic atrophy and neurodegeneration ( Cifelli et al. 2002) have been 
reported. 
Conventional magnetic resonance imaging (MRI) sequences such as 
T2 weighted sequences and Fluid attenuated inversion recovery (FLAIR), are 
very sensitive for detecting white matter lesions but are less sensitive in 
detecting CGM lesions. CGM lesions are not seen well on conventional T2w 
image because of the prolonged relaxation times of the grey matter which in 
turn results in a poor contrast between the lesional grey matter and the 
surrounding tissue. (Kidd et al. 1999) In comparison to WM lesions, CGM 
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lesions have a higher cellular density with a greater number of neurons and a 
lesser degree of inflammatory infiltrate and this is responsible for the increase 
in relaxation time. Other reasons that make the visualisation of CGM lesions 
difficult include the effects of partial volume due to the CSF. This particularly 
interferes with the detection of subpial pathology which is reported to be about 
60% of the cortical demyelination (Bø et al. 2003b). Imaging of CGM lesions 
is also limited by their small size and the minimal disruption of the blood brain 
barrier (which thus precludes the use of contrast agents like gadolinium to 
help increase identification)(Bø et al. 2009; Seewann et al. 2011).  
 
Other difficulties in the study of CGM lesions include the interference 
of white matter lesions in the development of automatic algorithms to segment 
the grey and white matter (Gandhi & Weiner 2012; Chard et al.  2010; 
Frohman 2006; Trapp et al.  1998). New techniques for overcoming this 
problem are being developed, including methods of lesion-filling which helps 
to minimize errors in the estimation of global and regional grey matter volume. 
(Ceccarelli et al.  2012b; Gelineau-Morel et al.  2011). In addition to CGM 
lesions, grey matter atrophy is a potentially more sensitive indicator of 
neurodegenerative processes; it increases over time and is more resistant to 
changes due to fluid volume fluctuations (Bø et al 2003b; Pirko et al. 2007) 
and imaging techniques that help with this will help improve our understanding 
of disease progression.  
 
While the ability to use stronger field strengths has improved GM 
lesion detection (1.5Tesla, 3Tesla),(Ceccarelli et al. 2012a) newer sequences 
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that allow visualization of different aspects of pathology have further 
enhanced this. DIR is one such sequence. It allows the classification of CGM 
as being intracortical (IC; corresponding to type II and IV) or leucocortical (LC; 
corresponding to Type I). (Geurts, Bø, et al. 2005a; Geurts & Barkhof 2008). 
Subpial (Type III) lesions however are not visualised. As the name suggests, 
DIR allows for a ‘double’ suppression of both CSF and white matter. In 
comparison to FLAIR, DIR has improved the detection of grey matter lesions 
by almost 2.6 times. (Calabrese et al.  2007; Seewann et al.  2012; Calabrese 
et al.  2010c; Rinaldi et al.  2010) Strong correlations have also been found 
between the grey matter lesion load (number and volume) and the markers of 
clinical disability (EDSS) and cognitive impairment tests in some studies 
(Calabrese 2010) and the results need to be reproduced by other centers. 
Consensus recommendations to help identify GM lesions on DIR were 
recently published based on a consensus of raters from six different centres. 
(Geurts 2011) CGM lesions have been shown in patients with early stages of 
disease (clinically isolated syndrome) (Filippi 2010b), and even in pediatric 
patients with MS. (Absinta et al.  2011; Giorgio et al.  2011; Ceccarelli et al.  
2012a)  
The increased use of imaging in the clinical setting today has often led 
to the detection of MRI findings which are suggestive of MS, in patients with 
no symptoms /signs of MS. This condition is referred to as the Radiologically 
isolated syndrome. It is believed that RIS is a pre-clinical / subclinical form of 
MS; with up to 2/3 of patients showing radiological progression and 1/3 
developing clinical evidence of MS. (Giorgio et al.  2011; Granberg et al. 
2012) CGM lesions have been reported even in this subset of patients 
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(Granberg et al. 2012; Giorgio et al. 2011), and the number and distribution of 
CGM lesions could potentially predict the progression to disease in these 
patients. 
However, more recent post-mortem work has suggested that DIR 
identifies only about 18% of the lesions seen prospectively with imaging. 
Histopathological and radiological comparison found that DIR has a high 
specificity but a low sensitivity to CGM lesions (Seewann et al. 2012); even 
after complying with the international consensus recommendations for 
marking lesions.(Gandhi & Weiner 2012; Trapp & Nave 2008; Bø et al. 2003b; 
Geurts et al.  2011) In addition, it has not been possible to classify the lesions 
to mirror histopathological subtypes, being potentially incapable of quantifying 
whether or not subpial lesions that dominate histopathological findings, are in 
fact seen using imaging.(Gandhi & Weiner 2012; Ceccarelli, Bakshi, et al.  
2012a). 
 
Other limitations of DIR include low SNR. The variable intensity of the 
image and the artefacts due to blood flow and partial volume effects of CSF 
further add to its limitations. In an attempt to overcome these problems and 
bridge the histopathological - radiological gap, newer sequences are being 
studied with the goal being to increase in-vivo detection of CGM lesions. 
Phase sensitive inversion recovery is one of the techniques that appears 
promising for improving detection of CGM lesions (Goris 2012; Nelson et al. 
2007a). It has also been suggested that DIR and PSIR be used in 
conjunction(Frohman 2006; Trapp 2008; Crawford 2004; Filippi 2010b; Zang 
et al.  2004; Gandhi & Weiner 2012; Nelson 2007b)  
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1.8 Cognitive impairment in MS 
In patients with MS, the prevalence of cognitive impairment (CI) 
ranges from 40 to 70%. Different aspects of MS pathology ( lesions, NAWM, 
GM atrophy) involving both the cortex and the connecting WM tracts are 
relevant in determining CI (Rao et al. 1991). 
Factors responsible for cognitive impairment in patients with MS 
include: (i) damage to the WM tracts, which is thought to contribute to 
impaired cognitive functions that rely on rapid transfer of information i.e. 
attention, Information processing and Executive function and (ii) abnormalities 
in the cortex such as focal cortical lesions , atrophy and abnormal cortical 
integrity (Jongen et al. 2012).  
The patterns of cognitive impairment seen in MS commonly affect 
domains of attention / processing speed; learning /memory and executive 
function. In addition episodic memory – requiring repetition or recall of serially 
presented verbal or visual information, is also affected in patients with MS 
(Filippi  et al.  2010a; Rao et al. 1991). 
These problems however are rarely picked up as these (i) are rarely a 
presenting symptom; (ii) are not picked up on the brief mental status 
examination done on the bedside; (iii) require assessment of a variety of 
functions to be able to identify dysfunction; (Lezak et al.  2012) and also (iv) 
tend to be overlooked in patients where physical disability is a prominent 
deficit (Rao et al. 1991) 
The association between T2 lesion load and neuropsychology is 
modest, allowing us to believe that following damage to the white matter, 
there is a functional disconnection between cortical and deep grey matter 
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structures. While the cerebral cortex has been recognised as a highly 
organised “seat” of control, the relation between a cortical location of lesions 
and an effect on behaviour / cognition can still not be confidently predicted. 
(Lezak et al.  2012)  
The interpretation of location – behaviour correlations is made difficult 
as the same function can involve different regions of the brain, and in turn 
each cortical location may be responsible for many tasks. At both the 
microscopic cellular levels, and also at the level of macroscopically definable 
cortical zones, there is a large degree of overlap and integration. The 
multitude of neuropsychological assessments are only able to measure the 
final effect on a particular behaviour or function, which may in turn comprise 
multiple tasks that occur in parallel.  
Widely used test batteries used in MS include the (i) Rao Brief 
Repeatable Neuropsychological Battery ( BRNB) (Strober et al. 2009), which 
requires less time and can be translated into many European languages; (ii) 
Minimal Assessment of Cognitive function in MS (MACFIMS) (Dusankove et 
al. 2012),which has a stronger psychometric foundation and includes 
assessment of spatial processing and higher executive function abilities. This 
can consist of either of the Symbol Digit Modalities Test ( SDMT) (Benedict et 
al. 2012) – which takes only 5 minutes to complete and has a slightly better 
ability to predict the diagnosis, disease course and work disability - (or) the 
Paced Auditory Serial Addition Task (PASAT) (Polman and Rudick 2010).  
 Speed dependent tasks and tasks requiring the transfer of information 
across cerebral hemispheres, unmask an impaired processing speed in 
patients with MS. (Archibald & Fisk 2000) This is more obvious with tasks that 
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require auditory verbal stimuli vs. those requiring visual stimuli. (Lezak et al.  
2012). As the extent of disease progresses, the performance in these tasks 
progressively deteriorates and is apparent on less demanding tasks as well. 
(Grant et al.  1984) It is also noted that alternating attention and divided 
attention are often impaired in MS and subtle deficits can be unmasked by 
using tasks that require patients to alternate between stimuli or perform tasks 
simultaneously (Archibald and Fisk 2000).Various tasks are used to 
demonstrate impairment in information processing speed. (Lynch et al.  2010) 
These include word fluency tests, symbol digit tests, the stroop colour word 
interference task and the PASAT. All these are designed so as to require the 
subject to process serial data rapidly, with the usual goal being to complete 
the maximum number of items in a given period of time. Impairment is often 
seen irrespective of disease status in those tasks that require inhibition of 
previously given correct responses. 
PASAT is the only cognitive test that is routinely a part of the MS 
functional composite score (Fischer et al.  1999). A series of 61 single digits 
are presented to the subject as an auditory stimulus, at a fixed rate. The task 
requires the subject to give the sum of each new number, and the one 
preceding it. The typical interval between tasks is 3 seconds. While 
considered to be a gold standard by some, this test has limitations. Often the 
participants skip alternate numbers (skipping strategy) and give a good 
performance. The effects of education, age and practices effects are noted as 
confounders. It is not a popular test among patients who often find this rather 
distressing. The task does not selectively assess processing speed and 
invokes other cognitive processes like working memory, complex attention 
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and mathematical skills. (Lynch et al.  2010). Poor performance on PASAT in 
MS patients is suggestive of slow processing speed rather than problems with 
working memory.  
The tests of cognitive function carried out in this project (Hayling, 
Stroop, immediate and delayed story and figure recall, PASAT and SDMT) 
were chosen based on their frequent use in clinical neuropsychology 
assessments. They form a comprehensive assessments of the domains that 
are known to be affected in people with MS – memory (Story and figure 
recall), information processing (SDMT and PASAT) and executive function 
(Hayling and Stroop). These tests are routinely used to assess cognitive 
function in people with MS within the Queen Square Hospital. An alternative 
approach would have been to use the Brief Repeatable Neuropsycholgical 
Battery, which is also a widely used measure of cognitive function in MS 
studies (Strober et al. 2009, Achiron et al. 2003). However this battery would 
not be as sensitive as the tests I  used. In addition, the tests used e.g. Stroop, 
are also widely used in other neurological conditions, not just MS, so it is 
easier to assess comparable effects (such as damage to specific networks) 
and gain converging evidence from other conditions.  
1.9 Summary 
MS is a neuro-inflammatory condition that affects both the white and 
grey matter. The understanding of grey matter pathology in MS has improved 
in recent times. This is due to improved methods of histopathological 
identification of lesions and improved radiological methods that allow in vivo 
detection of pathology. Conventional MRI using T2-weighted, or FLAIR 
sequences, reveals few CGM lesions, and is considerably less sensitive to 
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detection of CGM lesions. Double inversion recovery sequence is now 
accepted as an improved method of studying cortical pathology. However it is 
limited by artefacts and low signal to noise ratio. A T1w inversion recovery 
sequence has recently been developed, which improves the contrast between 
grey and white matter. This phase sensitive inversion recovery has a higher 
SNR and has the potential to improve the study of cortical pathology. 
Grey matter pathology in the form of demyelinating lesions and 
atrophy is present across all phenotypes of MS and is seen even in early 
stages like in CIS. Recent histopathology studies have demonstrated more 
extensive GM demyelination in people with progressive compared with 
relapsing-remitting (RR) MS, suggesting a potential role in the accrual of 
irreversible disability. In addition, CGM demyelination has been linked with 
meningeal inflammation, providing a plausible mechanism for this to occur 
independently of WM demyelination. However, it is not known how closely GM 
and WM lesion accrual is linked in life, and whether or not the relationship 
differs between RR and progressive forms of MS. This is important, as current 
disease modifying treatments for MS have been proven to reduce WM lesion 
accrual, but it cannot be assumed that they are equally effective against GM 
demyelination, particularly if the two processes are not closely related. 
Addressing this question with histopathological studies is difficult as 
tissue is usually only available from people with early atypical clinical 
presentations or at post mortem (i.e. those with clinically advanced MS) and 
examination of the whole brain is prohibitively time consuming. Similarly, 
addressing this question in vivo with magnetic resonance imaging (MRI) has 
been hampered by very limited GM lesion detection using conventional 
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scanning methods. Using MRI techniques such as double inversion recovery 
and more recently phase sensitive inversion recovery (PSIR), it is now 
possible to do so. 
In this project detection of CGM lesions on DIR was compared with a 
higher resolution (PSIR) sequence, to explore if it can help improve the study 
of CGM lesions. This work investigated the anatomical accuracy of PSIR 
versus DIR in detecting and localising CGM lesions respectively. A 
representative cohort, including patients with RR, PP and SPMS, was 
recruited in this project, together with controls in order to allow a comparison 
of findings with those healthy subjects who do not have MS. I aim to suggest 
possible guidelines for the detection of grey matter lesions using PSIR, 
highlighting the areas of artefacts / false positives. A study of the intra-rater 
and inter-rater reproducibility will help ascertain the ability of this sequence to 
be used across different raters and centres. 
Given the more detailed anatomical visualization on PSIR, I 
hypothesize that PSIR will improve the detection of CGM lesions, both 
quantitatively and qualitatively. Correlations of CGM lesion number and 
volume with cognitive function and physical disability measures has been 
studied using DIR. (Giorgio & De Stefano 2010; Jongen et al. 2012; 
Calabrese et al.  2011a; Calabrese et al.  2009) Cognitive impairment has 
been shown to correlate with CGM lesion load and I expect a similar 
correlation to be seen with lesion load on PSIR. Using the sequence, I 
recorded the distribution of CGM lesions within the cortex and across the 
cortical lobes; and studied the hypothesis that the distribution of lesions 
impacts on the pattern of cognitive impairment seen in patients. Patients with 
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RR and SPMS and some healthy controls, were also invited to take part in a 
follow up arm of this study. The follow up study was undertaken to understand 
how CGM lesions evolve with time.  
In order to investigate the specificity of PSIR-detected CGM lesions, I 
compared the findings of CGM lesion pathology in MS patients with patients 
diagnosed with other conditions that have white matter lesions. By comparing 
these findings with healthy controls and patients with another neurological 
disease (Fabry’s disease) I explored how detection of CGM lesions might help 
in differential diagnosis. Two main questions are the (i) significance of CGM 
lesions – with respect to clinical and cognitive impairment and whether the 
location and distribution of these lesions can aid in differentiating patients with 
MS from other neurological conditions that have white matter lesions. (ii) 
Secondly, from a mechanistic point of view, can the distribution, location and 
evolution of lesions help improve the understanding of the pathogenesis of 
cortical pathology and delineate possible pathogenic mechanisms in the 
evolution of grey matter lesions.  
 In vivo detection of CGM lesions has the potential to improve the 
understanding of pathogenesis and also guide diagnosis and management. 
Histopathological correlations with lesions, their classification using both DIR 
and PSIR and detailed analysis of topographical distribution seen with both 
these scans are future directions in the study of grey matter pathology in MS.  
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2 Improved detection of cortical grey 
matter lesions in MS using phase 
sensitive inversion recovery 
2.1 Abstract 
Objective 
CGM lesions are common in multiple sclerosis (MS), but usually not 
seen on MRI. I compared the performance of double inversion recovery (DIR, 
currently considered the best available imaging sequence for detecting CGM 
lesions) with phase sensitive inversion recovery (PSIR, a sequence allowing 
much higher resolution scans to be obtained in a clinically feasible time).  
Methods 
 Sixty MS patients and 30 healthy controls underwent MRI scanning 
on a 3 Tesla scanner. I compared intracortical (IC) and leucocortical (LC) 
lesion counts obtained with a standard DIR sequence (1x1x3mm resolution, 
obtained in 4 minutes) and a PSIR sequence (0.5x0.5x2mm, 11 minutes). 
Lesions were marked separately on DIR and PSIR scans.  
Results  
In the whole MS cohort, more CGM lesions were seen on the higher 
resolution PSIR than the DIR scans (IC mean±SD: 18.1±9.8 vs. 5.9±4.5, 
p<0.001; LC mean±SD: 13.4±12.9 vs. 7.3±8.0, p<0.001). On PSIR, ≥1 IC 
lesion was seen in 60/60 MS patients and 1/30 controls, and ≥1 LC lesion in 
60/60 patients and 6/30 controls. On DIR, ≥1 IC lesion was seen in 50/60 
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patients and 0/30 controls, and ≥1 LC lesion(s) in 60/60 patients and 5/30 
controls. 
Conclusions 
Compared with DIR, using PSIR I was able to detect a significantly 
greater number of CGM lesions. The presence of at least one IC lesion in 
every MS patient, but very few healthy controls, suggests that it may be a 
useful adjunct to conventional MRI when a diagnosis of MS is suspected but 
not confirmed 
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2.2 Introduction  
Histopathological studies of grey matter pathology (Bo et al. 2001; Bo 
et al 2003a) are limited by the specimens available (mostly progressive 
patients with long duration disease) and by technological limitations (each 
slice of brain examined is not representative of the variability seen across 
brain parenchyma). In vivo detection using imaging has the advantage of 
providing data across all phenotypes of disease, even in patients with short 
duration of disease and can be repeated non-invasively. DIR is currently the 
modality of choice for detection of CGM lesions (Geurts et al. 2011). However 
as demonstrated in histopathology literature, it identifies only a small part of 
the total pathology. There is a need to improve radiological detection of GM 
lesions. PSIR has been developed as a sequence to aid CGM lesion 
detection (Hou et al. 2005). 
The aim of this work is to investigate the use of the phase sensitive 
inversion recovery sequence versus double inversion recovery sequence, 
when used independently. I shall examine the correlations between lesion 
number estimated, using both DIR and PSIR, and scores of clinical and 
cognitive performance. It is hypothesised that grey matter pathology is 
responsible for poor performance on cognitive tests and by studying these 
correlations I will explore this relationship, and also study whether DIR and 
PSIR, help understand the contribution of cortical pathology to cognitive 
impairment.  
Given the improved resolution of PSIR, I hypothesised that there 
would be an improvement of CGM lesion detection in comparison to DIR. If in 
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spite of the improved SNR and grey/white contrast with PSIR, this is not seen, 
this could be possibly because (i) CGM lesions have been over-estimated 
using DIR or (ii) a different subset of lesions is identified using PSIR. Similarly, 
if correlation between cognitive tests and CGM lesion load is not seen, this 
could be due to a differential lesion detection in the two sequences / an 
overestimation of the true lesion load on DIR.  
2.3 Methods 
 
2.3.1 Participants 
A cohort of 60 patients with MS and 30 controls, all in the age group of 
18 to 65 years, were recruited for this study. This included 15 patients each 
with primary and secondary progressive disease(Lublin & Reingold 1996) and 
30 patients with relapsing remitting MS. Informed consent was taken from all 
participants. The study was approved by the local ethics committee. 
2.3.2 Data Collection 
All participants underwent scanning with a 3T Achieva TX system 
(Philips) using a 32 channel head coil. A detailed history and neurological 
examination was also recorded. Expanded disability status scale 
(EDSS(Kurtzke 1983)) was estimated and the Multiple Sclerosis Functional 
Composite(MSFC)(and its components- 9 hole peg test (9HPT), 25 foot timed 
walk 25TWT and PASAT Paced auditory serial addition test) (Polman & 
Rudick 2010) and Symbol Digit Modality Test (SDMT)conducted (Benedict et 
al.  2012) . 
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Table 2.1 Demographics of study participants 
 
MS Subtype N Age in years (mean ±SD, range) Sex M: F 
EDSS 
(median, range) 
Disease duration in years 
(mean±SD, range) 
Number who 
received DMTs 
 
PP 15 51.9±9.1 (34-65) 5:10 6 (1.5-6.5) 12.1±8.0 3 
SP 15 50.9±7.6 (36-64) 7:8 6.5 (4.5-8.5) 23.3±7.3 11 
RR 30 42.5±9.6 (25-64) 10:20 1.75 (1-6.5) 11.5±10.5 23 
All 60 47±9.9  (25-65) 22:60 4.75 (1-8.5) 14.6±10.4 37 
Controls 30 37.8±11.7(22-64) 12:18 - - - 
 
(PP=primary progressive; SP=secondary progressive; RR=relapsing remitting MS; DMD=disease modifying drugs) 
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Table 2.2 Acquisition Parameters 
 
 
 
 Resolution (mm) FOV (mm2) TR (ms) TE (ms) TI (ms) Slices SENSE Time (mins) 
T2 1x1x3 240 x180 3500 19/85 - 50 1.7 4.01 
FLAIR 1x1x3 240 x180 8000 125 2400 50 1.3 3.4 
DIR 1x1x3* 240 x180 16000 9.9 3400/ 325 50 2 4.16 
PSIR 0.5x0.5x2 240 x180 7306 13 400 75 - 11.26 
 
(FOV=field of view, TR=repetition time, TE=echo time, TI=inversion time, SENSE=sensitivity encoding factor. 
 *In one MS patient only, the DIR was acquired at 1x1x2mm) 
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2.3.3 Images Acquired 
 
Conventional images including PD and T2-weighted images were 
acquired, together with FLAIR, DIR and PSIR. The acquisition parameters 
used are given in Table 2.2. The resolution using PSIR was increased about 
six times (Figure 2.1). 
 
Each voxel on DIR (Figure 2.1) had an in-plane resolution of 1mm and 
a slice thickness of 3mm, giving it a voxel size of 3 mm3(Calabrese et al.  
2007; Simon et al. 2010). This was acquired in a scan time of 4.16 minutes. 
On PSIR, the in-plane resolution was 0.5mm, and a slice thickness of 2mm, 
giving it a voxel size of 0.5 mm3 and this was acquired in 11.26 minutes. Thus 
a much higher resolution (6 times) was obtained in a clinically acceptable time 
of eleven minutes.  
 
Image sequences such as 3D DIR have been studied at higher field 
strengths and provide a resolution with a voxel size of 1-2 mm3 (Seewann et 
al.  2012; de Graaf et al.  2012) While it is theoretically possible, to get sub-
millimeter voxels with DIR, this would lead to a prohibitively long scan time. In 
addition to the time taken to get the same resolution as PSIR, if 0.5x0.5x2mm 
scans are acquired using DIR, there will be a 27% loss in the SNR and in 
order to prevent this loss, the scan time would be further increased. The scan 
time is inversely proportional to the square root of SNR and thus the scan 
times would go up about six times. 
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Figure 2.1 Comparison of DIR and PSIR voxel size 
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2.3.4 Image Analysis 
JIM (version 6, Xinapse Systems) was used to mark and annotate 
lesions. Images were marked on DIR and PSIR independently. I marked 
lesions under supervision of two senior raters. I was blinded to the 
demographics of the patient. In order to prevent a bias, enough time was 
ensured between marking of the DIR and PSIR scans to prevent the memory 
of markings from influencing subsequent markings.  
CGM lesions were marked in the cerebral and cerebellar cortex – data 
for supra and infratentorial lesions was recorded separately. For marking 
lesions on DIR, the published recommendations (Geurts et al.  2011) were 
used as a guide: a lesion was considered to be hyper-intense with respect to 
the surrounding cortex. In addition each identified lesion was at least 3 pixels 
in size and could be seen on contiguous slices. Symmetrically located 
hyperintensities were likely to be artefacts. Regions of the insula, temporal 
poles, occipital vertices were identified as artefact prone regions and were 
marked with caution.  
As there were no published guidelines available for marking on PSIR, I 
established a set of rules was in consultation with an expert senior rater 
(Tarek Yousry, Professor of Neuroradiology). These rules are summarised in 
Table 2.3 below.  
Guidelines on marking grey matter lesions on PSIR 
These guidelines apply to lesions to be marked on PSIR images 
acquired using a 3T scanner, with a resolution of 0.5mm x 0.5mm x 2mm. On 
PSIR, a lesion is hypointense with respect to the surrounding cortex, and a 
corresponding hyperintensity on FLAIR and presence of lesion on contiguous 
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slices are features used to confirm lesions. A lesion that involves the CGM, 
even though if mostly in the white matter is considered a CGM lesion. If 
lesions appear to merge into one , they are counted as one lesion. To avoid 
marking false positive lesions PSIR slice is to be reviewed with corresponding 
FLAIR image when in doubt. For posterior fossa lesions, comparison should 
be made with corresponding PDT2 slices. This comparison helps confirm 
lesions and also helps reduce false positives due to vessels, CSF (especially 
in sulci), and artefacts.  
If small or faint, a lesion is to be accepted only if visible on 2 or more 
consecutive slices. Thin and linear hypointensities (more likely to be vessels) 
are to be avoided; some cortical lesions have a linear appearance and should 
be marked carefully using above criteria. Lesions that involved more than one 
slice were counted on the slice where they were most obvious. When marking 
lesions it is also important to keep a constant magnification and contrast 
settings. The insula, temporal poles were identified as regions prone to 
artefacts. VR Spaces may falsely give the impression of being lesions 
especially in the basal ganglia – lentiform nuclei, subcortical white matter of 
the temporal lobes  
Classification of lesions 
CGM lesions were classified based on their involvement of grey and 
white matter. An intracortical lesion is limited to the thickness of the grey 
matter; and is a pure CGM lesion. This could theoretically correspond to 
Types II, III or IV in the histopathological classification described in Chapter 1. 
Lesions that involved the grey matter, but also involved the white matter, were 
classified as mixed i.e. leucocortical lesions, corresponding to Type I in the 
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histopathological classification. Examples of these lesion types are shown in 
the Figure 2.2 and 2.3. The definition of the leucocortical lesion is also clearer 
on PSIR. 
A third type of lesion that could be identified on PSIR included the 
juxtacortical lesion. This is a white matter lesion, abutting but not involving the 
grey matter. It was identified by observing the preservation of the normal 
contour of the cortex and maintenance of the grey-white border. On DIR, 
these lesions could not be separated from the leucocortical lesions. See 
Figure 2.4 
Morphology of Lesions 
 While counting lesions, it was noted that lesions which had a 
curvilinear morphology were increasingly frequent amongst the patients 
group. The number of these lesions was also counted separately. The other 
shapes noted included oval and wedge shaped lesions. All these shapes have 
been described in earlier work using DIR. An example of a curvilinear shaped 
lesion is shown in corresponding PSIR and DIR images is shown in Figure 2.5 
Artefacts 
As on DIR, artefacts could be seen on PSIR. However these were 
fewer compared to DIR. These included Virchow Robin spaces, especially in 
the region of the insula and the temporal poles. As shown in the figure 2.6, 
these are perivascular spaces but as they appear as hypointensities on PSIR, 
they could be mistaken for lesions. Furthermore they do not have a consistent 
appearance on FLAIR and this can thus not be used to help identify these as 
artefacts. 
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Table 2.3: Rules for marking cortical grey matter lesions on PSIR 
 !
Inclusion! Lesions are hypointense relative to surrounding normal cortex!
They must involve the cortex in part or whole!
a.  A lesion confined to the cortex is called Intracortical (IC) !
b.  A lesion that involves both cortex and juxtacortical white matter 
is called leucocortical (LC) (See Figure 2.2,Examples of IC (top 
right ) and LC (below left ) lesions  
 
Figure 2.3,Figure 2.4) 
Caution! If small or ill-defined on a single slice, they must be visible on at 
least one other contiguous slice!
Equivocal lesions must be confirmed by retrospective detection of 
signal abnormality compatible with a lesion at the same location 
on the corresponding T2-weighted and/or FLAIR images!
Exclusion! Adjacent cerebrospinal fluid (partial volume effect), determined 
after reviewing adjacent PSIR slices and corresponding T2-
weighted and FLAIR scans; especially likely in sulcal regions, at 
the temporal poles and near the vertex!
Artefacts, sometimes recognized by their symmetrical appearance 
(as also seen in DIR images)!
Vessels, which form very thin linear hypo-intensities, especially 
those that do not follow the direction of the cortical ribbon (cortical 
lesions may have a curvilinear or linear appearance, but they are 
less thin and invariably follow the direction of the cortical ribbon 
(See Figure 2.7)!
Virchow-Robin spaces, which are prone to manifest in certain 
cortical regions (in particular the insula and temporal poles), 
especially if linear and multiple, forming mesh-like or bundle-like 
appearances (these were seen in patients and controls (See 
Figure 2.6). !
  
  
90 
 
Figure 2.2 : Examples of types of CGM lesions 
 
Examples of IC (top right ) and LC (below left ) lesions  
 
Figure 2.3 Comparative DIR and PSIR images  
 
Examples of IC and LC lesions as seen on DIR and PSIR 
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Figure 2.4 Example of a juxtacortical lesion  
 
 
 Note : Appears LC on DIR, but can be seen to be limited to WM on PSIR 
 
Figure 2.5 Curvilinear morphology of lesion shown on DIR and PSIR 
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 It was however noted, that unlike lesions, which seem to be uniformly 
hypointense, Virchow-Robin spaces had a mesh like appearance; this feature 
could sometimes be used to help identify them. An example is shown in 
Figure 2.6 Another common artefact seen on PSIR, included blood vessels 
(Figure 2.7) These also appear as linear hypointensities and thus can be 
mistaken to be a lesion. Looking at contiguous slices helps: a blood vessel will 
tend to travel with the slices, unlike a lesion, which would tend to remain 
localized to the same spot.  
Lesion Counting 
CGM lesion numbers for all different lesion types were counted 
separately. This included intracortical and leucocortical lesions on both DIR 
and PSIR. In addition juxtacortical lesions were counted on PSIR, but could 
not be counted on DIR. To assess non-juxtacortical white matter lesion loads, 
these were counted on PSIR and PD/T2 scans. 
To assess inter-rater reproducibility of marking lesions on PSIR, 10 
randomly selected scans were evaluated independently by three raters (Varun 
Sethi, Nils Muhlert and Declan Chard) using the guidelines described above. 
To assess intra-rater reproducibility, the scans of these 10 patients were 
marked three times by me. To assess the contrast-to-noise ratio between grey 
matter and white matter, 10 healthy controls were randomly selected. In each 
control, 12 regions of interest (ROI) were placed on three separate slices, in 
regions of normal-appearing CGM (at the level of vertex, insula and temporal 
poles) and neighbouring normal-appearing white matter. The ROI size was 
chosen to be large enough to sample grey matter signal, but small enough to 
be fully contained in the grey matter in each subject. The ROIs were placed in 
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the same location for each control on DIR and PSIR images. Mean absolute 
signal values were noted, and the relative contrast between grey matter and 
white matter on both sequences was calculated using the formula below, as 
described by Mainero et al. (Cgm-wm = Sgm_Swm/Vgm ; where Cgm-wm is the 
contrast between the grey matter and white matter; Sgm is the mean signal for 
the ROI placed in the grey matter; Swm is mean signal for the ROI placed in 
the white matter; and Vgm is the variance in the signal intensity of the grey 
matter ROIs ). 
 
Statistical Methods 
Lesion distribution was tested for normality using a Kolmogorov 
Smirnov test. As the distribution of lesions was not found to be normal, 
nonparametric tests were used for further analysis. Wilcoxon signed-rank 
tests were used to compare PSIR and DIR lesion counts in the MS cohort, 
and Spearman’s rank correlation coefficients were used to determine their 
association with clinical and cognitive variables. Differences in lesion counts 
between MS clinical subgroups were investigated with a Mann-Whitney test. 
SPSS (version 20) was used to perform the statistical analysis, and p<0.05 
was considered significant. Intra-class correlation coefficient (ICC) was 
calculated for both intra-rater and inter-rater PSIR lesion counts.  
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Figure 2.6 Virchow-Robin spaces 
 
  
Arrows indicate the VR spaces as seen in a healthy control and in a patient 
with MS 
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Figure 2.7 Blood vessels – a common artefact 
 
 
 
Sequential slices (note white arrow) showing how the linear hypointensity 
travels forward with very successive slice, indicating it’s a blood vessel and 
not a lesion. The effect of partial volume, due to CSF is a commonly known 
artefact and is seen especially in the regions of the vertex. 
 
96 
 
2.4 Results  
Demographic and clinical details are provided in Table 2.1 Relapsing 
remitting MS patients did not differ significantly in age from the controls, but 
both, the secondary and primary progressive MS patients, were significantly 
older. Patients with secondary progressive MS had a longer duration of illness 
than both, relapsing remitting and primary progressive MS (both p<0.001). 
Those with relapsing remitting MS had lower Expanded Disability Status 
Scale scores than either progressive groups (both primary and secondary 
progressive, p<0.001).The number of different types of lesions, across the 
different subtypes and controls are detailed in Table 2.4. The infratentorial 
lesions were counted separately and are recorded in Table 2.5. Control data 
is recorded in Table 2.6 and 2.7. 
The higher-resolution PSIR identified about three times more IC 
lesions than the lower-resolution DIR in the whole MS cohort (p<0.001; Table 
2.4). PSIR also identified more LC lesions than DIR (p<0.001); this increase 
was also approximately threefold when JC and LC lesions from PSIR were 
counted together. It was not possible to separate JC and LC lesions using 
DIR. PSIR IC lesion count correlated with DIR IC counts (rs=0.604, p<0.001), 
and PSIR LC with DIR LC (rs=0.651, p<0.001). In the cerebellum, using DIR, 
JC lesions could not be separated from the LC lesions. In contrast to the 
above findings (higher number of CGM lesions detected using PSIR than DIR) 
a higher number of lesions involving cerebellar cortex are detected using DIR. 
(DIR CGM> PSIR CGM; p<0.05) SP has the highest number of lesions across 
all lesion subtypes. SP has more lesions than PP (DIR p=0.15 ; PSIR p=0.05) 
and RR (DIR p=0.02 ; PSIR p=0.02)(See Table 2.5). 
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On PSIR, >=1 IC lesion(s) were seen in 60/60 MS patients and 1/30 
controls, and >=1 LC lesion(s) in 60/60 patients and 6/30 controls. On DIR, 
>=1 IC lesion(s) were seen in 50/60 patients and 0/30 controls, and >=1 LC 
lesion(s) in 60/60 patients and 5/ 30 controls. Curvilinear cortical lesions that 
followed the contour of gyral and sulcal folds were seen in 36% patients using 
DIR, and 85% patients using PSIR . Such lesions were not seen in the healthy 
control group. (See Table 2.6 and Table 2.7) 
 
On PSIR, relapsing remitting and secondary progressive MS patients 
had similar IC lesion counts, but primary progressive MS patients had 
significantly lower counts in comparison with both, relapsing remitting 
(p=0.023) and secondary progressive (p=0.029) patients. Secondary 
progressive MS patients also had significantly higher LC lesion counts than 
primary progressive (p=0.023) and relapsing remitting (p1=0.008) patients 
(See Table 2.4) On DIR, relapsing remitting and secondary progressive MS 
patients had similar IC lesion counts; primary progressive MS patients had 
significantly lower IC lesion counts than relapsing remitting patients (p=0.015). 
Secondary progressive MS patients also had significantly higher LC lesion 
counts than relapsing remitting (p=0.003) patients. 
 
All MS patients had white matter lesions on their T2 and PSIR scans, 
with a similar overall mean WM lesion count (See Table 2.4) and there was a 
close correlation between the two measures (rs=0.965, p<0.001). T2 lesion 
count also correlated with DIR LC (rs1=0.558, p<0.001) and PSIR IC and LC 
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(rs=0.331, p<0.05 and rs=0.0647, p<0.001) lesion counts. There was no 
correlation of CGM lesion counts with disease duration. 
 
Correlations between clinical measures and CGM lesions counts were 
limited to the relapse-onset (i.e., combined relapsing remitting and secondary 
progressive) MS cohort (See Table 2.8). Due to the number of p values 
reported in this analysis, caution must be taken in assessing significance due 
to the danger of Type 1 error. A bonferroni correction for the number of tests 
presented in Table 2.8, suggests that the threshold of significance of 0.003 
should be required to maintain an overall Type 1 error of 5%. Using this most 
consistent results are noted when considering the relapse onset group as a 
whole; the most consistent correlations were between the DIR IC lesion 
counts and 9-Hole Peg Test (rs=0.436, p=0.003) and PSIR LC counts with the 
Symbol Digit Modality Test (rs=-0.440, p=0.003) (See Table 2.8). None of the 
six controls with CGM lesion(s) on PSIR had cognitive abnormalities.  
 
 
The ICC for inter-rater variability for total CGM lesion counts (IC and 
LC) was 0.955 (p<0.001), and for intra-rater variability it was 0.995 (p<0.001). 
For IC and LC lesions separately, the ICC for inter-rater variability was 0.681 
(p<0.05) for IC and 0.955 (p<0.001) for LC counts, respectively. Intra-rater 
ICC was 0.990 and 0.984 for IC and LC lesions (both p<0.001) (See Table 
2.9a and Table 2.9b).There was a significantly higher grey matter minus white 
matter contrast (Cgm-wm) on PSIR than DIR images (mean=1.48, SD=0.71 
versus mean=0.05, SD= 0.03; p<0.05 paired sample t-test). 
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Table 2.4 CGM and WM lesion counts across study participants  
MS Sub-
type 
DIR PSIR PD/T2 
IC LC IC LC JC WM WM 
PP (n=15) 3.7 ±4.6 
6.1 
±4.8 
12.3 
±8.8 
11.6 
±12.7 
6.1 
±5.5 
50.4 
±31.7 
48.3 
±27.6 
SP (n=15) 6.5 ±5.3 
12.2 
±9.6 
21.3 
±10.0 
20.8 
±13.6 
11.1 
±11.2 
80.5 
±40.7 
72.9  
±33 
RR 6.6 
±3.9 
5.5 
±7.6 
19.5 
±9.2 
10.5 
±11.4 
5.8 
±6.8 
63.4 
±57.2 
61.2 
±51.2 (n=30) 
All (n=60) 5.9 ±4.5 
7.3 
±8.0 
18.1 
±9.8 
13.4 
±12.9 
7.1  
±8.1 
64.5 
±48.5 
60.9 
±42.5 
IC –Intracortical , LC –leucocortical, JC –Juxtacortical, WM –white matter , PP 
– Primary progressive, SP – secondary progressive, RR –relapsing remitting 
MS. All numbers below represent mean ± standard deviation. 
 
 
Table 2.5 Cerebellar CGM lesion counts on DIR and PSIR ! DIR PSIR ! IC LC Total IC LC JC Total 
PP 0.3±1.0 1.8±3.2 2.1±3.7 0.3±0.4 1±1.2 0.1±0.4 1.4 ± 1.7 
SP 1.6±1.6 2.7±2.2 4.3±3.5 0.9±1.1 2.3±1.8 0.1±0.3 3.2±2.5 
RR 0.9± 1.3 1.5± 2.1 2.3±3.2 0.3±0.5 1.2±1.5 0±0 1.5±1.9 
Total 0.9±1.3 1.8±2.5 2.8±3.4 0.5±0.7 1.4±11.6 0.1±0.2 1.9±2.1 
IC –Intracortical , LC –leucocortical, JC –Juxtacortical, WM –white matter , PP 
– Primary progressive, SP – secondary progressive, RR –relapsing remitting 
MS. All numbers below represent mean ± standard deviation 
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Table 2.6 Control Data  
 
 
DIR PSIR 
≥ 1 IC ≥ 1 LC ≥ 1 IC ≥ 1 LC 
Patients n=60 50 60 60 60 
Controls n=30 0 5 1 6 
( Above figures represent the number of people with >= 1 IC or LC lesion) 
 
 
 
 
 
 
 
Table 2.7Frequency of curvilinear shaped lesions  
 Patients Controls 
DIR 36% 0 % 
PSIR 85% 0 % 
 
. 
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Table 2.8 Correlations between lesion loads and clinical measures. 
   
RR SP RR and SP PP 
IC LC JC WM IC LC JC WM IC LC JC WM IC LC JC WM 
EDSS 
DIR r
2 
p 
0.213, 
0.259 
-0.173, 
0.362,   
-0.041, 
0.881 
-0.515, 
0.049   
0.039, 
0.802 
0.171, 
0.261   
-0.354, 
0.195 
-0.261, 
0.347   
PSIR 
r2 
p  0.013, 0.947 
0.142, 
0.454 
0.051, 
0.789 
0.181, 
0.338 
-0.114, 
0.685 
-0.451, 
0.091 
-0.291, 
0.293 
-0.511, 
0.051 
0.033, 
0.829 
0.300, 
0.045 
0.218, 
0.150 
0.212, 
0.161 
-0.378, 
0.165 
-0.205, 
0.464 
-0.075, 
0.791 
0.170, 
0.544 
MSFC 
DIR 
r2 
p  0.282, 0.131 
-0.097, 
0.611   
0.285, 
0.302 
-0.039, 
0.889   
0.246, 
0.104 
0.229, 
0.131   
-0.066, 
0.816 
-0.364, 
0.182   
PSIR 
r2 
p  -0.281, 0.132 
0.094, 
0.621 
0.252, 
0.179 
0.007, 
0.969 
0.088, 
0.755 
-0.014, 
0.960 
-0.346, 
0.206 
-0.309, 
0.262 
-0.068, 
0.659 
0.265, 
0.079 
0.225, 
0.138 
0.026, 
0.868 
-0.266, 
0.337 
-0.041, 
0.884 
-0.295, 
0.286 
0.179, 
0.524 
25TWT 
DIR 
r2 
p  -0.097, 0.611 
-0.239, 
0.203   
0.137, 
0.626 
-0.062, 
0.826   
-0.013, 
0.931 
0.199, 
0.190   
-0.217, 
0.438 
-0.447, 
0.095   
PSIR 
r2 
p -0.286, 0.126 
-0.150, 
0.427 
-0.142, 
0.456 
-0.035, 
0.854 
!0.031,'
0.913'
0.037, 
0.897 
-0.201, 
0.473 
-0.217, 
0.438 
-0.124, 
0.417 
0.095, 
0.536 
0.028, 
0.854 
0.035, 
0.820 
-0.334, 
0.224 
-0.148, 
0.598 
-0.182, 
0.517 
0.369, 
0.175 
9HPT 
DIR 
r2 
p  0.393, 0.032 
-0.027, 
0.889   
0.546, 
0.035 
-0.056, 
0.844   
0.436, 
0.003 
0.075, 
0.625   
-0.101, 
0.721 
0.038, 
0.893   
PSIR 
r2 
p  0.111, 0.557 
0.403, 
0.027 
0.183, 
0.333 
0.067, 
0.724 
0.458, 
0.086 
-0.032, 
0.909 
-0.307, 
0.266 
-0.379, 
0.163 
0.239, 
0.114 
0.211, 
0.163 
0.045, 
0.770 
-0.064, 
0.676 
-0.238, 
0.394 
0.291, 
0.293 
-0.113, 
0.689 
0.386, 
0.155 
PASAT 
DIR 
r2 
p  0.107, 0.575 
-0.115, 
0.547   
-0.162, 
0.563 
0.058, 
0.830   
0.009, 
0.953 
-0.057, 
0.710   
0.099, 
0.726 
-0.224, 
0.421   
PSIR 
r2 
p  -0.371, 0.044 
-0.068, 
0.723 
0.132, 
0.487 
-0.064, 
0.737 
-0.269, 
0.333 
-0.022, 
0.939 
-0.116, 
0.680 
-0.149, 
0.596 
-0.362, 
0.015 
-0.059, 
0.700 
0.039, 
0.801 
-0.106, 
0.489 
-0.050, 
0.861 
-0.166, 
0.555 
-0.520, 
0.047 
-0412, 
0.127 
SDMT 
DIR 
r2 
p  -0.274, 0.142 
-0.244, 
0.194   
-0.227, 
0.455 
0.069, 
0.822   
-0.228, 
0.142 
-0.278, 
0.071   
-0.042, 
0.882 
-0.071, 
0.802   
PSIR 
r2 
p  -0.332, 0.073 
-0.449, 
0.013 
-0.095, 
0.616 
-0.276, 
0.140 
-0.412, 
0.162 
-0.047, 
0.878 
-0.095, 
0.759 
-0.022, 
0.943 
-0.365, 
0.016 
-0.440, 
0.003 
-0.221, 
0.155 
-0.312, 
0.042 
-0.052, 
0.853 
-0.332, 
0.226 
-0.365, 
0.181 
-0.516, 
0.049 
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Table 2.9 Calculation of Inter-user (a) and Intra-user (b) variability 
SNo. 
 
User 1 User 2 User 3 
(A
) I
nt
er
-U
se
r V
ar
ia
bi
lit
y 
 
IC LC IC+LC IC LC IC+LC IC LC IC+LC 
1 33 113 146 6 85 91 37 61 98 
2 22 67 89 2 61 63 22 18 40 
3 15 47 62 26 24 50 64 10 74 
4 14 74 88 9 46 55 8 62 70 
5 1 11 12 0 4 4 5 1 6 
6 1 12 13 1 3 4 12 5 17 
7 3 28 31 2 11 13 8 7 15 
8 20 175 195 5 103 108 28 94 112 
9 0 4 4 1 1 2 2 2 4 
10 21 51 72 4 33 37 19 20 39 
SNo. Trial 1 Trial 2 Trial 3 
(B
) I
nt
ra
 U
se
r V
ar
ia
bi
lit
y 
 
IC LC IC+LC IC LC IC+LC IC LC IC+LC 
1 41 71 112 37 61 98 37 78 115 
2 36 12 48 22 18 40 24 24 48 
3 62 19 81 64 10 74 59 21 80 
4 14 54 68 8 62 70 12 44 66 
5 5 0 5 5 1 6 4 1 5 
6 18 4 22 12 5 17 11 9 20 
7 14 8 22 8 7 15 11 14 25 
8 24 75 99 28 94 112 26 78 104 
9 2 1 3 2 2 4 2 2 4 
10 15# 30# 45# 19 20 39 16 35  51 
Above table indicates raw data for CGM lesions across 10 
participants. Table 2.9a – data for three separate users; 2.9 b – data for same 
user (myself), recorded three times. 
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2.5 Discussion 
The aim of this work was to compare PSIR with DIR as a sequence to 
detect CGM lesions and to study correlations of lesion number with clinical 
and cognitive measures of disability. These data suggest that PSIR does 
indeed improve the detections of CGM lesions by about 3x. This was true for 
both intracortical and leucocortical lesions. In the cerebellum however, the 
number of CGM lesions detected was greater using DIR than PSIR. As 
expected by studies of natural history, (Ebers & Daumer 2008; Scalfari et al.  
2010; Weinshenker et al.  1989) patients with secondary progressive disease 
had a significantly longer duration than either primary progressive / relapsing 
remitting and the patients with progressive disease were older than the 
controls and RRMS patients(Table 2.1). 
As mentioned, secondary progressive patients had the highest lesion 
load and this was expected. Interestingly while the number of intracortical 
lesions in secondary progressive and relapsing remitting patients was similar, 
the number of leucocortical lesions in secondary progressive patients was 
almost double that of RR. This is interesting as it suggests either that 1) 
leucocortical lesions continue to accrue with time or that 2) intracortical 
lesions keep accruing, but also evolve into leucocortical lesions. This would 
need to be verified using longitudinal studies but this could help understand 
whether the primary pathology is in the white or grey matter.  
All patients had at least one intracortical lesion but this was seen only 
in one control with PSIR. This contrasting finding suggests that intracortical 
lesions may be specific for MS patients. DIR also identified these intracortical 
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lesions but given that this was true only of 50/60 patients as compared to 
60/60 for PSIR, it suggests that PSIR is probably more sensitive in identifying 
them. None of the controls had an intracortical lesion on DIR, and this was in 
accordance with other reports. (Roosendaal et al. 2009; Ciccarelli 2012) 
The occurrence of the curvilinear shape also seems to be 
characteristic for patients with MS. Earlier work by Calabrese et al. has shown 
the frequency of these lesions to be about 25%(Calabrese et al. 2007); my 
findings were similar at 36% on DIR. The identification of a curvilinear 
morphology on PSIR, together with the identification of an intracortical lesion 
in a patient, may help in the differential diagnosis of MS when suspected, but 
not confirmed.  
Given that at least 11 of the patients had a disease duration of < 5 
years, this suggests that intracortical lesions are seen very early in the 
disease and could perhaps help to categorise and prognosticate patients with 
clinically isolated syndromes. A recent study of biopsy specimens has also 
suggested a high frequency of demyelinating CGM lesions in patients 
subsequently confirmed to have MS. (Lucchinetti et al.  2011) 
Correlations between white matter count on PSIR and PDT2 suggest 
that PSIR might effectively replace the latter for the purposes of estimating 
white matter lesion load. Thus, in addition to being a high resolution sequence 
at a clinically acceptable time, it is effectively giving information about both 
grey matter and white matter. This is in effect replacing DIR (for grey matter) 
and FLAIR (for white matter).  
Histopathological studies have shown subpial lesions as being the 
most dominant type. On PSIR, while pure intracortical lesions were identified, 
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these were limited to the deeper layers of the cortex / seemed to involve the 
entire thickness of the cortex. Pure subpial lesions were not seen. This could 
be possibly due to (i) very small size and low contrast of subpial lesions or (ii) 
Perhaps the subpial lesions are being counted as intracortical lesions. Future 
imaging work that allows us to segment the cortex and see the exact layers of 
the cortex that are affected in a lesion, may allow us to separate the subpial 
lesions from the intracortical lesions.  
 
On looking at correlations between the CGM lesion counts and the 
clinical measures, lesion counts on DIR correlated with the 9HPT, which is a 
test of motor function. LPM (mapping (Calabrese et al.  2010a) work done 
using DIR noted that the CGM lesions were largely localised to the region of 
the frontotemporal lobes; particularly in the motor regions. This may explain 
the correlations of CGM lesion counts with tasks of motor function such as the 
9HPT.  PSIR detected CGM lesion counts on the other hand, correlated with 
SDMT, which is a test of cognitive dysfunction. It is  possible that  PSIR is 
sensitive for CGM lesion detection in other regions and that different regions 
are preferentially identified by these two techniques. A better understanding of 
these findings may emerge when regional lesion counts are compared for 
PSIR and DIR sequences. To understand this further, similar work would 
need to be done on PSIR. In addition, the counts of lesions in different lobes 
may have better correlations with specific cognitive tests and this needs to be 
explored in future. 
In patients with primary progressive MS, CGM lesion counts were 
smaller than in those with relapse onset MS. This is similar to findings on T2 
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white matter lesion counts. Only 15 primary progressive patients were part of 
this cohort and a larger cohort should be studied to understand the implication 
of this observation. 
Why did I choose to compare PSIR with 2D DIR? There are other 
sequences including 3D MPRAGE and 3D DIR which give useful information. 
Because DIR has been recently accepted as a modality that helps increase 
GM lesion detection, I used a sequence with different resolution and contrast 
mechanisms for this comparison. However as has been highlighted in other 
work, different scans maybe more sensitive at picking up different aspects of 
the pathology of the disease and perhaps the combined use of different 
sequences will help us understand and identify pathology better.  
As shown in Figure 2.1, an increased resolution of six times (from a 
voxel size of 3 mm3 on DIR to 0.5mm3 on PSIR) is achieved. While other 
techniques like using multislab scanning with DIR, 3D DIR etc. may help in 
the future; resolution/unit time achieved with PSIR remains a strong 
qualitative advantage of PSIR. As scan times increase, problems such as 
motion artefacts do also tend to increase, especially in a cohort of patients 
with progressive disease. It also needs to be remembered that PSIR (in 11 
minutes) provides information about grey matter (DIR 4 minutes) and white 
matter (FLAIR 7 minutes). Thus in a similar amount of scan time, it will be 
possible to use just one sequence to give us information about both grey and 
white matter.  
In an attempt to bridge the gap between detection of grey matter 
lesions seen histopathologically and on imaging, PSIR shows potential to aid 
this measure. On comparison with the current gold standard, DIR, there is a 
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significant increase in the quantity and quality of detection of lesions using 
PSIR.  
While earlier work with DIR has shown correlations between lesion 
volume an cognitive measures, this needs to be reproduced with PSIR to 
establish if cognitive impairments can in fact be predicted by the number and 
distribution of CGM lesions.  
As mentioned, this cohort included some patients who were on 
disease modifying drugs. Do these drugs affect the number / evolution of 
lesions? Can the distribution of lesions be used to ascertain the point of 
starting / stopping treatment? These answers require long-term follow up of 
these patients, with serial scans and analysis models that account for the 
specific disease modifying therapy.  
By studying patients longitudinally, PSIR has the potential to study the 
evolution of lesions. In an interesting observation, the contrasting finding 
between patients and controls, suggest that the detection of an intracortical 
lesion and a curvilinear morphology, may have a role to aid in the differential 
diagnosis of patients with MS, when a diagnosis is suspected but not 
confirmed. Should histopathological correlation of PSIR findings be achieved, 
this would be a possible strong argument to include detection of GM lesions 
as one of the criteria considered in the diagnosis of this neuroinflammatory 
condition.  
Using post mortem verification, the sensitivity of DIR to detect CGM 
lesions has been reported to be 18%, as compared to almost ~9% with 
FLAIR. (Seewann et al. 2012) Given that PSIR improved detection by almost 
three fold, the sensitivity of PSIR can be predicted to be around 50%. 
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Retrospective comparisons had improved the sensitivity from 18% to 37% in 
the study done by Seewan et. al. Based on the above analysis, the combined 
analysis of DIR and PSIR, could likely further improve the sensitivity to detect 
CGM lesions.  
The greater number of cerebellar CGM lesions being detected on DIR, 
suggest differences in the sensitivity of both sequences, when comparing 
supra-tentorial vs. infratentorial regions (Gilmore et al. 2009). There are 
various reasons why this maybe possible. From an anatomical point of view, 
the structure of the cerebellar cortex is less compact in comparison to the 
cerebral cortex. Flow artefacts due to the vicinity to blood vessels and motion 
artefacts are other factors that possibly contribute to the low CGM detection 
on PSIR. Conventional MRI scans are also noted to demonstrate differences 
in sensitivity for different regions of the brain. For the study of lesions in deep 
grey matter and the posterior fossa, PD/T2 is preferred in comparison to 
FLAIR. The difference in T1 contrast for different tissues may contribute to 
this difference, and also to the above reported difference in PSIR/DIR for the 
study of CGM lesions. The different degree of demyelination noted between 
the cerebellar and the cerebral cortex are also likely to affect the use of 
different sequences. Lastly, most brain protocols are optimised using the brain 
(cerebral cortex) as the centre, not the cerebellum; and this together with 
above features might contribute to the difference reported above.  
These results suggest that with the use of PSIR, the detection of CGM 
lesions is improved by about 3x as compared to DIR. In addition, the 
improved resolution allows more confident classification of lesions, allowing 
the separation of JC lesions separate from the LC lesions. Like with double 
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inversion recovery, post mortem verification of CGM lesions will truly help 
understand the sensitivity and specificity for detection of CGM lesions using 
PSIR.  
Refining the guidelines for lesion identification using PSIR will help 
minimize the number of lesions missed. However in order to improve the 
sensitivity and specificity of these guidelines, similar analysis should be 
reproduced across centres and a consensus reached over regions more /less 
likely to be ‘lesional’. A retrospective PSIR to DIR analysis would not provide 
any additional information and is limited by the extent of lesions seen on 
PSIR.  
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3  Comparison of classification of 
lesions from DIR to PSIR 
3.1 Abstract 
Objective 
Accurate identification and localization of CGM lesions in MS is 
important when determining their clinical relevance. Double inversion recovery 
(DIR) scans have been widely used to detect MS CGM lesions. Phase 
sensitive inversion recovery (PSIR) scans have a higher signal to noise, and 
can therefore be obtained at a higher resolution within clinically acceptable 
times. This enables detection of more CGM lesions depicting a clearer cortical 
and juxtacortical anatomy. In this study, I systematically investigated if the use 
of high resolution PSIR scans changes the classification of CGM lesions, 
when compared with standard resolution DIR scans.  
Methods:  
60 patients (30 RR(Relapsing remitting) and 15 each with PP(Primary 
progressive) and SP(Secondary progressive) MS) were scanned on a 3T 
Philips Achieva MRI scanner. Images acquired included DIR (1x1x3mm 
resolution) and PSIR (0.5x0.5x2mm). CGM lesions were detected and 
classified on DIR as intracortical (IC) or leucocortical (LC). I then examined 
these lesions on corresponding slices of the high resolution PSIR scans and 
categorized them as IC, LC, Juxtacortical white matter (JC-WM, abutting but 
not entering cortex) and other white matter (WM, not 
juxtacortical).Classifications using both scans were noted. 
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Results: 
 282 IC and 483 LC were identified on DIR. Of the IC lesions, 61% 
were confirmed as IC on PSIR, 35.5% were reclassified as LC and 3.5% as 
JC-WM or other WM only. Of the LC DIR lesions, 43.9% were confirmed at 
LC on PSIR, 16.1% were reclassified as IC and 40% as JC-WM or other WM 
only. Overall, 50% (381/765) of CGM lesions seen on DIR were reclassified, 
and 26.5% (203/765) affected WM only. 
Conclusions:  
When compared with higher resolution PSIR, a significant proportion 
of lesions classified as involving CGM on DIR appear to either contain more 
white matter than expected or to not involve CGM at all. 
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3.2 Introduction  
 Double inversion recovery (DIR) (Seewann et al. 2012; Calabrese, et 
al. 2010a; Geurts et al.  2005b) has been most extensively used to study 
CGM lesions in vivo, and it has been shown that accrual of CGM lesions 
relates to disability in established MS (Calabrese et al. 2010a; Geurts et al. 
2005b) and their presence may also improve the specificity of current MS MRI 
diagnostic criteria (Chapter 2) (Filippi et al. 2010b). 
MS CGM lesions have been histopathologically sub-classified based 
on (1) location i.e. relative to GM/CSF and GM/WM boundary and (2) 
morphology. Based on their location they have been sub-classified as abutting 
the cerebrospinal fluid (CSF) but not extending through the whole cortical 
ribbon, traversing the full thickness of the cortex from the CSF to WM 
interfaces, or confined to the centre of the cortex (not touching either the CSF 
or WM boundaries)(Chapter 2) (Filippi et al 2010b; Geurts et al. 2011; Bø et al 
2003b). 
Using DIR it is difficult to reliably identify subtypes of GM lesions 
(Chapter 2) In particular, juxtacortical WM lesions (JC-WM) - one of the 
subtypes of WM lesions that count towards MS MRI diagnostic criteria 
(Nelson et al.  2011; Geurts, Pouwels, et al.  2005b; Polman et al.  2011) - 
have the potential to be confused with mixed GM-WM lesions using DIR. In 
comparison, high resolution PSIR scans detect about three times as many 
CGM lesions, as shown in the previous chapter. In addition, they considerably 
improve the anatomical depiction of the cortical ribbon and adjacent WM, and 
can separate juxtacortical WM (JC-WM) lesions from mixed GM-WM lesions 
(Chapter 2) (Lazeron et al.  2000). These lesion subtypes have been studied 
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in context of their diagnostic role (Calabrese, et al. 2011a; Filippi et al 2010b) 
and also in relation to their association with cognitive impairment (Chapter 2) 
(Papadopoulou et al. 2013; Calabrese et al.  2011a) but to be reliable, such 
analyses depend on accurate lesion subtype identification.  
CGM lesions have also been divided into subtypes based on 
morphology, on DIR (Nelson et al 2007a; Calabrese et al.  2010a) and PSIR 
(Seewann et al. 2012; Lucchinetti et al. 2011). More recent work has 
suggested that curvilinear lesions may help differentiate age-associated GM 
lesions from those due to neuroinflammation (Chapter 2) (Calabrese, 
Battaglini, et al.  2010a; Bø et al. 2003b; Geurts et al.  2005b).  
 
In Chapter 2, the results are indicative that PSIR helps improve the 
detection of CGM lesions as compared to DIR. In order to study the effects of 
these lesions on clinical and cognitive morbidity, and further ascertain the 
contribution of both grey and white matter, the accurate identification and 
localization of CGM lesions in MS is important. As suggested by observation 
in Chapter 2, cortical and juxtacortical anatomy is more clearly visible using 
PSIR. The separation of JC from LC lesions is significant as it not only helps 
study the effects of JC lesions, but also prevents the misclassification of a 
lesion on the basis of its grey / white matter involvement. In this chapter, I 
outline a systematic investigation of the change of classification of cortical and 
juxtacortical lesions on using the high resolution PSIR scans, in comparison to 
DIR.  
I hypothesized that the higher resolution of PSIR will improve the 
accuracy of classifying CGM lesions in clinically acceptable scanning times. A 
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better understanding of the extent of grey matter involvement and possibly the 
morphology of lesions, will improve the specificity of observations made in the 
context of MS and reduce the noise while interpreting correlations between 
CGM lesion and parameters of cognitive and clinical parameters.  
Different groups have investigated the roles of DIR (Calabrese, 
Battaglini, et al.  2010a; Geurts, Pouwels, et al.  2005b; Geurts et al.  2011), 
PSIR (Filippi et al 2010b) and a combination of DIR and PSIR in improving 
lesion detection (Chapter 2). (Geurts et al. 2011; Nelson et al. 2007a; Bø et al. 
2003b; Nelson et al. 2011). A comparison of lesion classification across these 
scans has not been studied before. 
3.3 Methods 
3.3.1 Participants and Image acquisition  
Scans collected from the same cohort of 60 patients {30 relapsing-
remitting (RR) MS, 15 each with primary (PP) and secondary progressive 
(SP) MS} recruited in the earlier part of this project (Chapter 2) were now 
studied to investigate the change in classification of lesions across both these 
scans. Image acquisition and was performed as described in Chapter 2.   
3.3.2 Image Analysis  
CGM lesions were identified and classified on both DIR and PSIR 
scans as described in Chapter 2. ( Geurts et al. 2011). With an aim to study 
the change in classification from DIR to PSIR, I then examined these CGM 
lesions seen on DIR, on corresponding slices of the high resolution PSIR 
Scans; subtype classification in relation to the grey–white boundary was 
noted. All lesions were marked under supervision of senior raters (including 
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an experienced neuroradiologist).  
The CGM lesions detected on DIR (IC or LC) were classified on PSIR 
scans in to one of 4 categories: IC, LC, JC-WM lesions (WM lesions abutting 
but not entering the cortex), or other WM lesions (non-JC). It can be recalled 
that JC lesions could not be separated from LC lesions on DIR, but this was 
possible on PSIR. Based on their morphology, CGM lesions were sub-
classified by shape as curvilinear (lesions that follow the contour of sulcal and 
gyral folds), oval or wedge shaped (Chapter 2) (Calabrese, Battaglini, et al.  
2010a).Classification of DIR visible CGM lesions was noted using DIR and 
then at the corresponding location seen on PSIR. I noted changes in 
classification from either IC / LC on DIR to IC/LC/JC or WM on PSIR. 
3.4 Results  
765 CGM lesions were marked on DIR, 282 of these were IC and 483 
LC. Of the 282 IC lesions, 172 (61%) were confirmed as IC on PSIR, and 
110(39%) were reclassified (100 LC (35.5%), 8 JC-WM (2.8%) 2 Non-JC WM 
(0.7%)). Of the 483 LC DIR lesions, 212 (43.9%) were confirmed as LC on 
PSIR, and 271 (56.1%) were reclassified (78 IC (16.1%), 155 JC-WM, 38 WM 
(i.e., 40% involved WM only) (See Table 3.1 and Figures 3.1 to 3.4) 
 Morphologically, on DIR, 665 of CGM lesions were initially classified 
as oval, 59 curvilinear and 41 wedge shaped. Using PSIR 148/765 (19.3%) 
were reclassified. The most striking difference was the higher number of 
lesions classified as curvilinear on PSIR than on DIR. (See Table 3.2 and 
Figure 3.2) 
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Table 3.1: Change in lesion subtype, from DIR to PSIR  
Change in classification based on type of lesions 
  As subsequently seen on PSIR 
IC LC JC WM 
On 
DIR 
IC (N=282) 172(61) 100(35.5) 8(2.8) 2(0.7) 
LC (N=483) 78 (16.1) 212 (43.9) 155(32.1) 38 (7.9) 
(number (percentage)) Each row corresponds to a lesion type seen on DIR, 
and each column how the same lesion was classified on PSIR. E.g. of the IC 
lesions so classified on DIR, 60% remained so on PSIR 
 
 
Table 3.2 Change in lesion morphology, from DIR to PSIR  
Change in classification based on Morphology of lesions 
 
As subsequently seen on PSIR 
Oval Wedge Curvilinear 
On DIR 
Oval (N=665) 523 (78.6) 26 (3.9) 116 (17.4) 
Wedge (N=41) 0 30 (73.2) 11(26.8) 
Curvilinear (N=59) 5 (8.5) 0 54 (91.5) 
(number (percentage)) of lesion numbers based on morphology of lesions, as 
seen on DIR and PSIR 
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Figure 3.1 Conversion of lesion classification from DIR to PSIR  
 
The pie chart on the left indicates % of IC and LC lesions using DIR; on the 
right is the figure with revised % of lesions using PSIR 
 
Figure 3.2Corresponding images on DIR and PSIR  
 
LC lesions on DIR (arrow and chevron on left ) appears to be a JC white 
matter lesion on PSIR (arrow and chevron on right); The lesion shown by the 
arrow appears oval on DIR abut wedge shaped on PSIR 
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Figure 3.3Corresponding images on DIR and PSIR 
 
LC lesion on DIR (left )appears to be a limited to white matter on PSIR (right) 
 
Figure 3.4:Corresponding images on DIR and PSIR 
 
  
LC lesion on DIR appears to be an IC on PSIR 
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3.5 Discussion 
In this study I found that MS lesions reported to involve the CGM on 
DIR were often reclassified in a different anatomical location when viewed on 
a higher resolution PSIR sequence. Specifically, 39% (110/282) lesions 
thought to only involve CGM on DIR (i.e. IC lesions) where noted to extend 
into WM on PSIR, and of the mixed GM-WM lesions on DIR (i.e. LC) about56 
% (271/483) were reclassified on PSIR, with about 40% (193/483) classified 
as being purely in the WM.  
A recent combined histopathological and MRI study reported that 90% 
of CGM lesions seen on a high resolution 3D DIR scan (using a scan 
resolution of 1.1 by 1.1 by 1.3 mm, which is higher than those commonly used 
in vivo) were histopathologically confirmed (Filippi et al. 2010b; Seewann et 
al. 2012). However, the present study suggests that at the resolution that has 
been more often employed in clinical DIR studies published to date 
(1x1x3mm3) a larger proportion of DIR identified CGM lesions may actually 
be false positives.  
In Chapter 2, the results indicate that when CGM lesions were marked 
independently on DIR and high resolution PSIR, about three times more CGM 
lesions were detected on PSIR . (Papadopoulou et al.  2013; Calabrese et al.  
2011a). However, the high frequency in the present study with which DIR 
CGM lesions were reclassified as WM lesions suggests that the increase in 
true CGM lesion detection on PSIR may be even higher, perhaps about 6 
times that of DIR.  
Not surprisingly, DIR-classified LC lesions were more likely than IC 
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lesions to be reclassified as being entirely in the WM (40% and 3.5% 
respectively). JC-WM lesions seen on conventional T2-weighted and FLAIR 
sequences are included in the current McDonald 2010 diagnostic criteria 
(Calabrese, et al. 2010a; Polman et al. 2011) but CGM lesions seen on DIR 
have been suggested as more predictive of conversion from a clinically 
isolated syndrome to MS (Chapter 2) (Filippi et al. 2010b). Intracortical lesions 
have been suggested as having a role in diagnostic criteria (Bø et al. 2003b; 
Filippi et al. 2010b) and accurate sub-classification into lesion subtypes, will 
have important implications when using GM lesions to improve MS MRI 
diagnostic criteria.  
A question arises whether the diagnostic value of lesions in this region 
is coming from true CGM lesions, or JC-WM lesions, or both. Prospective 
studies following CIS patients who have had high resolution PSIR scans at 
presentation could address this question. Higher resolution DIR scans also 
warrant investigation as they could potentially also improve accuracy of lesion 
classification compared with the standard resolution DIR scans that were 
investigated in this study. 
Cognitive impairment, is seen in about 40 – 65% patients with MS. 
Previous work using standard resolution DIR has demonstrated correlations 
with measures of cognitive and clinical disability supporting a role for lesions 
in or near the cortex in determining clinical outcomes(Geurts, Pouwels, et al.  
2005b; Nelson et al. 2011; Geurts et al. 2011), while study using FLAIR scans 
reported an association of cognitive impairment with JC-WM lesions (Chapter 
2) (Lazeron et al. 2000) The observed limited accuracy of DIR again raises 
questions about the relative clinical and cognitive effects of true CGM and JC-
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WM lesions. Accurate sub-type classification is important in establishing the 
association between CGM lesion number and volume with cognitive 
impairment(Nelson et al 2007a; Calabrese et al.  2011a; Nelson et al. 2011). 
A higher CGM lesion number has been reported in those MS patients who are 
cognitively impaired and CGM lesion volume has been found to be an 
independent predictor. Accurate classification and quantification of lesional 
grey matter is key in studying whether this impairment is driven by pathology 
in the grey/ white matter.  
Curvilinear lesions have been reported to be seen in 36% of people 
with MS (using DIR) and in 85% patients using PSIR. In contrast, no similar 
morphology was seen in healthy controls (Chapter 2). Given the frequency of 
this lesion morphology, I was keen to understand the difference in the above 
percentages across both scans. Of the CGM lesions seen on DIR, 27% of the 
wedge shaped and 17% of the oval shaped lesions were reclassified as 
curvilinear on PSIR. Thus on reclassification a more accurate morphological 
categorization is also facilitated using PSIR. However, it is important to study 
larger cohorts and also compare with other neurological disease groups in 
order to ascertain the specificity and implications of these findings. 
In conclusion, these data suggest that lesions classified as involving 
CGM on standard resolution DIR images are reclassified as WM-only lesions 
when viewed on a higher resolution PSIR sequence. While DIR has improved 
CGM lesion detection, PSIR, which further improves detection, is in addition 
more representative of the actual grey matter lesional load.  
 This finding cautions against using DIR in isolation, for the 
classification of CGM lesions. In future the multimodal approach, using 
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multiple scans like DIR and PSIR, may help with lesion detection (Geurts et 
al.  2011; Nelson et al. 2007a) (Chapter 2) but PSIR is a more robust 
sequence for accurate classification of lesion subtype and morphology. The 
findings of this work warrant attention while studying the role of CGM lesions 
in MS diagnostic criteria and in investigating how elements of CGM pathology 
affect cognitive or neurological function. While post mortem verification of 
CGM lesions using DIR (Calabrese et al.  2010a; Seewann et al.  2012; 
Lucchinetti et al.  2011) has recently been studied, similar verification of PSIR 
visible CGM lesions will allow an improved understanding of these results.  
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4 Cortical and Juxtacortical lesions in 
multiple sclerosis: their distribution 
on MRI and impact on cognition 
 
4.1 Abstract 
Background 
The spatial distribution of CGM lesions in multiple sclerosis (MS) is 
predominantly fronto-temporal in histopathological studies. CGM lesions have 
been associated with cognitive impairment and progressive disability in MS. 
PSIR (Phase sensitive inversion recovery) MRI has improved the detection of 
CGM lesions and has the potential to improve the characterization of regional 
distributions of CGM lesions in vivo. CGM and juxtacortical (JC) white matter 
(WM) lesions have both been linked with cognitive dysfunction in multiple 
sclerosis (MS). Little is known about their relative associations with cognition, 
and if such associations vary across cortical lobes and MS phenotypes. 
Aim 
To determine the lobar distribution of CGM and JC lesions and their 
associations with cognitive deficits in people with different MS subtypes. 
Methods 
Using a Philips 3T Achieva system, PSIR scans (0.5x0.5x2 mm3) were 
acquired for 30 people with relapsing remitting (RR), 15 primary (PP) and 15 
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secondary progressive (SP) MS. On the PSIR scans intracortical (IC) or 
leucocortical (LC) CGM lesions and JC WM lesions were identified. Lesion 
volumes were estimated for frontal, temporal, parietal, occipital lobes. A 
frontal cognitive z-score was derived from Hayling and Stroop test z-scores; a 
temporal cognitive z-score was computed using immediate and delayed story 
recall, and immediate and delayed complex figure recall; an attention z-score 
was calculated using Symbol digit modality test (SDMT) and Paced auditory 
serial addition test (PASAT). Differences between phenotypes and 
associations with cognitive measures were examined using multiple 
regression to adjust for potential confounders. Global WM lesion volume, age, 
gender, disease duration, pre-morbid IQ and intracranial volume were 
included as covariates. 
 
Results  
Mean (standard deviation) CGM lesion volume (mm3) was 434.3 
(528.5) in the frontal, 272.9 (280.1) in the temporal, 142.0 (184.0) in the 
parietal and 17.2 (54.2) in the occipital lobes. Performance in the frontal 
cognitive tests was not found to be associated with frontal lesion volumes (IC , 
LC or JC). Larger temporal JC lesion volume was associated with a lower 
temporal cognitive z-score (p<0.001). A larger frontal IC lesion volume 
(p=0.019) and a higher parietal LC lesion volume (p=0.073) were 
independently associated with a lower attention z-score. No differences in 
these associations were noted between clinical subgroups. 
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Conclusion:  
This imaging study identified a fronto-temporal dominance and 
occipital paucity of CGM lesions. Different CGM and JC lesion subtypes are 
associated with cognitive function, and their relationship is influenced by the 
lobar location of lesions and the cognitive function being assessed. 
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4.2 Introduction 
 
Histopathological studies have demonstrated a fronto-temporal 
predominance of CGM lesions, albeit in samples from people with mostly 
long-standing progressive disease (Nichtweiss et al.  2012; Brownell & 
Hughes 1962; Assareh et al.  2010; Lumsden 1970). Such lobar predilections 
may, in part, explain the pattern of cognitive deficits seen in people with MS 
but it is not clear whether or not the relative lobar distribution of GM lesions is 
the same throughout the clinical course of MS. Further, lesions involving GM 
may also extend into WM, and it is not clear if the previous associations 
between GM lesions and cognitive function that have been observed 
(Calabrese et al.  2009) (Giorgio & De Stefano 2010) are mostly driven by the 
GM or WM component of such lesions (Hulst et al.  2013; Mueller et al.  2010; 
Papadopoulou et al.  2013).  
Technological limitations have made it difficult to reliably detect GM 
lesions in vivo, although a substantial improvement was achieved (when 
compared with conventional magnetic resonance imaging (MRI) techniques) 
with the introduction of double inversion recovery (DIR). However DIR yields 
images which have a low signal to noise compared with conventional MRI 
methods, and it is very difficult to determine reliably whether or not a lesion is 
confined to the cortex, extends into the WM, or abuts but does not enter the 
cortex (a juxtacortical (JC) WM lesion). Building on this, I have demonstrated 
the use of a high resolution phase sensitive inversion recovery (PSIR) 
(Chapter 2) sequence, originally used to confirm lesions seen on DIR (Nelson 
et al 2007a) . PSIR increased GM lesion detection by two to three fold 
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compared to DIR ( Chapter 2) and enabled CGM lesion subtypes (intracortical 
(IC) lesions confined to CGM and leucocortical (LC) lesions involving both 
CGM and JC-WM) and JC WM lesions to all be separated more robustly 
(Chapter 3)  
Radiologically detected WM lesion load correlates only modestly 
(Calabrese et al.  2009; Kacar et al.  2011; Barkhof 2002a; Bakshi et al.  
2008; Barkhof et al.  2009a; Gonzalez et al.  1994) with the extent of disability 
seen in patients with MS leading to a clinical – radiological paradox (Giorgio & 
De Stefano 2010; Barkhof 2002a). It has been hypothesized that CGM lesions 
might be responsible for the clinical presentation of patients, and may be the 
missing piece of the puzzle. (Hulst et al.  2013; Calabrese, Rinaldi, Poretto, et 
al.  2011b; Mueller et al.  2010; Chard & Miller 2009; Papadopoulou et al.  
2013). However with conventional imaging, sub-classification of lesions and 
detection of CGM lesions has been limited. By improving contrast between 
the grey and white matter boundary, and lesional and non-lesional tissue, 
studies using DIR and PSIR have been able to study the clinical impact of 
cortical and juxtacortical lesions. 
Cognitive impairment is often seen in people with MS, (Nelson, 
Poonawalla, Hou, Huang, Wolinsky & Narayana 2007a; Bobholz & Rao 2003; 
Rao et al.  1991) affecting executive tasks, memory, attention and processing 
efficiency. People with progressive forms of MS have more cognitive 
dysfunction than patients with relapsing remitting (RR) disease. The impact of 
topographic distribution of WM lesions on pattern of cognitive deficit has been 
studied (Tiemann et al.  2009; Sperling et al.  2001; Gonzalez et al.  1994). 
Both cortical and subcortical lesions have also been implicated as a possible 
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pathological substrates (Kutzelnigg & Lassmann 2006; Rovaris & Filippi 2000; 
Calabrese, Rinaldi, Grossi, et al.  2011a) (Roosendaal et al.  2009) of 
cognitive dysfunction and in recent years. Modest associations between 
cognitive impairment and global CGM lesion volume (Calabrese et al.  2009), 
intracortical (Nelson et al.  2011) leucocortical (Nielsen et al.  2013) and 
juxtacortical (Lazeron et al.  2000) lesions have been reported. Other 
measures such as cortical atrophy (Giorgio & De Stefano 2010) and MTR 
(Summers et al.  2008) have also been investigated with regards to their 
correlation with cognitive impairment. The distribution of GM lesions has been 
associated with specific patterns of cognitive impairment. (Polman et al.  
2011; Tiemann et al.  2009; Nielsen et al.  2013). However, there has been 
little investigation to elucidate the relative contribution of the distribution of 
CGM lesion subtypes (IC, LC, JC) (Chapter 2). Using PSIR, accurate 
detection of IC and LC lesions (Chapter 3) now allows us to explore if these 
lesions subtypes are responsible for cognitive impairment.   
In order to study the relationship of CGM and JC-WM lesions with 
cognitive impairment, it is important to use reliable and accurate measures of 
these parameters. The distribution of lesions can be studied based on their 
location (i) in the anatomically defined lobes (frontal, temporal, parietal, insular 
and occipital) and (ii) through the thickness of the cortex. Based on their 
locations within the thickness of the cortex, CGM lesions are pathologically 
classified into four distinct types, Type I -IV. Type I lesions are situated at the 
GM/WM junction, furthest away from the CSF. On the other hand, the subpial 
lesions (Type III) are adjacent to the CSF and furthest away from the white 
matter. Type II lesions are surrounded by GM in their entirety and Type IV 
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lesions extend all the way from the subpial surface to the GM/WM boundary 
(Bø & Bø 2009). Radiologically, using PSIR, it is possible to classify lesions in 
and adjacent to the cortex as LC (equivalent to Type I), IC (Types II- IV) and 
JC (Chapter 2). 
In this work I assessed: (i) the distribution of IC and LC CGM lesions, 
and JC WM lesions, across lobes; (ii) the associations of lesion type and 
location with cognitive dysfunction; (iii) whether or not distributions and 
associations (i and ii) differed between MS subtypes. 
4.3 Methods  
4.3.1 Participants 
 
Sixty people (30 Relapsing remitting (RR), 15 primary progressive 
(PP) and 15 (SP) MS) with a clinically definite diagnosis of MS,(Polman et al.  
2011) no other known neurological condition, and aged between 18 and 65 
years, were enrolled as part of an earlier study assessing the use of PSIR for 
CGM lesion detection. (Chapter 2; Table 2.1). All participants provided a 
written informed consent for this study which was approved by the local 
institutional ethics committee.  
4.3.2 Image acquisition and analysis  
 
A Philips 3T Achieva (Philips Healthcare, Best, The Netherlands) 
system was used to acquire images for this study, using a 32-channel head 
coil. The protocol included FLAIR, PSIR and the volumetric T1-weighted 
gradient echo (3DT1)sequence. Details of acquisition parameters are given in 
(See Chapter 2, Table 2.2) 
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4.3.3 Marking and classifying GM lesions 
Guidelines for defining CGM lesions using PSIR were as previously 
described in Chapter 2. CGM were subdivided into IC or LC; and WM lesions 
touching but not entering the cortex were classified as juxtacortical (JC) 
lesions. All other white matter lesions (non-JC) were also marked separately. 
Marking of all scans was carried out blinded to clinical features. Lesion 
marking and contouring was done using the software JIM v 6.0. Both number 
and volume of lesions was determined.  
4.3.4 Estimating lobar lesion counts 
Frontal, temporal, parietal, insular and occipital lobe masks in MNI152 
space from the Wake Forest University Pick-Atlas (Maldjian et al.  2003) were 
registered to each participants' PSIR via the volumetric T1-weighted image. 
All registrations were carried out using NiftyReg 
(http://sourceforge.net/projects/niftyreg) (Modat et al.  2010). The steps for 
this included the following : 
 
Step 1 : Creating a template brain  
To account for brain atrophy (in particular enlarged ventricles) seen in 
MS, a cohort specific brain template was built from the T1w images from 
patients in the cohort. The 3D T1 scans had all been lesion filled. This was 
generated by repeatedly creating an average of the T1w images and 
registering each image to the average. This was done initially using linear 
registration and then refined by non-linear registration. The process was 
repeated 9 times to obtain a clear template. 
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Step 2 : Registrations (See Figures 4.1, 4.2 and 4.3)  
i. The MNI152 1 mm T1w template brain was non-linearly registered 
to the cohort specific template brain. 
ii. The cohort specific template brain was then non-linearly registered 
to the individual participants’ T1w scan. 
iii. Each individual participant’s T1w scan was rigidly-aligned with their 
PSIR scan. 
iv. The transformation fields from steps i, ii and iii were concatenated 
and used to transform the lobar masks from MNI space into 
native PSIR space. 
 
To enable the relative proportion of lesion to normal-appearing 
(NA)GM to be calculated in each lobe, i.e. to determine if any differences in 
lobar lesion loads were simply due to the differences in the size of the lobes, 
lobe specific GM masks were generated : 
 
v. The T1w images were segmented using unified segmentation in 
SPM8 into GM, WM and CSF tissue classes. These were 
binarised using a maximum likelihood algorithm (Muhlert et al.  
2013). The binarised grey matter mask was then transformed into 
native PSIR space using the parameters from step iii. 
vi. PSIR space lobar masks were intersected with GM masks from 
step v, to create lobar GM masks. 
vii. For each participant a total intracranial volume measurement was 
calculated by first binarising the tissue volumes using a maximum 
likelihood algorithm, then summing their volumes (i.e. grey matter 
+ white matter + CSF). This was done to normalise the grey 
matter volume measurements. 
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Using in house software, lobar number and volume of each lesion type 
(IC/LC/JC) was determined. Lobar volumes were calculated and divided by 
each participants’ total intracranial volume. (calculated by summing the 
volumes from each of the binarised tissue classes from step v). Lesion density 
measured by the lesion volume as a proportion of the lobar volume was also 
calculated. 
 
 
Figure 4.1 Overlaying lobar masks in PSIR space 
 
 
PSIR image showing marked CGM lesions (1A) and overlayed left frontal lobe 
mask(1B) 
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Figure 4.2 Overlaying lobar masks in PSIR space 
 
Axial (top panel) and sagittal (bottom panel) PSIR images with lobar masks 
(registered from MNI-152 brain template to PSIR); frontal, temporal, parietal 
and occipital lobes (left to right) 
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Figure 4.3 Estimating lobar lesion counts 
 
 
 
 
Above figure combines the steps in figures 4.1 and 4.2 ; Once the marked 
region of interest file was superimposed on the lobar masks, the lesions for 
each lobe were then quantified. 
 
  
135 
 
4.3.5 Clinical and cognitive assessment 
A brief medical and a more detailed neurological history was recorded 
for all participants. A clinical examination, similar to a normal neurology 
outpatient clinic review was performed by an experienced clinician. Their 
Expanded Disability Status Scale (Kurtzke 1983) and MSFC (MS Functional 
Composite) (Cutter et al.  1999; Fischer et al.  1999) scores (comprising the 
9HPT(9 hole peg test), 25TWT (timed walk test) and PASAT (Paced auditory 
serial addition test)) were also determined. The individual components were 
analysed as Z scores: for PASAT by standardizing the raw score to using the 
group mean and standard deviation, for the other two components by 
standardizing the reciprocal of the mean times, after substituting a zero for 
subjects not completing the tasks 
Detailed cognitive assessment was performed by an experienced 
neuropsychologist (NM), for each participant. The cognitive functions 
examined were grouped into three major domains: (i) executive function (ii) 
memory and (iii) information processing speed / attention. 
 Executive function was tested using the Hayling sentence completion 
and Stroop tests. The Hayling sentence completion test and Stroop colour-
word (Van der Elst et al. 2006) interference test were used to assess 
vulnerability to interference. To assess memory, immediate and delayed 
figure recognition and immediate and delayed story recall tasks from the Adult 
Memory and Information Processing Battery (Coughlan AK, Hollows SE, 
1985; The Adult Memory and Information Processing Battery (AMIPB), Leeds, 
St James' University Hospital) were used. For the information processing 
speed/attention composite measure, PASAT and symbol digit modalities test 
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(SDMT) (Smith 1982) were used.  
All cognitive measures were converted into z scores by subtracting 
from sample means and dividing by sample standard deviations. For the 
purposes of analysis, the three domains, executive, memory and information 
processing/attention were analysed together 1) “executive”, comprising the 
Hayling and Stroop measures 2) “memory”, comprising four measures: the 
immediate and delayed figure recognition and story recall tasks; 3) “attention” 
comprising two measures, PASAT and SDMT. A composite z score was 
calculate for each of the three by averaging across the individual z scores. 
4.3.6 Statistical Methods 
Lesion volumes tend to be positively skewed and thus render 
unreliable some analyses which assume normality. One approach is to 
normalise by log transformation; however, this is not advisable when, as in 
these data, there are many zero volumes which have no valid logarithm. For 
linear regression, however, the normality assumption applies only to 
residuals, not to individual regression variables, and often a skewed response 
variable may still give rise to normal residuals. The approach taken here 
therefore is, where linear regression is employed, to use the untransformed 
lesion volume, but where there was evidence of residual non-normality, to 
confirm or replace results with a bootstrapped regression which makes no 
normality assumption.   
Spearman correlation was used to investigate if, for a given lobe, 
patients with higher lobar volume also had higher lesion volume in that lobe. 
While this would be a correlation between patients, a different question is 
whether within patients their larger lobes (e.g. frontal and temporal) contain 
137 
 
larger lesion volumes than their smaller lobes (e.g. insula and occipital): this 
involves a type of ‘paired’ test. since lobes are not independent within 
patients, and was performed by testing for within-patient variation in lesion 
density across lobes using a multivariate regression with five lobe density 
response variables, jointly testing equality of the five mean densities. 
Lesion density variables and proportions of lesions in a lobe or 
location were compared between patient groups using multiple linear 
regression on group indicators with disease duration and gender covariates; 
when age was substituted for duration results were not materially altered. To 
compare absolute lesion volumes aggregated over lobes between 
phenotypes, intracranial volume was entered in addition to duration and 
gender. To compare lobe-specific absolute lesion volumes between 
phenotypes, the relevant lobar volume was entered in addition to duration, 
gender and intracranial volume. 
MSFC component scores rather than the composite were analysed for 
two reasons: firstly, because of the separate information conveyed by the 
components, particularly, in this context, the PASAT. Secondly, because the 
composite standardly requires the walk times to be used, which are almost 
always skewed, and this skew persists in the standard composite. By 
analysing the reciprocal of the walk times (walk speed) the measure is 
normalized (Kapoor et al.  2010). 
 
It was hypothesised that the “attention” and “executive” measures may 
be associated with lobar (frontal, temporal) lesion variables. Due of the 
relatively large number of individual cognitive measures, in order to address 
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hypotheses with a relatively small number of statistical tests, three 
multivariate multiple regressions were used, for each domain simultaneously 
regressing their individual cognitive measures on lesion predictors. This 
allows joint testing of the null hypothesis that none of the individual domain 
measures is associated with the lesion predictors. By reporting individual 
associations only where the corresponding joint test is significant for the 
domain, there is less danger of spurious significant results. Additionally, the 
domain-averaged single z scores were examined in a single multiple 
regression, though this loses the measure-specific information.  For these 
cognitive measure regressions, potential confounders entered as covariates 
were age, gender, pre-morbid IQ, intracranial volume and lobar volume. 
Regression residuals were examined for normality and where there 
was evidence of non-normality results were checked using a non-parametric 
bootstrap with 1000 replicates. Analyses were performed in Stata 13.1 (Stata 
Corporation, College Station, Texas, USA). 
4.4 Results 
The demographics of patients in this study have been detailed in 
Chapter 2 (Table 2.1). The WM lesion and intracranial volume measures for 
the cohort are reported in Table 4.1  
4.4.1 Distribution of lesions 
Distribution of Lesions in the whole cohort 
 
All results below are reporting lesion volume. Lesion density and 
lesion number results were reflective of similar results and are reported as 
supplementary data. (See 4.6) Lesion volumes for IC, LC and JC lesions were 
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found to be the highest in the frontal and lowest in the occipital lobes (See 
Table 4.2, Figure 4.4).The mean percentage of GM lesions in each lobe for 
the whole group of patients are frontal 43.2%, temporal 28.4%, parietal 
15.7%, insular 9.4% and occipital 3.2%. 
Distribution of lesions between MS subtypes 
 
The total IC lesion volume (in mm3) across all lobes, was significantly 
higher in SP than PP (adjusted difference in means 233.478, 95% confidence 
interval (CI) 3.620, 463.336; P=0.047), but not than RR (P=0.198); LC lesion 
volumes were substantially and significantly greater in SP than both PP and 
RR (adjusted difference in means respectively 525.769, 95% CI 95.836, 
955.702; P=0.017, and 621.094 95% CI 233.115, 1009.073; P=0.002). SP 
had double the JC lesion volume than PP and RR. There was also a trend for 
patients with SPMS to have a higher WM lesion count and volume than those 
with RRMS or PPMS, but this did not reach statistical significance. The CGM 
lesion volume (IC and LC volumes combined) was significantly higher in SP 
than PP or RR (adjusted difference in means respectively 776.333, 95% CI 
207.622, 1345.044; P=0.008 and 756.827, 95% CI 243.612, 1270.042; 
P=0.005). 
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Table 4.1 Measure of white matter lesion load and other covariates  
 
 
Type 
PSIR 
WM 
lesion 
number 
PSIR WM 
lesion 
volume 
(mm3) 
Age 
(years) M:F 
Disease 
duration 
(years) 
ICV 
(mm3) GMF 
RR 
(n30) 63.9 (57) 
6881.9 
(10949) 
42.5 
(9.6) 5:10 
11.5 
(10.5) 
1460.9 
(156.2) 
0.47 
(0.01) 
PP 
(n15) 
50.1 
(31.8) 
6486.8 
(8046.3) 
51.9 
(9.1) 7:8 12.1 (8.0) 
1475.1 
(149.5) 
0.47 
(0.02) 
SP 
(n15) 
79.5 
(38.9) 
7482.6 
(5424.2) 
50.9 
(7.6) 10:20 23.3 (7.3) 
1431 
(150.7) 
0.47 
(0.01) 
 
Above data reported as mean (SD); PSIR –Phase sensitive inversion 
recovery, GMF – grey matter fractions, ICV – Intracranial volume , M- Males, 
F- Females 
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Table 4.2 Distribution of CGM lesions (Volumes)  
 Frontal Temporal Parietal Occipital Insular 
 IC LC JC IC LC JC IC LC JC IC LC JC IC LC JC 
RR 
(n30) 
175 
(114.2) 
138.7 
(241) 
45.9 
(73.8) 
125.9 
(101.8) 
130.6 
(169.4) 
15.6 
(21.7) 
84 
(64.9) 
51.4 
(75.5) 
22 
(33.8) 
6.8 
(17.7) 
4.2 
(10.9) 
4.4 
(10) 
48.7 
(99) 
22.7 
(59.5) 2 (8) 
PP 
(n15) 
153.3 
(143.7) 
264.5 
(404.5) 
36.4 
(47.4) 
74 
(66.6) 
94.3 
(93.1) 
32.4 
(52) 
42.4 
(55.2) 
77.8 
(121.9) 
9.5 
(13.1) 
6.1 
(13.5) 
4.2 
(12.1) 
4.9 
(9.7) 
59.2 
(110.3) 
4.6 
(10.1) 
3.7 
(11.8) 
SP 
(n15) 
235.2 
(234.8) 
457.1 
(466.9) 
201.1 
(261.1) 
138.5 
(78.7) 
272.4 
(251.4) 
64.5 
(118.8) 
62.4 
(75) 
114.6 
(169) 
45.6 
(94.8) 
11 
(29.6) 
25.9 
(64.2) 
13.8 
(29.2) 
137.1 
(159.7) 
45 
(67) 
8.7 
(15.2) 
All 
(n60) 
184.6 
(159.2) 
249.7 
(369.3) 
82.3 
(155.5) 
116.1 
(90.8) 
157 
(189.5) 
32  
(68) 
68.2 
(66.6) 
73.8 
(117.4) 
24.8 
(53.9) 
7.7 
(20.2) 
9.6 
(34.1) 
6.9 
(17) 
73.4 
(123.1) 
23.8 
(55.1) 
4.1 
(11.3) 
 
Lesion volumes reported as Mean (SD ) in mm3  
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Figure 4.4 Distribution of lesions (By MS Phenotype) 
 
Above graphs shows the distribution of lesions (IC, LC and JC) across the five lobes (frontal, temporal, parietal, insular and 
occipital) in the three phenotypes of MS patients (RR, PP and SP). All above data is based on lobar lesion volume 
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Distribution of IC, LC and JC lesions between lobes  
 
Within patients, lobar volumes decreased in the order: frontal, 
temporal, parietal, insula, occipital; however, the lesion volume contained in 
the lobes did not decrease proportionately, as reflected in a significant 
variation in lesion density across the lobes (P<0.0001): frontal and temporal 
lobes have similar density, 0.2%, while parietal (0.1%) and occipital (0.04%) 
have lower densities and insula the highest (0.7%). However, there was no 
evidence to suggest that, for a given lobe, patients with larger lobes also had 
higher lesion volume in that lobe: for example, patients with larger frontal 
lobes did not contain significantly higher frontal lesion volume than patients 
with smaller frontal lobes.  
 
Comparing lesion locations across the five lobes studied, SPMS had 
significantly higher lesion volume than both PP and RR for: frontal JC 
(adjusted difference in means vs. PP, 120.608, 95% CI 8.826, 232.389 
P=0.035; vs. RR 104.099, 95% CI 2.857, 205.3412 P=0.044); occipital LC 
lesion volume (adjusted mean difference in means vs. PP 27.116, 95% CI 
0.264, 53.967 P=0.048; vs. RR 27.432, 95% CI 3.170, 51.693 P=0.027). 
SPMS had a higher frontal LC than RRMS (adjusted difference in means vs. 
RR 321.050, 95% CI 76.240, 565.860 P=0.011) but not PPMS (195.931, 95% 
CI 74.36353, 466.2257 P=0.152). Comparison between subtypes for other 
lobes and locations were not significantly different. 
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4.4.2 Association between lesion volumes and measures of 
cognition 
 
Frontal Cognitive measures (See Table 4.3; Table 4.4) 
There was no evidence that that either of the two cognitive measures 
was associated with WM lesion volume (P=0.186 for joint test). Nor was there 
evidence they were associated with the frontal IC volume (P=0.121 for the 
joint test). Nor was there evidence that these cognitive measures were 
associated frontal LC or JC lesion volumes or with lesion volumes from the 
other lobes. There was also no evidence that the lesion density was more 
strongly associated than the absolute volume. 
 
Temporal Cognitive measures (See Table 4.3 Table 4.5) 
The temporal z score was significantly (p<0.001) associated with 
temporal JC volume, adjusting for potential confounders. The joint test of 
association between the four temporal cognitive measures and temporal JC 
lesion volume was highly significant (p<0.0001) with significant evidence of 
negative association in all four. The adjusted standardized regression 
coefficients for story immediate, story delayed, figure immediate and figure 
delayed were respectively -0.373 (95% CI -0.563, -.183 P<0.001), -0.403 
(95% CI -.584, 0.223 P<0.001) -0.469 95% CI -0.657, -0.282 P<0.001) and -
0.489 (95% CI -0.510, -0.089 P=0.005).  
There was no evidence that temporal JC lesion density was a better 
predictor than absolute volume. There was no evidence of association with 
the temporal IC or LC volumes, independent of the JC volume; nor was there 
evidence of association, independent of temporal JC volume with volume 
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measures in other lobes. There was no evidence that any of the four temporal 
cognitive measures was associated with WM lesion volume (p=0.584 on the 
joint test).  
Attention scores ( See Table 4.3 Table 4.6) 
Frontal IC volume and Parietal LC volume were independently 
negatively associated with the attention measures. In a model with both lesion 
measures as predictors (and adjusting for potential confounders), the joint test 
of association gave P=0.035 for Frontal IC and P=0.023 for Parietal LC. For 
Frontal IC the adjusted standardized regression coefficients for PASAT and 
SDMT respectively were -0.239 (95% CI -0.447, -0.030 P=0.025) and -0.222 
(95% CI -0.409, -0.035 P=0.020); and for parietal LC, -0.099 (95% CI -0.323, 
0.125 P=0.387) and -.278 (95% CI -0.470, -0.086 P=0.005) respectively. This 
suggests the parietal LC volume may be more strongly associated with SDMT 
than PASAT. The attention Z score was also significantly associated with 
frontal IC volume (P=0.019) and borderline significantly associated with 
parietal LC (P=0.073), adjusting for potential confounders.  
 There was no evidence that lesion densities were more strongly 
predictive than absolute volumes. There was no significant association 
between WM lesion volume and attention scores (p=0.575 for the joint test) 
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Table 4.3 Mean (SD) Z Scores for cognitive measures 
 z_front z_temp z_attention 
RR (n30) 0.1 (0.8) 0.3 (0.7) 0.2 (0.8) 
PP (n15) -0.1 (0.7) -0.3 (0.9) -0.2 (0.8) 
SP (n15) -0.1 (0.8) -0.5 (1.1) -0.2 (1.0) 
All (n60) -0.01 (0.8) 0.0 (0.9) 0.0 (0.9) 
Z_front : Z score of cognitive tasks used to assess frontal lobe function, 
z_temp : Z score cognitive tests used to measure temporal lobe function and 
z_attention – z score of PASAT and SDMT tasks 
 
Table 4.4 Z Scores for individual tests for Frontal Lobe function 
 z_hayling z_inv_stroop 
RR (n30) 0.0 (1.1) 0.3 (1.0) 
PP (n15) 0.0 (1.0) -0.3 (1.0) 
SP (n15) 0.1 (0.9) -0.2 (0.8) 
All (n60) 0.0 (1.0) 0.0 (1.0) 
 
Z score for Hayling (z_hayling) and stroop (z_inv_stroop) tasks that were part 
of assessment of frontal lobe function 
 
Table 4.5 Z Scores for individual tests of Temporal lobe Function 
 z_story_imm z_story_del z_figimm z_figdel 
RR (n30) 0.2 (0.9) 0.3 (0.8) 0.4 (0.9) 0.4 (0.8) 
PP (n15) -0.1 (1.0) -0.1 (0.9) -0.5 (1.0) -0.4 (1.1) 
SP (n15) -0.4 (1.2) -0.4 (1.3) -0.3 (1.0) -0.4 (1.0) 
All (n60) 0.0 (1.0) 0.0 (1.0) 0.0 (1.0) 0.0 (1.0) 
Z score for immediate (z_story_imm) and delayed (z_story-del) story recall 
and for immediate (z_figimm) and delayed (z_figdel) figure recognition; these 
tests comprised assessment of the temporal lobe function 
 
Table 4.6 Z Scores for MSFC and SDMT 
 z_inv_walk z_inv_9HPT z_pasat z_sdmts 
RR 
(n30) 
0.6 (0.8) 0.2 (0.7) 0.0 (1.0) 0.4 (0.8) 
PP 
(n15) 
-0.2 (1.0) 0.1 (1.0) -0.1 (1.1) -0.3 (0.8) 
SP 
(n15) 
-0.9 (0.7) -0.5 (1.4) 0.1 (0.9) -0.5 (1.2) 
All 
(n60) 
0.0 (1.0) 0.0 (1.0) 0.0 (1.0) 0.0 (1.0) 
Z score of 25 foot timed walk (z_inv_walk), 9HPT (z_inv_9HPT), 
PASAT (z_pasat) and the SDMT (z_sdmt) tests; the former three are part of 
the MSFC score 
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4.5 Discussion 
The results indicate a fronto-temporal dominance and occipital paucity 
of CGM lesions. There was no evidence to suggest that, for a given lobe, 
patients with larger lobes had higher lesion volume in that lobe. Frontal IC 
volume and Parietal LC volume were negatively associated with the attention 
measures and deficits in memory function were found to be associated with 
temporal JC lesion volume. These were independent of whole brain WM 
lesion load, demonstrating that different CGM and JC lesion subtypes are 
relevant to cognitive function, but the exact relationship depends on where the 
lesions are present and which cognitive function is being assessed. 
Distribution of lesions  
A greater proportion of CGM lesional volume was seen in the frontal 
(43.2%) and temporal (15.7%) lobes. Occipital lobe contributed the least 
(3.2%) to the CGM lesional volume. This is in keeping with similar 
observations made in histopathological (Lumsden 1970; Brownell & Hughes 
1962) and neuroimaging studies (sparing of the lateral occipital gyrus 
(Calabrese, Battaglini, et al.  2010a)). 
CGM (IC plus LC) was as expected (Bjartmar et al.  2003; Lassmann 
et al.  2012), higher in SP than both PP and RR. However, on looking at 
subsets, the IC lesion load was not significantly different in SP and RR; the 
difference in CGM lesional volume, is largely driven by differences in LC 
lesion count. A possible explanation for the differences between SP and 
RRMS is that there is a shift in new GM lesion formation from being centered 
on the cortex in RRMS to the cortico-WM junction in SPMS. Alternatively, 
CGM lesions continue to form in both RR and SPMS, but extend into the 
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adjacent WM more often in SPMS. Longitudinal studies looking at the 
evolution of CGM lesions are limited and these would be needed to better 
understand these findings.  
JC lesion loads were also higher in SP than RRMS, contributing to the 
increase in pathology seen at the GM/WM boundary. Histopatholgical data 
(Brownell & Hughes 1962) and recent imaging studies (Nielsen et al.  2013) 
suggest a predominance of lesions at the junction of the GM/WM boundary 
and SP (vs. RR) patients had significantly higher lesional volume at the 
boundary. However, it needs to be examined whether these findings also 
reflect an enlargement of existing lesions to the boundary region (from 
adjacent cortex or white matter) or represent a true increase of new LC and 
JC lesions. Longitudinal studies looking at the evolution of CGM lesions are 
limited and these would be needed to better understand the phenotypical 
differences in CGM lesion load. 
Association between lesion volumes and measures of cognition 
The commonly affected cognitive domains in MS include attention / 
processing speed; learning /memory and executive function. In earlier work 
with PSIR (Chapter 2) I had noted only modest correlations between global 
CGM lesion numbers and cognitive performance assessed using the MSFC.  
The results of my lobar analysis indicate a poor association between 
executive function and frontal lobe lesions. It is possible that executive 
function may be affected by CGM lesions not seen on PSIR (especially 
subpial lesions) or by other structural and functional changes in normal 
appearing frontal grey matter. In addition, impaired executive function is 
reported following damage to a wide network, including the thalamus and 
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cerebellum, which weren’t assessed in this study. Future work can assess the 
additional predictive value of NAGM changes in MTR, diffusion measures etc., 
and in damage within broad networks.  
 The temporal cognitive measures studied were significantly associated 
with temporal JC volume. The extent and severity of white matter damage 
(Hulst et al.  2013), presence of juxtacortical lesions (Lazeron et al.  2000) 
and lesions in the underlying U fibers (Miki et al.  1998) have all been reported 
to be associated with cognitive impairment in previous studies. It is possible 
that the temporal lobe functions that were assessed are more network driven 
and thus affected by WM lesions.  
The results suggest that memory function is more sensitive to 
temporal lobe lesions than executive function is to frontal lobe lesions, which 
may have implications for the relative plasticity of these functions, i.e., the 
potential for adaptation by other brain regions when there is pathological 
involvement of a region that has a key role in mediating a particular cognitive 
function.  
The association of lower attention z-scores with both frontal IC and 
parietal LC lesion load is consistent with a contribution of more widely 
distributed CGM lesions to this also common manifestation of cognitive 
dysfunction in MS.  
While the cerebral cortex is recognized as a highly organized seat of 
control, the relation between a CGM location of lesions and an effect on 
behaviour / cognition can still not be confidently predicted (Lezak et al.  2012). 
Interpretation of location – functional correlations is made difficult as the same 
function can involve different regions of the brain, and in turn each CGM 
150 
 
location may be responsible for many tasks. Thus, it is important to observe 
caution while investigating the functional localization of cognitive deficits 
Limitations 
 This study has several limitations. Firstly, the MRI sequence used to 
detect GM lesions in this study, while improving detection when compared 
with DIR, is still probably missing a substantial proportion of subpial CGM 
lesions. About 50-65% of CGM demyelination has been reported to be 
present in the subpial region. This is largely in regions such as the insula, 
cingulate, frontobasal and temporobasal cortices, and the cerebellum (Bø, 
Vedeler, Nyland, Trapp & Mørk 2003b; Lassmann et al.  2007; Albert, Antel, 
Brück & Stadelmann 2007b) In my study however, I was not able to identify 
any subpial lesions. Radiological visibility of these lesions is limited by their 
location, size and intrinsic properties (minimal inflammation, lack of a blood 
brain barrier disruption and a lesser degree of contrast between the lesional 
/non-lesional cortex). The proximity of the lesions to the CSF also causes 
susceptibility artefacts. (Schmierer et al.  2010) It is also possible that some of 
the subpial demyelination (especially that which extends to the WM boundary, 
as Type IV lesions) has been counted in my dataset as IC. The effect on 
cognition of CGM lesions may be relatively underestimated, when compared 
with WM lesions (including JC lesions), that are much more readily identified 
(Geurts & Barkhof 2008). Secondly, the SP and PPMS groups are smaller 
than the RRMS group, and this will have reduced sensitivity to subtle 
phenotypic differences in lesion distributions and associations with cognitive 
outcomes, although this is unlikely to have significantly influenced the main 
findings of this work. 
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 In conclusion, my data is in consensus with pathological studies that 
previously reported fronto-temporal predominance of CGM lesions. This is not 
simply due to differences in the size of the cortical lobes but represents a true 
predilection for lesion formation in these regions. Interestingly, when 
comparing people with RR and SPMS, while CGM lesion loads are higher in 
SPMS this appears to be mostly due to higher LC rather than IC lesion 
burden, which may reflect either the enlargement of pre-existing IC or JC into 
LC lesions, or the more frequent development of new LC lesions as a person 
with MS moves from RR to SPMS. The specific associations observed in my 
study between lesions and cognitive measures suggests that the presence, 
extent and regional location of CGM/JC lesions may all contribute to the 
patterns of cognitive impairment that occur in MS. 
4.6 Supplementary results 
Lesion numbers 
Lesion numbers for IC, LC and JC lesions were found to be the 
highest in the frontal and lowest in the occipital lobes (See Table 4.7 ). The 
association between lesion numbers and measures of cognition followed the 
same pattern as noted as noted for lesion volume. However the associations 
were stronger for volume than for number of lesions.  
Lesion Density ( lesion volume as a proportion of the lobar volume) 
SP had a significantly higher frontal lesion density than both RR and 
PP (adjusted difference in mean density respectively 0.00214, 95%CI 0.007, 
0.003 p=0.002; 0.001, 05% CI 0.0001, 0.003 p=0.034). In the temporal, 
insular and occipital lobes, the lesional density was significantly greater in SP 
than PP, but not RR: adjusted differences in mean density vs. PP was 0.001, 
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95% CI 0.0003, 0.003 p=0.015; 0.007, 95% CI 0.001, 0.013 p=0.023 and 
0.007, 95% CI 0.001, 0.013 p=0.02 respectively in temporal, insular and 
occipital lobes. There was no difference by phenotype detected in the parietal 
lobe. 
 
153 
 
  
Table 4.7 Distribution of CGM lesions (Numbers) 
 
 Frontal Temporal Parietal Occipital Insular 
 IC LC JC IC LC JC IC LC JC IC LC JC IC LC JC 
RR 
(n30) 
8.8 
(4.7) 
4.3 
(5.6) 
2.7 
(3.4) 
5.3 
(3.9) 
3.9 
(4.3) 
1.2 
(1.7) 
4.4 
(2.7) 
1.8 
(2.2) 
1.4 
(2.0) 
0.5 
(1.0) 
0.3 
(0.7) 
0.3 
(0.8) 
1.3 
(1.2) 
0.3 
(0.5) 
0.1 
(0.4) 
PP 
(n15) 
5.6 
(3.8) 
6.3 
(8.7) 
2.6 
(2.8) 
3.5 
(2.8) 
3.0 
(2.5) 
1.8 
(2.3) 
1.9 
(2.3) 
1.8 
(2.8) 
0.9 
(1.4) 
0.4 
(0.7) 
0.3 
(1.0) 
0.3 
(0.5) 
1.6 
(1.6) 
0.2 
(0.4) 
0.1 
(0.4) 
SP 
(n15) 
9.5 
(5.9) 
10.0 
(8.7) 
6.1 
(6.7) 
5.2 
(3.5) 
6.7 
(5.0) 
2.1 
(1.8) 
3.1 
(2.9) 
3.7 
(4.0) 
2.2 
(3.3) 
0.9 
(1.8) 
0.6 
(0.8) 
0.7 
(1.5) 
2.3 
(2.1) 
0.9 
(0.7) 
0.5 
(0.8) 
 
Mean (SD) for CGM lesion numbers (IC /LC/JC) across the five lobes and three phenotypes studied. 
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5 Accrual and evolution of cortical grey 
matter lesions : observations on 
follow up 
 
5.1 Abstract  
Background 
 
Cortical grey matter (CGM) lesions are seen in all subtypes of MS. 
Histopathological studies have demonstrated more extensive GM 
demyelination in people with progressive compared with relapsing-remitting 
(RR) MS, suggesting a potential role in the accumulation of irreversible 
disability. CGM demyelination has also been linked to meningeal 
inflammation, providing a plausible mechanism for this to occur independently 
of white matter (WM) demyelination. It is not known how GM demyelination 
progresses and whether or not it is related to WM damage. Longitudinal data 
studying the evolution of CGM lesions over time is limited. The objective of 
this study was to study the accrual and evolution of CGM lesions in people 
with multiple sclerosis (MS). 
 
Methods  
49 MS patients (27 RR, 22 SP (secondary progressive)) and 13 
healthy controls were scanned using a Philips 3T Achieva System. PSIR 
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(0.5x0.5x2mm) and PDT2 (1x1x3mm) scans were acquired at baseline and at 
follow-up and at least one year apart. Follow-up images were registered to 
baseline, using the niftyreg package using an affine transformation. On 
baseline scans, CGM lesion were marked and sub classified as intracortical 
(IC, only involving cortex) and leucocortical (LC, mixed GM-WM lesions); WM 
lesions touching but not entering the cortex were classified as juxtacortical 
(JC) lesions. On follow up scans, new IC, LC and JC lesions were identified, 
and any change in classification of lesions previously observed was noted. 
New WM lesions were counted on follow-up PDT2 scans. 
 
Results  
At baseline, the mean (standard deviation) number of lesions noted 
was 20.3 (9.8) IC, 16.4 (11.9) LC and 7.6 (9.3) JC in RR and 23.5 (10.6), 23.1 
(15.3) and 11.6 (12.5) in SPMS . Controls had 1.6 (2.6) LC lesions and no IC 
or JC lesions. After a mean(SD) follow up period of 20.5 (7.2) months, accrual 
of new IC lesions was greater in in SP 2.4 (2.6) than RR 1.1 (2.0); Mann-
Whitney p =0.050. No new JC / LC lesions were noted on follow up. RRMS 
had a greater increase in the number of WM lesions than SPMS (1 (1.9)) vs. 
0.5 (0.7); Mann-Whitney p=0.690, and WM lesion number did not change in 
controls on follow-up. More IC lesions became LC lesions in SP (2.1 (1.9)) 
than RRMS (1.7 (1.5));Mann-Whitney p=0.564) The change in CGM (IC and 
LC) lesion load did not correlate with the change in WM lesion load.  
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Conclusion 
 
People with SPMS have a significantly greater accrual of cortical 
demyelinating lesions than those with RRMS, but increase in IC lesions 
counts are offset by the extension of IC lesions into WM (so becoming LC) 
with time. This process appears to be mostly independent of WM lesion 
accrual. 
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5.2 Introduction 
Histopathological (Seewann et al.  2009; Bø, Vedeler, Nyland, Trapp & 
Mørk 2003b; Bø & Bø 2009; Geurts, Pouwels, et al.  2005b) and radiological 
studies have clearly established that grey matter (GM) pathology is 
substantial and clinically relevant in multiple sclerosis (MS). CGM lesions are 
seen across all subtypes of MS, (Seewann et al.  2009; Geurts, Pouwels, et 
al.  2005b; Nelson, Poonawalla, Hou, Huang, Wolinsky & Narayana 2007a; 
Bø, Vedeler, Nyland, Trapp & Mørk 2003b) and even in patients with clinically 
isolated syndrome (CIS) (Filippi, Rocca, Calabrese, Sormani, Rinaldi, Perini, 
Comi & Gallo 2010b). Histopathology studies have demonstrated more 
extensive GM demyelination in people with progressive compared with 
relapsing-remitting (RR) MS (Kutzelnigg et al.  2005a). Longitudinal studies 
have demonstrated only moderate correlations between change in white 
matter T2 MRI lesion load and accumulation of disability, (Fisniku et al.  2008) 
and it is plausible that increasing cortical demyelination has a potential role in 
the accumulation of irreversible disability. Longitudinal studies could also 
provide an understanding the relationship between accumulating CGM lesions 
and disability (Roosendaal et al.  2009). 
The investigation of CGM lesion accrual is difficult using 
histopathological studies; tissue is usually only available at only one time 
point, and comes either from people with early atypical clinico-radiological 
presentations that necessitate biopsy, or from post mortem (i.e. those with 
clinically advanced MS). Furthermore, pathological examination of the whole 
brain is also very time consuming. Until recently, it has been challenging to 
visualise CGM lesions even using magnetic resonance imaging 
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(MRI).However, with the development of sequences such as the double 
inversion recovery (Geurts et al.  2011; Turetschek et al.  1998) this has 
become possible. Using DIR, the accrual of CGM lesions over time has also 
been studied (Filippi & Rocca 2010; Roosendaal et al.  2009; Calabrese et al.  
2008). In a 3 year follow up in patients with RRMS (Calabrese, Rocca, et al.  
2010c), CGM lesions were found to accumulate with time and were 
associated with progression of disability (Calabrese et al.  2013) 
As demonstrated in my cross sectional comparisons of PSIR and DIR 
(Chapters 2, 3). PSIR is both more sensitive and more accurate in depicting 
and quantifying CGM lesions. I thus decided to investigate new CGM lesions 
using follow-up PSIR. With the improved identification and classification of 
lesions using PSIR, (Chapters 2 and 3) (Nelson, Poonawalla, Hou, Huang, 
Wolinsky & Narayana 2007a) I aim to study the accrual of CGM lesions, their 
location (IC, LC) ,whether they evolve differently in RRMS and SPMS, and 
whether they enlarge to involve more than one region over time, e.g., IC to LC 
or JC to LC, or whether they become smaller, i.e., changing from LC to IC. 
Patients with the common relapse onset form of MS can become 
disabled either through the effect of relapses with incomplete recovery during 
the relapsing remitting phase of the disease or from a steady accumulation of 
deficits in the secondary progressive phase. The accrual of new CGM lesions 
in relapse-onset MS has not been previously studied using PSIR.  
Another question is whether the accumulation of new CGM lesions is 
correlated with or independent of the accumulation of new WM lesions. In 
comparison to WM lesions, CGM lesions have less inflammation and are 
characterized by demyelination together with axonal transection and 
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apoptosis leading to neuronal loss (Peterson et al.  2001). CGM 
demyelination has also been linked with meningeal inflammation, providing a 
plausible mechanism for this to occur independently of WM demyelination. 
However, it is not known how closely GM and WM lesion accrual is linked in 
life, and whether or not the relationship differs between RR and progressive 
forms of MS. This is important, as current disease modifying treatments for 
MS have been proven to reduce WM lesion accrual, but there is limited data 
on their effect against GM demyelination, although in a recent study, using 
DIR, natalizumab has been found to suppress the accrual of CGM lesions and 
cortical atrophy (Rinaldi et al.  2011; Rinaldi et al.  2012).  
Using a high resolution PSIR sequence, I studied the accrual and 
evolution of CGM lesions, how this related to changes in WM lesions, and to 
relapses and the progression of disability. My focus was on RRMS and SPMS 
and a comparison of the two, in order to investigate the hypothesis that SPMS 
is characterized by a greater accumulation of CGM lesions. 
5.3 Methods  
Sixty five people participated in this follow up phase of the project. All 
patients gave a written informed consent for the study. Scans from 3 patients 
with RRMS had to be excluded due to motion artefacts. Amongst the 
remaining 62 people, 49 had clinically definite MS (Lublin et al.  1996; Polman 
et al.  2011) (27 RR(relapsing remitting), 22 SP(secondary progressive)) and 
13 participants were healthy controls (See Table 5.1). Of these, 12 RR, 8 SP 
and 11 healthy controls had also taken part in the first part of this study 
(Chapter 2). A detailed clinical history was recorded and neurological 
examination conducted. Disease duration, number of relapses since baseline 
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visit and any change of disease modifying therapy were recorded. Expanded 
disability status scale score was estimated (Kurtzke 1983) and the MS 
Functional composite with its three components (9-hole peg test, 25 foot 
timed walk and Paced auditory serial addition test (PASAT)(Polman & Rudick 
2010; Smith 1982)was also assessed.  
PSIR (0.5x0.5x2mm) and PDT2 (1x1x3mm) scans were acquired on a 
3T Philips Achieva system, at baseline and at follow-up, at least one year 
apart (Chapter 2 ; Table 2.2). No upgrades to the hardware were undertaken 
during this period. Follow-up images were registered to baseline, using the 
niftyreg package using an affine transformation. On baseline scans, CGM 
lesion were marked as intracortical (IC) and leucocortical (LC); WM lesions 
touching but not entering the cortex were marked as juxtacortical (JC) lesions. 
On follow up scans, new IC/LC/JC lesions were counted, and the anatomical 
location of old CGM lesions was studied to observe any change (e.g. IC to 
LC). New WM lesions were also counted on follow up PDT2 scans. All lesion 
marking was done under the supervision of an experienced neuroradiologist 
(TY). Marking of all scans was done blind to clinical details.  
The statistical analysis was performed using SPSS version 21 (SPSS, 
Chicago, IL, USA). Differences in demographic and clinical variables between 
RR and SPMS were examined using independent sample t-tests. Since lesion 
numbers tend not to be normally distributed, changes in lesion numbers were 
compared between patient groups using the Mann-Whitney test. Spearman 
rank correlation was used to investigate associations between demographic / 
clinical variables and both lesion accrual and cross-sectional lesion variables 
(baseline and follow-up). 
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5.4 Results  
5.4.1 Demographics 
The demographic and clinical details are recorded in Table 5.1. As 
expected people with SPMS were older (53.4(7.3) vs. 41.7 (10.9); p<0.001) 
and had longer disease durations than RRMS (25.4(10) vs. 13.1(9.5); 
p<0.001). The mean (SD) follow up period for patients with RR was 20.8 (7.6) 
months and for SP (18.0 (6.2) months) was not significantly different. The 
median EDSS for patients with RRMS was 1 at baseline (range 1 – 6) and 1.5 
(range 1-6) at follow up and for SPMS this was 6.5 (range 4-8.5) at both time 
points. 
In the interval between baseline and follow up, disease modifying 
therapy was started for one patient and stepped up/changed in 5 patients (3 
switched to natalizumab and 1 each changed to interferon beta-1a taken once 
weekly intramuscularly and thrice weekly subcutaneously). 
5.4.2 Baseline comparisons 
At baseline, the mean (SD) number of lesions was 20.3 (9.8) IC, 16.4 
(11.9) LC and 7.7 (9.3) JC in RR and 23.5 (10.6), 23.1 (15.3) and 11.6 (12.5) 
respectively in SP. Controls had 1.6 (2.5) LC lesions and no IC/JC lesions. 
The baseline IC (p=0.487), LC (p=0.124) and JC (p=0.183) lesion numbers 
did not differ significantly between the RR and SP groups 
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Table 5.1 Participant demographics 
 Age 
(years) 
M:F EDSS 
Median 
(Range) 
(baseline) 
Disease 
Duration* 
(years) 
Interval 
(months) 
EDSS 
Median 
(Range) 
(baseline) 
C 
(n=13) 
35.1 
(12.2) 
6 : 7   24.0 
(6.8) 
 
RR 
(n=27) 
41.7 
(11.0) 
9: 13 1 
(1 - 6.0) 
13.1  
(9.5) 
20.8 
(7.6) 
1.5 
(1 - 6.0) 
SP 
(n=22) 
53.4 (7.3) 6 : 21 6.5 
( 4 -8.5) 
25.4  
 (10) 
18.0 
(6.2) 
6.5 
( 4 -8.5) 
 
(Mean (SD) indicated below for C-Controls, SP=secondary progressive; 
RR=relapsing remitting MS) 
 
 
Table 5.2 Number of CGM lesions seen at baseline and follow up 
At Baseline At Follow Up 
MS 
type 
IC LC JC New 
IC 
IC to 
LC 
Net 
Gain 
of IC 
IC LC JC 
C 
(n13) 
Nil 1.6 
(2.6) 
Nil Nil Nil Nil Nil 1.6 
(2.6) 
Nil 
RR 
(n27) 
20.3 
(9.9) 
16.4 
(11.9) 
7.7 
(9.3) 
1.1 
(2.0) 
1.7 
(1.5) 
-0.2 
(2.2) 
19.7 
(10.2) 
18.2 
(12.2) 
7.7 
(9.2) 
SP 
(n22) 
23.5 
(10.6) 
23.1 
(15.3) 
11.6 
(12.5) 
2.4 
(2.6) 
2.1 
(1.9) 
0.8 
(2.9) 
23.7(1
0.6) 
25.2 
(16.0) 
11.6 
(12.5) 
 
(Mean (SD) indicated below for C-Controls, SP=secondary progressive; 
RR=relapsing remitting MS) 
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5.4.3 Changes over time  
As at baseline, even on follow up, SP had a higher number of lesions 
than RR (Table 5.2) but there was no significant difference between the two 
groups for IC (p=0.181) , LC (p=0.097) and JC (p=0.183) lesions. All lesions 
seen at baseline were still visible at follow up. The accrual of new IC lesions 
(Figure 5.1,Figure 5.2) was greater in patients with SPMS (2.4 (2.6)) than 
RRMS (1.1 (2.0)) (Mann-Whitney p =0.050). No new JC or LC lesions were 
seen. RRMS had a greater (though non-significant) increase in the number of 
WM lesions than SPMS 1 (1.9) vs. 0.5(0.7); Mann-Whitney p=0.690). WM 
lesion number did not change in controls on follow-up.  
The mean number of lesions converting from IC ( at baseline) to LC 
lesions ( at follow up ) was (non-significantly) greater in SPMS than RRMS 
(2.1 (1.9) vs. 1.7 (1.5); Mann-Whitney p=0.564). (See Figure 5.3 ). No JC 
lesion was seen to change to LC. No new CGM lesions were seen in controls.  
The mean (SD) number of new IC and WM lesions in people who had 
a relapse during the study period (n=11), were 1.2 (1.5) and 1.6 (2.7) 
respectively and the mean number of lesions changing from IC to LC was 1.6 
(1.1). In the remaining 38 patients who did not have a relapse, the figures 
were 1.8 (2.5), 0.5 (0.8) and 1.9 (1.8) respectively. These numbers did not 
differ between the relapsing and non-relapsing group. (Mann-Whitney 
p=0.959, 0.912 and 0.419 for differences in new IC, new WM and IC to LC 
lesions respectively). 
To account for the difference in duration of follow up in the RR and SP 
groups, the ratio of number of lesions to time lag was compared. Taking into 
account duration in this way had no effect on the difference in WM (Mann-
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Whitney p=0.806) or IC (Mann-Whitney p=0.07) lesion accrual. 
The absolute number of IC lesions at follow-up have to be interpreted 
allowing for both accrual of lesions and conversion of IC to LC lesions. These 
data show a small net increase of IC lesions in SP +0.3(2.6) vs. a small net 
decrease in RR -0.6(2.2) (Mann-Whitney p=0.426). 
5.4.4 Relationship between new IC lesions, new WM lesions 
and lesions evolving from IC to LC  
In the entire patient group, there was no correlation between the 
number of new WM(0.7(1.5)) lesions and mean number of lesions converting 
from IC to LC (1.8(1.6)) (r=0.242; p=0.093). There was also no correlation 
between number of new WM lesions and number of new IC lesions 1.6(2.3) 
(r=-0.166; p=0.254). When examining this for individual phenotypes, this 
observation did not change. ( RR: new WM and IC to LC r=0.248 p=0.212, 
new WM to new IC r=-0.244 p=0.219; SP: new WM and IC to LC r=0.248, 
p=0.265, new WM to new IC r =-0.150, p=0.504). 
5.4.5 Correlations between lesion counts and clinical features 
( Table 5.3) 
On reviewing the clinical history 11 people (8 RR, 3 SP) had 
experienced a relapse during the follow up period, 9 of whom received 
treatment with steroids (3 oral 5 intravenous, and one received both). 
Following the relapse, there was a 0.5 step increase in EDSS for 2 patients 
(RR) and an increase of 1 step in one RR patient. Considering the whole 
cohort (n=49) 17 patients had a worsening of EDSS (11RR and 6SP). 
Amongst these 17, 15 patients had a 0.5 EDSS step increase on follow up 
and 2 patients worsened by 1 step. One patient was seen to transition from 
165 
 
RR to SP during the follow up. 
In patients who had a worsening of EDSS (n=17) the mean (SD) 
increase in IC and WM lesions was 1.4 (2.7) and 0.8 (1.7) respectively, and 
the number changing from IC to LC was 1.4(1.3). In patients where there was 
no change in EDSS (n=32), the increase in IC and WM lesions was 1.8 (2.2) 
and 0.6(1.5) respectively; the number changing from IC to LC was 2.1(1.7). 
Differences between these two groups of EDSS worsening, and non-
worsening patients, for new IC (p=0.145), new WM (p=0.471) and IC to LC 
(p=0.172) were not significant.  
Performance on the PASAT correlated significantly with LC and JC 
lesion counts at baseline (r=0.477 p0.001, r=0.436 p=0.001) and follow-up 
(r=0.425, p=0.002; r=0.436, p=0.002; Table 5.3). EDSS also correlated 
modestly with number of LC and JC lesions at baseline (r=0.307 p=0.032, 
r=0.286,p=0.046); however, at follow up the EDSS did not correlate 
significantly with JC lesions, while a modest correlation with LC lesion number 
remained (r=0.0321, p=0.02). There was no significant correlation of either the 
number of new lesions or the number of lesions changing from IC to LC with 
EDSS or MSFC components at follow up. Age and duration of illness did not 
correlate with the number of new lesions or change in lesion location. 
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Figure 5.1 New Intracortical (IC) lesion  
 
PSIR images at baseline (left ) and follow-up (right) time point 
 Arrow showing a new IC lesion seen on follow up scan (right) (block arrow) 
 
 
Figure 5.2 New Intracortical (IC) lesion  
 
 
 
PSIR images at baseline (left ) and follow-up (right) time point 
Arrow showing a new IC lesion seen on follow up scan (right) (block arrow) 
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Figure 5.3 Change in lesion location on follow up 
 
 
Corresponding PSIR images at baseline (left) and follow-up (right) showing 
progressive involvement of WM in a IC lesion ( at baseline) that then becomes 
LC on follow up 
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Table 5.3 Correlations between lesion numbers and demographics / MSFC components 
  
  Baseline  At Follow Up 
  IC (B) LC(B)  JC (B) IC (F) LC (F) JC(F)  New IC New WM IC to LC 
Age r -0.034 -0.084 -0.105 0.056 -0.076 -0.105 0.213 -0.053 -0.050 
p 0.819 0.567 0.474 0.700 0.606 0.474 0.142 0.715 0.731 
Baseline 
EDSS 
r 0.003 0.307* 0.286* 0.069 0.320* 0.286* 0.194 0.140 0.121 
p 0.984 0.032 0.047 0.636 0.025 0.047 0.181 0.337 0.406 
Disease 
Duration 
r -0.036 0.130 0.251 -0.001 0.136 0.251 0.048 -0.036 0.037 
p 0.808 0.371 0.081 0.995 0.351 0.081 0.746 0.806 0.802 
Timed 
walk    
(z-score)* 
r -0.167 -0.182 -0.091 -0.110 0.183 -0.091 0.056 0.286* -0.028 
p 0.252 0.211 0.530 0.452 0.203 0.530 0.702 0.047 0.847 
9HPT    
(z-score)* 
r -0.237 -0.233 -0.074 -0.224 -0.261 -0.074 -0.074 0.225 -.294* 
p 0.101 0.107 0.616 0.122 0.070 0.616 0.614 0.121 0.040 
Pasat  
(z-score)* 
r -0.151 0.477 0.436 -0.146 0.425 0.436 -0.076 0.015 -0.024 
p 0.301 0.001 0.002 0.318 0.002 0.002 0.605 0.918 0.737 
EDSS * r 0.082 0.314* 0.273 0.144 0.321* 0.272 0.155 -0.089 0.106 
p 0.578 0.030 0.087 0.330 0.026 0.087 0.292 0.538 0.473 
(F) at follow-up ; (B) at baseline ; IC-Intracortical, LC-leucocortical and JC-juxtacortical .Bold font indicates p<0.01 
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5.5 Discussion  
In 49 relapse onset patients studied I confirmed – as already reported 
in Chapters 2 and 3 - that SPMS patients had a higher CGM lesion load than 
RRMS. In previous data, development of CGM lesions has been reported 
considering IC, LC and JC together as CGM lesions (Roosendaal et al.  2009) 
but using PSIR it was possible to demonstrate the accrual at different 
locations separately. People with SPMS had significantly more new IC lesions 
than those with RRMS (p=0.050), and showed a non-significant tendency for 
existing IC lesions become LC more often. The increase in WM lesions was 
greater in RRMS than SPMS (p=0.690). The accrual of GM lesions appeared 
to be independent of new WM lesion formation. Modest correlations were 
noted between LC lesions and baseline EDSS at both baseline and follow-up. 
In comparison to IC lesions, more robust correlation of LC and JC lesion 
counts were seen with PASAT. No new CGM or WM lesions were seen in the 
healthy controls.  
The total number of IC lesions at baseline and follow-up were higher in 
SP than RR, suggesting that focal cortical pathology is more extensive in the 
SP phase of disease (Roosendaal et al.  2009). Though this is strongly 
supported by histopathological studies (Bø, Vedeler, Nyland, Trapp & Mørk 
2003b; Kutzelnigg et al.  2005a), the majority of cortical demyelination noted 
histopathologically is subpial. Lesions that I identified as IC may partially be 
involving the subpial region although in this study, it was not possible to 
identify lesions involving the subpial region. This is probably because of 
multiple factors including small size of lesions, proximity to CSF, and a low 
contrast between demyelinated and non-demyelinated subpial cortex; which 
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in turn is because the normal density of myelin is lowest in this part of the 
cortex. 
In these data about 10% of IC lesions became LC, with a slightly 
higher frequency of this evolution seen in SP (2.1(1.9)) than RR (1.7(1.5)). 
This suggests that expansion of IC lesions to involve the adjacent JC white 
matter is a not uncommon occurrence in relapse onset MS. However, it was 
not specific to the SP phase of the disease and therefore does not seem 
useful in distinguishing the RR and SP phases of MS.  
The GM/WM boundary has been reported to be a site of predilection 
for accrual of CGM lesions in histopathological (Brownell & Hughes 1962) and 
radiological studies(Nielsen et al.  2013)(Chapter 4). The data in my serial 
suggest that even during the relapsing remitting phase of disease, there is a 
shift in pathology towards the GM/WM boundary, with time. Even amongst the 
27 RRMS patients, LC lesions increased from 16.4(11.9) to 19.7(10.2) on 
follow up. 
While IC lesions were seen to involve the JC WM and become LC, no 
de novo appearance of LC lesions was noted during the study period. Further, 
I saw no lesions converting from JC to LC. Further studies looking at larger 
cohorts and longer durations of follow up will help ascertain if LC lesions truly 
represent a pathological process distinct from that of purely WM lesions. The 
accrual of WM lesions this cohort was greater in RR > SP (though the 
difference was not significant), with numbers similar to those in other studies. 
(Calabrese et al.  2008). 
The absolute number of IC lesions at follow-up have to be interpreted 
allowing for both accrual of lesions and conversion of IC to LC lesions. I found 
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a small net increase of IC lesions in SP vs. a small net decrease in RR 
(Mann-Whitney p=0.426). As IC lesions did not disappear, the reduction in 
overall IC counts in RRMS can be attributed to existing IC lesions becoming 
LC more often than new IC lesions appearing. On the other hand, in SPMS 
there was a higher number of new IC lesions than existing IC lesions 
becoming LC.  
Unlike my experience with PSIR, in longitudinal studies using DIR, 
disappearing CGM lesions have been noted on follow-up. It has been 
hypothesized that only more inflammatory lesions are visible on DIR (Bagnato 
et al.  2006) and thus have a greater propensity to disappear on follow up 
(Roosendaal et al.  2009). CGM lesions in themselves have generally less 
inflammation than WM lesions (Bo1 et al.  2001), and this may reduce the 
sensitivity of DIR to detect them. It is possible that PSIR is more able to 
identify CGM lesions beyond the initial inflammatory state. Disappearing 
lesions could also possibly be due to remyelination (Albert et al. 2007b) which 
if effective and complete may no longer appear lesional; post-mortem 
verification of findings using PSIR shall help establish correlations between 
pathology and radiology.  
A comparison of lesion numbers between patients who had relapses 
(n=11) and those who did not (n=38) suggests that IC lesion accrual and 
conversion (to LC lesions) continued independently of the relapses. On the 
other hand, consistent with many previous published studies, patients with 
relapses had a higher accrual of new WM lesions (1.6(2.7) vs. 0.5 (0.8)).  
Studies with larger number of patients and longer duration of follow-up 
are needed to investigate the evolution of new WM and CGM lesions at 
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different stages of MS. The overall number of new lesions that I observed 
were quite small and larger and longer studies would undoubtedly add power 
in searching for differences in the patters of CGM lesion evolution between 
RR and SPMS. It may also be useful to separately monitor new CGM in 
treatment trials: if they develop through mechanisms that are independent of 
those causing new WM lesions, it can not be assured that treatments that are 
effective at suppressing WM lesion formation will be as effective against GM 
lesion accrual, particularly in progressive MS. Although Roosendaal et al. 
(Roosendaal et al.  2009) reported significant correlations between CGM 
lesions and WM lesions, in their study, JC lesions, which are essentially WM 
lesions were also included as CGM. My study using high resolution PSIR 
scans emphasizes the importance of being able to separate JC lesions from 
LC and IC lesions in order to accurately determine the relationship between 
each lesion type and clinical use.  
When considering these observations, it should be recalled that even 
with PSIR it is likely that the majority of GM lesions are still not detected. In 
particular subpial lesions, that make up the bulk of those identified 
histopathologically and that have been most closely associated with 
meningeal inflammation, have not been convincingly seen on PSIR. 
Longitudinal studies that maybe able to quantify accrual of subpial lesions 
using ultra-high field scanning (9.4T; (Schmierer et al.  2010) or could help to 
test the hypothesis relating to the contribution of meningeal inflammation to 
cortical demyelination. 
The one patient who transitioned from RR to SP during the study 
period, had a disease duration of 17 years. The interval between baseline and 
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follow-up for this patient was 27 months. No relapses occurred during this 
period and treatment with beta-interferon had continued though the study 
period. Though at both time-points this patient was able to walk a distance of 
100m with unilateral assistance (EDSS 6), there was a slowing noted, with 
raw time on the 25TWT test increasing from 10.9 to 15.1 seconds. An accrual 
of one IC lesion, and a shift of one IC to LC was noted (net gain zero) with no 
new PDT2 lesions. Though just one case, this case highlights (i) the ongoing 
cortical demyelination in the absence of relapses and (ii) progression 
independent of an accrual of WM lesions.  
Healthy controls had 3.7(5.7) WM lesions at baseline and 1.6 (2.6) 
CGM lesions, all of which were LC. There was no accrual of new CGM lesions 
or change in CGM lesions classification noted in these subjects. Though 
limited by the small number of controls, this is suggestive of a specificity of my 
findings of new IC lesions for MS per se although further investigation is 
warranted with larger group of healthy controls and especially in other 
neurological conditions that have white matter lesions e.g. migraine, small 
vessel disease etc.  
Correlations with clinical measures and global lesion loads were 
modest (as in Chapter 2). As reflected in the results of Chapter 4, the regional 
distribution of lesions based on lobes and anatomical locations improves 
correlations with cognitive measures. EDSS correlated modestly with both LC 
and JC lesion counts at baseline; however on follow up there was a loss of 
this correlation with JC lesions. This may indicate that the involvement of 
CGM (as a component of LC) lesions continues to contribute to progressive 
irreversible disability with progression of disease. The more robust correlation 
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between PASAT and LC and JC lesion counts at both time points is 
consistent with both cortical and immediately adjacent WM pathology having 
an influence on attention deficits in MS.  
Observations regarding number of IC / LC lesions in RR and SP at 
both baseline and follow up, are similar to those reported in the cross-
sectional study in Chapter 2 and consolidates the original cohort observations, 
as the cohort reported in this Chapter includes a substantial number of new 
subjects. This consistency in my observations has probably also been 
assisted by the use of guidelines that I established for the marking of CGM 
lesions on PSIR (see Chapter 2). Multicenter studies testing these guidelines 
are needed so that consensus recommendations can be prepared for use of 
PSIR, allowing a standardization of methods, observations and results.  
The mean duration of follow up in this follow up study was 21 months 
– and it is possible a longer period of follow up studies will provide an 
opportunity to extend the present observations and clarify the similarities and 
differences in CGM lesion evolution that occur in RRMS and SPMS. Primary 
progressive MS patients are thought to be pathologically different (Montalban 
et al.  2009; Brück et al.  2002; Lucchinetti & Brück 2004) from relapse onset 
disease, with a fewer cerebral WM lesions and a relatively more prominent 
involvement of the spinal cord, including a neurodegenerative component, 
from the onset. A future study of CGM evolution in the subset of PPMS 
patients will allow a good comparison with relapse onset MS patients.  
In conclusion, I found in this longitudinal study that new CGM lesions 
appear to develop independently of new WM lesions and to occur relatively 
more often in SPMS than RRMS whereas new WM lesions appear more often 
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in RRMS. These observations suggest that detection of new CGM lesions on 
MRI sequences sensitive to their presence provides additional insights in to 
disease evolution over and above the detection of new WM lesions on 
conventional MRI. Suppression of cortical demyelination as an end point in 
therapeutic trials warrants further investigation, with the potential to control / 
slow the accumulation of irreversible disability and cognitive dysfunction seen 
in patients with MS in so far as these functional effects can be related to 
cortical demyelination. 
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6 Are grey matter lesions specific to 
MS? : A comparison with Fabry's 
disease  
6.1 Abstract  
Background 
The detection and distribution of CGM lesions in MS has been studied 
extensively and discussed in the preceding chapters. Detection of white 
matter lesions is an important feature for establishing the diagnosis of MS. 
However, white matter lesions are commonly see in other conditions such as 
small vessel disease, migraine and neuroinflammatory conditions such as 
sarcoidosis. Fabry’s (also known as Anderson-Fabry) disease is a X linked 
inherited disorder and findings similar to small vessel disease have been 
reported on neuroimaging. The occurrence and frequency of CGM lesions 
may help differentiate from MS when the diagnosis is suspected but not 
confirmed.  
Aim 
To use high resolution PSIR at 3T, to study CGM lesions in Fabry's 
disease and investigate if this can be used to as an aid in the differential 
diagnosis of MS. 
Methods 
PSIR and PDT2 scans were acquired for 15 patients with Fabry's 
disease. These were compared with the participants in the earlier study 
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described in Chapter 2. (30 RRMS, 15 SPMS, 15PPMS and 30 healthy 
controls). CGM lesions were marked using JIM version 6.0 (Xinapse 
Systems), as per the guidelines outlined in Chapter 2. Lesions were identified 
as intracortical (IC), leucocortical (LC) or juxtacortical (JC), and counted 
separately. Additional note was made of the morphology of lesions. SPSS 
(version 21, Chicago) was used for the statistical analysis 
Results 
The mean (SD) number of lesions in the Fabry’s disease patients was 
IC 2.4(1.9), LC 9.6(4.8) and WM 4.0(4.3). No juxtacortical lesions were noted. 
Within the Fabry's group, there  were  significantly more LC than IC lesions 
(p=0.001). In comparison to Fabry's, people with MS were found to have a 
higher number of IC and WM lesions (p<0.001). Oval, wedge shaped and 
curvilinear lesions were noted in both MS and Fabry's and 21.6% of the 
curvilinear lesions were located along the gyral crown in Fabry’s whereas in 
MS all such lesions were along the sulcal pit. 
Conclusion 
Cortical lesions (IC and LC) are seen in patients with Fabry’s, The 
frequency of CGM lesions in the Fabry’s cohort was more than of healthy 
controls, but less than that observed in people with MS. IC lesions and a 
curvilinear morphology are see in both MS and Fabry’s. 
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6.2 Introduction 
In the previous chapters I have reported the frequency, distribution, 
accrual and evolution of CGM lesions in patients with MS and in healthy 
controls. If these changes are specific for MS then CGM lesions can help us 
differentiate MS from other conditions with white matter lesions when the 
diagnosis is suspected but not confirmed. This includes conditions such as 
small vessel disease (Nichtweiss et al.  2012; Assareh et al.  2010), migraine 
(Nichtweiss et al.  2012; Colombo et al.  2011; Assareh et al.  2010; Rossato 
et al.  2010), other headache disorders (Applebee 2012), neuroinflammatory 
conditions such as sarcoidosis (Fels et al.  2004), lupus (Cikes et al.  2008) , 
other connective tissue diseases and systemic vasculitides (Schedel et al.  
2010).  
Grey matter abnormalities in the form of CGM lesions, atrophy and 
quantitative changes (MTR, DTI measures) have been reported in other 
neurological conditions. Cortical microinfarcts (van Veluw et al.  2012) in 
vascular disease have been studied in the context of vascular dementia. In 
Alzheimer’s disease the evolution of disease is associated with the 
occurrence of CGM lesions which initially occur in the temporal lobe. Epilepsy 
(Kakita 2013), heat stroke (Fuse et al.  2013) and schizophrenia (Narr et al.  
2005; Pol et al.  2001) are some other conditions in which cortical pathology 
has been observed, in the form of lesions and changes in cortical thickness. 
The presence of focal CGM lesions may have potential to aid differential 
diagnosis; the lack of CGM lesions has been reported in neuromyelitis optica 
(Calabrese et al.  2012) and this observation needs further investigation 
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across other neuroinflammatory conditions.  
Fabry’s (also known as Anderson-Fabry) disease is a X linked 
inherited disorder. It was first described as a condition affecting the skin, in 
1898. A defect in GLA gene (Kint 1970) leads to deficiency of alpha 
galactosidase A, which is a functionally active enzyme. Hemizygotes with the 
condition have no detectable activity of this enzyme. In female carriers an 
intermediate level of enzyme activity is seen. This results in a disorder of 
lysosomal storage with cellular accumulation of glycosphingolipids with 
terminal alpha galactosyl moieties such as globotriaosylceramide (ceramide 
trihexoside, gal-gal-gal-glc-ceramide), most notably in blood vessels 
(Paavilainen et al.  2013), and galabiosylceramide (gal–gal–
ceramide)(Prineas 1997) in various tissues. Prominent pathological features 
in the nervous system include deposition of glycosphingolipids in the 
endothelial and smooth muscle cells of bloods vessels. This leads to a 
vasculopathy leading to cerebral ischemia / infarcts. Deposits of 
glycosphingolipid (Møller & Jensen 2007) are seen in the Schwann cells and 
deramide trihexoside deposits have been observed in the blood vessels of 
entorhinal cortex; these are also seen in the brain stem, amygdala, 
hypothalamus, spinal cord and ganglia, leptomeningeal cells (deVeber et al.  
1992) and astrocytes (Sobel et al. 2008) however, studies have reported no 
storage of glycolipids in the cerebral cortex (Kahn 1973).   
Clinical manifestations of Fabry’s disease can vary and multi-system 
affections are commonly seen. Neurological symptoms affecting both central 
and peripheral nervous systems (Ginsberg et al.  2007) are seen in about 
72% patients (Hoffmann 2009) and is often seen early in disease (Mehta et al. 
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2004). The central nervous system is involved as a result of a cerebral 
vasculopathy affecting both small and larger vessels; transient ischemia 
attacks and cerebral infarcts are often seen. Peripheral neuropathy results in 
intermittent paraesthesia, neuropathic pain and acroparaesthesia, which can 
affect the whole body (Hoffmann 2009). In addition, cortical presentations 
including seizures and cognitive impairment have been reported in Fabry’s 
disease. 
Neuro-radiological characteristics of Fabry’s disease are varied. 
Lesions indicative of small vessel disease are seen in patients with Fabry’s 
disease(Prineas 1997). Other findings include infarcts involving grey and 
white matter, T2 signal abnormalities in the periventricular region and T1 
hyperintensities in the pulvinar region. Areas of abnormal signal (hypointense 
on T1w scans) in the sub-cortical white matter have also been reported in 
patients with Fabry’s (Ginsberg et al.  2007). It is not clear whether the WM 
lesions represent areas of ischemia or demyelination (Ginsberg et al.  2007). 
The accumulation of disseminated white matter lesions (Ginsberg et al.  2007) 
in about 80% patients (male and female) (Buechner et al.  2008), combined 
with intermittent sensory symptoms sometimes leads to a fulfillment of the 
McDonald criteria (Polman et al.  2005; Polman et al.  2011; McDonald et al.  
2001) for possible/ definite MS (Böttcher et al.  2013). CSF analysis in Fabry’s 
disease may suggest aseptic meningitis (Lidove et al.  2009) and can be 
interpreted incorrectly. Fabry’s disease may thus sometimes be considered in 
a differential diagnosis of MS (Saip et al.  2007; Böttcher et al.  2013; 
Solomon & Weinshenker 2013; Callegaro & Kaimen-Maciel 2006).  
Global and regional grey matter volumes have not been found to differ 
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between people with Fabry’s, and healthy controls (Paavilainen et al.  2013). 
Cortical regions that appear normal on conventional scans, have shown a 
reduction of N-acetyl aspartate on proton MR spectroscopy (Prineas 1997), 
perhaps due to underlying cerebral ischemia (Tedeschi et al.  1999). Cerebral 
atrophy has also been reported (Buechner et al.  2008) but the occurrence of 
CGM lesions has not been explored in radiological studies. 
In previous chapters I have reported that in comparison to controls, 
the occurrence of pure intracortical lesions, and a curvilinear morphology are 
more frequent in MS patients. In this study I investigated the frequency, 
subtype (IC, LC and JC) and morphology (curvilinear, oval and wedge-
shaped) of CGM lesions in patients with Fabry’s disease and explore whether 
it differed from patients with MS (and healthy controls).  
6.3 Methods 
PSIR and PDT2 scans had been acquired for 60 patients (30 RRMS, 
15 SP and 15PPMS) and 30 healthy controls (Chapter 2). In addition, PSIR 
scans were acquired for 15 patients with Fabry’s disease, who were recruited 
by colleagues in the Department of Metabolic disease. Acquisition parameters 
for PSIR and PD/T2 scans were the same as described in earlier Chapters 
(2,3,4). For this group of patients with Fabry’s, FLAIR scans were not 
available. Demographic distribution of this group of 15 Fabry's patients was 
also recorded. 
Scans for the cohort of 60 MS patients were reviewed. I identified 
CGM lesions and further examined the marked lesions that had a curvilinear 
morphology and noted whether they were in the sulcal pit or over the gyral 
crown (as reported in Chapter 2). For the 15 Fabry's patients, CGM lesions 
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were marked using JIM version 6.0 (Xinapse Systems), as per the guidelines 
outlined in Chapter 2. Lesions were identified as intracortical (IC), 
leucocortical (LC) or juxtacortical (JC), and counted separately. Additional 
note was made of the morphology of lesions; the number of curvilinear, oval 
and wedge shaped lesions was counted. For curvilinear lesions I noted 
whether they stretched along the sulcal pit or over the gyral crown. The 
number of white matter lesions (non-JC) were counted using PDT2 and PSIR 
scans. All lesion marking was under in under supervision of two experienced 
researchers (DC, TY). The appearance of VR spaces in the insular region 
was also noted. All methods were the same as used for data from MS patients 
in the preceding chapters (Chapter 2, 3) 
SPSS (version 21, Chicago) was used for the statistical analysis. 
Since lesion numbers tend not to be normally distributed, the following non-
parametric tests were used: Wilcoxon signed rank for comparison of 
differences within subjects; Mann-Whitney for comparison of differences 
between groups; and Spearman correlation for investigating associations 
between quantitative variables. A value of p<0.05 is reported as significant.  
6.4 Results 
Demographic details for healthy controls and MS patients have been 
detailed in Chapter 2, Table 2.1. The fifteen patients with a confirmed 
diagnosis of Fabry’s disease (8 male and 7 female) had a mean (SD) age of 
43.3(12.4) years; the diagnosis had been confirmed using genetically 
confirmed GAL mutations. These subjects were participating in a separate 
research study involving multiparameter MRI and neuropsychological 
investigation. For the present analysis of PSIR scans for CGM lesions, no 
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additional clinical or imaging data was used. 
6.4.1 Group of patients with Fabry’s disease  
Amongst these 15 patients, at least one IC lesion was seen in 12 
patients and all patients had at least one LC lesion. The mean (SD) number of 
lesions per patient (See Table 6.1) in the Fabry’s disease patients was IC 
2.4(1.9), LC 9.6(4.8) and WM 4.0(4.3). No juxtacortical lesions were noted in 
any of the patients with Fabry’s disease using PSIR scans at 3T. Within the 
Fabry’s group, there  were  significantly more LC than IC lesions (Wilcoxon 
signed rank p=0.001).  
 The mean number of WM lesions on PSIR (4 (4.3)) correlated 
strongly with the WM lesion count on PDT2 scans (mean=5.6 (5.3)) 
(Spearman correlation r=0.985; p<0.001). The number of IC, LC and WM 
lesions did not differ significantly between males and females (all p>0.500). 
On the PSIR scans, there was no significant correlation between the number 
of IC lesions and number of WM lesions (r=0.447, p=0.095).  
6.4.2 Comparison in lesion numbers : Fabry’s vs. MS and vs. 
Controls 
The mean(SD) number of lesions for the MS cohort are detailed in Chapter 2 ( 
 
 
Table 2.4). On comparing the number of lesions between the two 
groups, MS and Fabry’s, people with MS were found to have a higher number 
of IC and WM (on both PSIR and PDT2) lesions than Fabry’s(for all 
comparisons Mann-Whitney p<0.001). There was no significant difference in 
number of LC lesions between the MS cohort and Fabry’s disease. As 
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reported above, no JC lesions were seen in Fabry’s. 
 
 
Table 6.1 Distribution of lesions in the study participants  
 
 On PSIR On PD/T2 
 IC LC JC 
Non JC 
WM 
Non JC 
WM 
Controls 
n=30 One 0.7 (1.8) Nil 2.6 (4.4) 3.7 (5.3) 
PP N=15 12.3 (8.8) 
11.7 
(12.7) 6.1 (5.5) 50.4 (31.7) 48.3 (27.6) 
SP N=15 21.3 (10) 20.9 (13.7) 
11.1 
(11.2) 80.5 (40.7) 72.9 (33) 
RR N=30 19.5 (9.2) 
10.5 
(11.4) 5.8 (6.8) 63.4 (57.2) 61.2 (51.2) 
Fabry’s N=15 2.4 (2.0) 9.6 (4.9) Nil 4.0 (4.3) 5.7 (5.3) 
Above data indicates mean (SD) of number of lesions across the study 
participants 
 
 
 
 
Table 6.2 Comparison of lesion morphology 
 
 
 
 
 
 
Numbers above are the number of patients with at least one lesion of the 
respective morphology 
 
  
 Oval lesions 
Curvilinear 
lesions 
Wedge shaped 
lesions 
Fabry’s 15/15 15/15 8/15 
MS 47/60 51/60 20/60 
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Figure 6.1 Examples of CGM lesions in Fabry’s disease 
 
Example of an IC (bold chevron ) lesion; the blocked arrow indicates a LC 
lesion with a curvilinear morphology along the gyral crown  
 
I further anlaysed comparisons with Fabry’s by looking at each 
phenotype of MS separately. The above results remained unchanged on 
considering patients with primary progressive MS and relapse-onset MS 
separately versus Fabry's disease. On comparing SPMS with Fabry’s 
disease, the difference in LC lesions was also significant (Mann-Whitney 
p=0.011) (See Figure 6.1, Table 6.1). In comparison to controls, patients with 
Fabry’s disease had a higher number of IC and LC lesions (Mann-Whitney 
p<0.001 for both); WM lesion numbers did not differ significantly between 
controls and Fabry’s disease.  
6.4.3 Comparison in lesion morphology : Fabry’s vs. MS and 
vs. Controls 
I compared the number of oval, curvilinear and wedge shaped lesions 
across the participants. Using Fisher's exact test, comparisons of proportions 
for oval, curvilinear and wedge lesions between the Fabry’s and MS cohort 
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showed no significant differences. (Oval 15/15 (100%) vs. 47/60 (78%) 
(p=0.059), curvilinear 15/15 (100%) vs. 51/60 (85%) (p=0.190) and wedge 
8/15 (53%) vs. 20/60 (33%) (p=0.232)) See Table 6.2. 
In comparison to controls, curvilinear lesions were found to be more 
specific for MS ( at least one curvilinear lesion see in 51/60 patients with MS 
and in 0/ 30 controls, Chapter 2). I studied these further by observing the 
location of curvilinear lesions as being along the sulcal pit vs. the gyral crown. 
There is no standard definition to demarcate the sulcal region from the gyrus 
in imaging studies (Samson et al.  2013). For purposes of this work, I 
recognised the part of the cortex abutting the dura mater as gyral and the rest 
as sulcal. In the MS patients, all curvilinear lesions were noted in the sulcus 
and none in the gyrus. In Fabry's 21.6% of the total curvilinear lesions were 
located along the gyral crown. 
6.5 Discussion 
In this study I identified the presence of CGM lesions (IC and LC) in 
patients with Fabry’s disease. Cortical pathology in Fabry’s disease was 
largely at the GM/WM boundary and pure CGM lesions (IC) were 
considerably less common. The frequency of CGM lesions in the Fabry’s 
cohort was more than the normal population, but less than that observed in 
people with MS.  
Using PSIR at 3T, involvement of both intracortical and leucocortical 
locations was noted: 2.4 (1.9) IC and 9.6 (6.8) LC lesions were identified. The 
pathological substrate of these lesions in Fabry’s disease is not known. These 
lesions appear hypointense (low signal, implying long T1) and ischemia 
leading to cortical infarcts is a possibility. The mechanism of cerebral 
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ischemia could be due to the underlying vasculopathy (Ginsberg et al.  2007) 
that causes hypoxia. Hypoxia in turn has been reported causes alterations in 
the endothelial cells leading to a disruption of the blood brain barrier (Kaur & 
Ling 2008). In addition hypoxia leads to a derangement of the tight junction 
proteins and these factors together maybe leading to increased permeability 
of the blood brain barrier. This is the more likely mechanism for CGM lesions, 
as opposed to lipid deposition in lepotomeningeal cells (Elleder et al.  1994), 
which would shorten the T1, causing a hyper-intense appearance on T1 
weighted imaging.  
No significant difference between lesions numbers was noted in males 
in comparison to females. Heterozygous females are relatively less 
symptomatic than affected males but can develop symptoms with increasing 
age (Prineas 1997); the impact of genotype on CGM lesions would require 
further genotype details, which were not available in this study and could be 
explored further in a future study.  
 In the patients with Fabry’s disease, the number of WM lesions on 
PSIR correlated well with the detection on PDT2 (Spearman’s correlation 
r=0.985; p=0.000). This is similar to the finding in Chapter 2 and re-
emphasises the utility of PSIR for detection of WM lesions in addition to being 
able to CGM. I found a non-significant trend for correlation between IC and 
WM lesion numbers (r=0.447, p=0.095) in Fabry’s disease; investigation of 
larger cohorts is needed to clarify whether there is indeed a relationship. 
My study indicates that the occurrence of IC lesions is not specific to 
MS alone, although they occurred in higher numbers in MS than in Fabry’s 
disease. Intracortical lesions have been suggested as a diagnostic aid in MS 
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because of a high specificity (Filippi, Rocca, Calabrese, Sormani, Rinaldi, 
Perini, Comi & Gallo 2010b; Sinnecker et al.  2012; Calabrese et al.  2012); 
however my observations in Fabry’s disease clearly indicates that such a 
lesion location is not exclusive to MS. Further investigation for evidence of IC 
lesions using PSIR-MRI is warranted in other neurological conditions that are 
considered in the differential diagnosis of MS.  
Curvilinear, oval and wedge shaped CGM lesions were all seen in 
Fabry’s disease. In controls I did not observe curvilinear lesions. The relative 
absence of an intracortical location and a curvilinear morphology was 
characteristic of controls in comparison to both diseases investigated (MS and 
Fabry’s disease). While 85% patients with MS were found to have a 
curvilinear lesion, all patients with Fabry’s were found to have at least one 
curvilinear lesion: thus the simple appearance of a curvilinear CGM lesion 
does not appear specific for MS; however, investigation for this type of lesion 
in other conditions that enter the MS differential diagnosis would seem 
warranted. 
I compared the location of  curvilinear lesions between MS and 
Fabry’s disease and found that while none of these lesions were located over 
the gyral crown in MS; 21.6% curvilinear lesions were in the gyral crown in 
Fabry’s disease (See Table 6.2). The suclal region showed preferential 
involvement in patients with MS. CSF flow is likely to be slower in the regions 
of the sulcus (Samson et al.  2013) and a prolonged exposure to inflammatory 
triggers, with meningeal inflammation leading to subpial demyelination, has 
been proposed as a theory for sulcal predilection of CGM MS lesions. The 
occurrence of gyral crown curvilinear lesions in Fabry’s disease may reflect a 
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different pathogenic mechanism. A sulcal predominance (and gyral sparing) of 
CGM lesions maybe more characteristic of MS than other disease states but 
this needs to be investigated in a broader range of conditions that enter the 
differential diagnosis of MS.  
No juxtacortical lesions were noted in patients with Fabry’s or in 
healthy controls. JC lesions were therefore specific for patients with MS in this 
study. Juxtacortical lesions have been identified as a significant predictor for 
conversion of CIS to clinically definite MS (Barkhof et al.  1997), providing 
more information than periventricular lesions, hypointense T1 lesions and the 
total number of T2 lesions. Their presence has also been correlated with 
neuropsychological impairment (Lazeron et al.  2000). JC lesions are an 
important aid in the diagnosis of MS, and have been studied extensively using 
conventional scans such as FLAIR (Yousry et al.  1997; Herskovits et al.  
2001). Juxtacortical lesions are part of the McDonald criteria for dissemination 
in space (Polman et al.  2011; Polman et al.  2005) and my finding of their 
absence in controls and Fabry’s disease using high resolution PSIR scans 
further supports their specificity for MS. The use of PSIR provides more 
accurate classification of JC lesions distinct from LC and IC lesions, and my 
findings raise the possibility that true JC lesions are more specific for MS than 
has been suggested in previous work using FLAIR scans where it is likely that 
some lesions classified as JC were actually LC.  
In conclusion, in comparison to MS using high resolution PSIR, 
patients with Fabry’s disease have fewer CGM lesions, involvement of the 
gyral crown and absence of involvement of the juxtacortical region.  
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7 Conclusion 
The projects undertaken above have aimed to assess (i) the detection 
and classification of CGM lesions using PSIR, (ii) evaluate the significance of 
CGM lesions in the clinical setting and (iii) researched the distribution, location 
and evolution of CGM lesions to help improve the understanding of the 
pathogenesis of CGM lesions in MS. 
7.1 Detection of Cortical grey matter lesions using PSIR 
Using a cohort representative of all common MS phenotypes, (RR, SP 
and PPMS), I first compared the detection of CGM lesions on a standard 
resolution DIR (1x1x3mm)(Geurts et al.  2011) vs. high resolution PSIR (0.5 
x0.5 x 2mm), acquired using Philips 3T Achieva system. The results 
(Chapter2) indicated that PSIR detects a significantly greater number of CGM 
lesions (about three times) than DIR (Geurts et al.  2011). In addition to the 
quantitative improvement (Chapter 2), a qualitative improvement with respect 
to the anatomical accuracy of lesions (Chapter 3) was also demonstrated with 
the use of PSIR. Subpial regions could however not be seen using PSIR at 
3T. PSIR can be used to study both grey and white matter (Chapters 2 and 5), 
and has the potential to be included in routine scanning protocols across 
clinical and research centres.  
7.2 Clinical impact of cortical lesions 
The clinical impact of CGM lesions includes a potential role in 
diagnosing MS and differentiating it from other conditions, understanding of 
differences in MS subtypes, association with cognition and disability.  
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7.2.1  Diagnosis and differential diagnosis  
In this project I attempted to determine if the findings of CGM lesions 
are specific to patients with MS. Intracortical lesions, were seen only in one 
control (Chapter 2), and in Fabry’s, their occurrence was significantly less 
compared to MS (Chapter 6). The curvilinear morphology of lesions, while 
common in MS patients and not seen in controls and was observed in all 
patients with Fabry’s. It is not clear whether the morphology of lesion is 
indicative of a separate pathological process. In keeping with the role of JC 
lesions in diagnosing MS, using conventional scans, I also observed that 
these lesions were specific for MS. I noted no JC lesions in controls or in 
people with Fabry’s disease. 
7.2.2 Can cortical lesions help differentiate phenotypes? 
In this work the data suggests that people with secondary progressive 
disease have a greater number of CGM lesions at all locations –IC, LC and 
JC (Chapters 2, 4 and 5) and can be seen early in disease. The shortest 
disease duration amongst all patients in this study was 1 year in a patient with 
RRMS; 9 IC and 2 LC, JC each were identified in this patient. No people with 
clinically isolated syndrome were recruited in this study, however literature 
suggests that CGM lesions are seen even in people with CIS (Filippi et al. 
2010b). One healthy control was noted to have an isolated IC lesion in my 
data, and should be followed up in time, considering the possibility that this 
may represent a radiologically isolated syndrome. Regional distribution of 
lesions, across lobes was not found to be significantly different between MS 
phenotypes.  
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7.2.3 Impact on Cognition and disability 
When comparing total CGM lesion counts, correlations between 
clinical measures and CGM lesions counts were limited to the relapse-onset 
group; the most consistent correlations were PSIR LC counts with the Symbol 
Digit Modality Test (Chapter 2). I expected correlations to improve on 
comparing regional CGM lesions, measured as volumes. Results in chapter 4 
indicate that both CGM and juxta-cortical lesions are associated with cognitive 
defects; the associations varying with different lobar regions. Functional 
localization of cognitive dysfunction has to be interpreted with caution allowing 
for differences between tasks that are more network driven as compared to 
others. 
7.2.4 Treatment 
Current disease modifying therapy (DMT) is aimed at reducing the 
accrual of WM lesions and number of clinical relapses. During the follow up 
period, patients with relapses had a higher accrual of WM lesions; 
Conversely, IC lesion accrual and conversion (to LC) was independent of the 
relapses (Chapter 5). These data suggest that the influence of DMT on CGM 
demyelination cannot be presumed to be the same as that on WM, and merits 
further investigation. If these new CGM lesions represent ‘cognitive relapses’ 
then it is important to recognise the accrual of new lesions and use this an 
end point in future clinical trials.  
7.3 Relevance to pathogenesis 
 The pathology of GM MS lesions has been suggested to be location 
dependent (Brink et al.  2005; Bø & Bø 2009) and the location differences 
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represent differences in pathogenesis of lesions at different sites (Reynolds et 
al.  2011; Kutzelnigg et al.  2005a); e.g. complement activation causes 
oligodendrocyte and myelin damage and is seen to be low in pure CGM 
lesions in comparison to LC and pure WM lesions.  
The data reported in this thesis suggest heterogeneity in the number 
of CGM lesions at different locations and across different lobes and clinical 
MS phenotypes. With progression of disease a major proportion of CGM 
lesions are found to be located at the GM/WM boundary (Chapters 2, 4 and 5) 
and accrual of IC lesions continues. It is possible that lesions that I have 
classified as IC may represent lesions that have subpial component and then 
extend into the thickness of the cortex, and are influenced by the meningeal 
inflammation. On follow up no new LC lesions were noted and no JC lesions 
were seen to transform to LC. The accrual of LC lesions was due to IC lesions 
extending to involve the subcortical WM, suggesting that their pathogenesis is 
linked to subpial and IC pathology, possibly remaining separate from WM 
triggers.  
There were no significant correlations between the accrual of new WM 
lesions and development of new IC lesions (Chapter 5). IC lesions thus 
appear to increase independent of the rate of new inflammatory WM lesions, 
consistent with the concept that intracortical demyelination continues with an 
intact blood-brain barrier and minimal inflammation (Reynolds et al.  2011), 
possibly representing a compartmentalisation of pathogenic processes with 
progression of disease (Frischer et al. 2009). Furthermore, the number of 
relapses did not impact the accrual of CGM lesions (Chapter 5) suggesting 
greater neurodegeneration (vs. neuroinflammation) in cortical pathology 
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(Reynolds et al.  2011). Recent studies have reported the origin of CGM 
lesions as being outward from a central vein (Gaitan et al.  2012) In this data 
the proximity of lesions to blood vessels has not been studied and should be 
planned in future studies. 
7.4 Limitations and future direction 
 
In this study subpial lesions could not be identified, using 3T imaging. 
Limited detection of subpial lesions may not matter should CGM lesion 
detection per se prove useful for diagnosis, but may be relevant when 
monitoring evolving pathology, especially in progressive MS. In the 
longitudinal study in this thesis, patients with primary progressive disease 
have not been included and this comparison with relapse-onset MS should be 
studied in the future to help understand difference in pathogenesis. In this 
thesis, regional differences in distribution of CGM lesions have been explored 
by lobe; by being more selective in regions of comparison - e.g. cingulate 
gyrus, hippocampus - a stronger association between CGM lesions and 
clinical and cognitive measures may become apparent. 
Further studies are needed to reproduce these observations using 
PSIR for the study of CGM in MS. A comparison across centres will allow 
standardisation of marking criteria enabling the formation of consensus 
recommendations for detection of CGM lesions. Combined radiology and 
pathology studies will improve the understanding of the significance of CGM 
lesions, their frequency and morphology. To elucidate the specificity of 
findings in MS, a comparison with other neurological conditions is also 
warranted.  
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In conclusion, CGM lesions are important in the pathogenesis of MS 
and Phase sensitive inversion recovery, a T1w MRI sequence, can improve 
detection and classification of CGM lesions, in clinically acceptable times. 
CGM lesions are seen across all subtypes of MS, being more common in 
progressive disease, and have a potential role to help with diagnosis of MS 
when it is suspected but not confirmed. The distribution, accrual and evolution 
of lesions provides insights into the pathogenesis of MS and the contribution 
of CGM lesions to neurological and cognitive impairment. The use of CGM 
lesions as endpoints in clinical trials needs to be explored further. 
  
196 
 
8 Bibliography 
Absinta, M. et al., 2011. Cortical lesions in children with multiple sclerosis. 
Neurology, 76(10), pp.910–913. 
Absinta, M. et al. 2013. Seven-tesla phase imaging of acute multiple sclerosis 
lesions: A New Window into the Inflammatory Process. Annals of 
neurology, 74(5), pp.669-678. 
Achiron, A. et al., 2003. Cognitive impairment in probable multiple sclerosis. 
Journal of Neurology, Neurosurgery & Psychiatry, 74(4), pp.443–446. 
Albert, M. et al., 2007a. Extensive cortical remyelination in patients with 
chronic multiple sclerosis. Brain pathology (Zurich, Switzerland), 17(2), 
pp.129–138. 
Albert, M. et al., 2007b. Extensive Cortical Remyelination in Patients with 
Chronic Multiple Sclerosis. Brain Pathology, 17(2), pp.129–138. 
Allen, I.V. et al. 2001. Pathological abnormalities in the normal-appearing 
white matter in multiple sclerosis. Neurological Sciences, 22(2), pp.141–
144. 
Amato, M.P. et al., 2004. Neocortical volume decrease in relapsing-remitting 
MS patients with mild cognitive impairment. Neurology, 63(1), pp.89–93. 
Andersson, M. et al., 1994. Cerebrospinal fluid in the diagnosis of multiple 
sclerosis: a consensus report. Journal of Neurology, Neurosurgery & 
Psychiatry, 57(8), pp.897–902. 
Applebee, A., 2012. The clinical overlap of multiple sclerosis and headache. 
Headache, 52 Suppl 2, pp.111–116. 
Archibald, C.J. et al., 2000. Information Processing Efficiency in Patients with 
Multiple Sclerosis. Journal of Clinical and Experimental Neuropsychology 
(Neuropsychology, Development and Cognition: Section A), 22(5), 
pp.686–701. 
Assareh, A. et al., 2010. The Genetics of White Matter Lesions. CNS 
Neuroscience & Therapeutics, 17(5), pp.525–540. 
Bagnato, F. et al., 2006. In vivo detection of cortical plaques by MR imaging in 
patients with multiple sclerosis. AJNR. American journal of 
neuroradiology, 27(10), pp.2161–2167. 
Bakshi, R., 2003. Fatigue associated with multiple sclerosis: diagnosis, impact 
and management. Multiple sclerosis (Houndmills, Basingstoke, England), 
9(3), pp.219–227. 
197 
 
Bakshi, R. et al., 2008. MRI in multiple sclerosis: current status and future 
prospects. Lancet neurology, 7(7), pp.615–625. 
Barkhof, F. et al., 1997. Comparison of MRI criteria at first presentation to 
predict conversion to clinically definite multiple sclerosis. Brain : a journal 
of neurology, 120 ( Pt 11), pp.2059–2069. 
Barkhof, F., 2002a. The clinico-radiological paradox in multiple sclerosis 
revisited. Current opinion in neurology, 15(3), p.239-245. 
Barkhof, F., 2002b. Whole-brain T 1 -relaxation time measurements in 
multiple sclerosis. Journal of neurology, 249(10), pp.1451–1452. 
Barkhof, F. et al., 2003. Remyelinated lesions in multiple sclerosis: magnetic 
resonance image appearance. Archives of neurology, 60(8), pp.1073–
1081. 
Barkhof, F. et al., 2009a. Imaging outcomes for neuroprotection and repair in 
multiple sclerosis trials. Nature Publishing Group, 5(5), pp.256–266. 
Barkhof, F. et al., 2009. Multiple sclerosis: MRI - the perfect surrogate marker 
for multiple sclerosis? Nature reviews. Neurology, 5(4), pp.182–183. 
Barnett, M.H. et al., 2004. Relapsing and remitting multiple sclerosis: 
pathology of the newly forming lesion. Annals of neurology, 55(4), pp.458–
468. 
Bender, B. et al., 2010. Double inversion recovery: impact of incidental 
magnetic transfer effects on optimal inversion times. Investigative 
radiology, 45(4), pp.196–201. 
Benedict, R.H. et al., 2012. Reliability and equivalence of alternate forms for 
the Symbol Digit Modalities Test: implications for multiple sclerosis clinical 
trials. Multiple sclerosis, 18(9), pp. 1320-1325. 
Bjartmar, C. et al., 2001. Axonal loss in normal-appearing white matter in a 
patient with acute MS. Neurology, 57(7), pp.1248–1252. 
Bjartmar, C. et al., 2003. Axonal loss in the pathology of MS: consequences 
for understanding the progressive phase of the disease. Journal of the 
neurological sciences, 206(2), pp.165–171. 
Bø, L. et al. , 2001. Intracortical Multiple Sclerosis Lesions Are Not Associated 
With T Lymphocyte Infiltration. Acta Neurologica Scandinavica, 103(5), 
pp.323-333.  
Bø, L., et al., 2003a. Intracortical multiple sclerosis lesions are not associated 
with increased lymphocyte infiltration. Multiple sclerosis (Houndmills, 
Basingstoke, England), 9(4), pp.323–331. 
Bø, L., et al., 2003b. Subpial demyelination in the cerebral cortex of multiple 
sclerosis patients. Journal of neuropathology and experimental neurology, 
198 
 
62(7), pp.723–732. 
Bø, L., et al., 2006a. Grey matter pathology in multiple sclerosis. Acta 
neurologica Scandinavica, 113(s183), pp.48–50. 
Bø, L., et al., 2006b. Grey matter pathology in multiple sclerosis. Acta 
neurologica Scandinavica. Supplementum, 183(s183), pp.48–50. 
Bø, L. et al., 2009. The histopathology of grey matter demyelination in multiple 
sclerosis. Acta neurologica Scandinavica, 120(189), pp.51–57. 
Bobholz, J.A. et al., 2003. Cognitive dysfunction in multiple sclerosis: a review 
of recent developments. Current opinion in neurology, 16(3), pp.283–288. 
Borrello, J.A., et al., 1990. Regional phase correction of inversion-recovery 
MR images. Magnetic resonance in medicine : official journal of the 
Society of Magnetic Resonance in Medicine / Society of Magnetic 
Resonance in Medicine, 14(1), pp.56–67. 
Böttcher, T. et al., 2013. Fabry disease - underestimated in the differential 
diagnosis of multiple sclerosis? PloS one, 8(8), p.e71894. 
Boulby, PA. et al. 2004 Optimized interleaved whole-brain 3D Double 
inversion recovery for imaging the neocortex. Magnetic Resonance in 
Medicine (51) pp 1181-86. 
Bramow S. et al., 2010. Demyelination versus remyelination in progressive 
multiple sclerosis. Brain (133) pp. 2983-2998. 
Brink BP. et al., 2005. The pathology of multiple sclerosis is location 
dependent : no significant complement activation is detected in purely 
cortical lesions. Journal of neuropathology and experimental 
neurology(64) pp 147-155. 
Brink, B.P. et al., 2005. The Pathology of Multiple Sclerosis Is Location-
Dependent: No Significant Complement Activation Is Detected in Purely 
Cortical Lesions. Journal of neuropathology and experimental neurology, 
64(2), p.147. 
Brownell, B. et al., 1962. The distribution of plaques in the cerebrum in 
multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 25, 
pp.315–320. 
Brück, W. et al., 2002. The pathology of primary progressive multiple 
sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 8(2), 
pp.93–97. 
Buckner, R.L. et al., 2005. Molecular, structural, and functional 
characterization of Alzheimer's disease: evidence for a relationship 
between default activity, amyloid, and memory. The Journal of 
neuroscience : the official journal of the Society for Neuroscience, 25(34), 
pp.7709–7717. 
199 
 
Buechner, S. et al., 2008. Central nervous system involvement in Anderson-
Fabry disease: a clinical and MRI retrospective study. Journal of 
Neurology, Neurosurgery & Psychiatry, 79(11), pp.1249–1254. 
Burgess, P.W. et al., 1997 The Hayling and Brixton Tests, Thames Valley 
Test company/ Pearson Assessment, Bury St Edmunds, Suffolk. 
Calabrese, M. et al., 2007. Detection of Cortical Inflammatory Lesions by 
Double Inversion Recovery Magnetic Resonance Imaging in Patients With 
Multiple Sclerosis. Archives Neurology, 64(10), pp.1416–1422. 
Calabrese, M. et al., 2008. Morphology and evolution of cortical lesions in 
multiple sclerosis. A longitudinal MRI study. NeuroImage, 42(4), pp.1324–
1328. 
Calabrese, M. et al., 2009. Cortical lesions and atrophy associated with 
cognitive impairment in relapsing-remitting multiple sclerosis. Archives of 
neurology, 66(9), pp.1144–1150. 
Calabrese, M. et al., 2010a. Imaging distribution and frequency of cortical 
lesions in patients with multiple sclerosis. Neurology, 75(14), pp.1234–
1240. 
Calabrese, M. et al., 2010b. Cortical lesions in multiple sclerosis. Nature 
Publishing Group, 6(8), pp.438–444. 
Calabrese, M. et al., 2010c. A 3-year magnetic resonance imaging study of 
cortical lesions in relapse-onset multiple sclerosis. Annals of neurology, 
67(3), pp.376–383. 
Calabrese, M. et al., 2011a. Cortical pathology and cognitive impairment in 
multiple sclerosis. Expert review of neurotherapeutics, 11(3), pp.425–432. 
Calabrese, M. et al., 2011b. The puzzle of multiple sclerosis: gray matter finds 
its place. Expert review of neurotherapeutics, 11(11), pp.1565–1568. 
Calabrese, M. et al., 2011c. Cortical diffusion-tensor imaging abnormalities in 
multiple sclerosis: a 3-year longitudinal study. Radiology, 261(3), pp.891–
898. 
Calabrese, M. et al., 2012. No MRI evidence of cortical lesions in 
neuromyelitis optica. Neurology, 79(16), pp.1671-1676. 
Calabrese, M. et al., 2013. The changing clinical course of multiple sclerosis: 
a matter of gray matter. Annals of neurology, 74(1), pp.76–83. 
Calabresi, P.A., 2011. Inflammation in multiple sclerosis--sorting out the gray 
matter. The New England journal of medicine, 365(23), pp.2231–2233. 
Callegaro, D. et al., 2006. Fabry's disease as a differential diagnosis of MS. 
Int MS Journal, 13(1), pp.27-30. 
200 
 
Ceccarelli, A. et al., 2008. A voxel-based morphometry study of grey matter 
loss in MS patients with different clinical phenotypes. NeuroImage, 42(1), 
pp.315–322. 
Ceccarelli, A. et al., 2012a. MRI in multiple sclerosis: a review of the current 
literature. Current opinion in neurology, 25(4), pp. 402-409. 
Ceccarelli, A. et al., 2012b. The Impact of Lesion In-Painting and Registration 
Methods on Voxel-Based Morphometry in Detecting Regional Cerebral 
Gray Matter Atrophy in Multiple Sclerosis. American Journal of 
Neuroradiology, 33(8), pp.1579-1585. 
Cerasa, A. et al., 2012. Cerebellar-parietal dysfunctions in multiple sclerosis 
patients with cerebellar signs. Experimental neurology, 237(2), pp.418–
426. 
Chard, D.T. et al., 2002. Brain metabolite changes in cortical grey and normal-
appearing white matter in clinically early relapsing-remitting multiple 
sclerosis. Brain : a journal of neurology, 125(10), pp.2342–2352. 
Chard, D.T. et al., 2009. Grey matter pathology in clinically early multiple 
sclerosis: evidence from magnetic resonance imaging. Journal of the 
neurological sciences, 282(1-2), pp.5–11.  
Chard, D.T. et al., 2010. Reducing the impact of white matter lesions on 
automated measures of brain gray and white matter volumes. Journal of 
magnetic resonance imaging : JMRI, 32(1), pp.223–228. 
Charil, A. et al., 2006. MRI and the diagnosis of multiple sclerosis: expanding 
the concept of “no better explanation.” The Lancet Neurology, 5(10), 
pp.841–852. 
Chen, X. et al., 2012. Iron deposition of the deep grey matter in patients with 
multiple sclerosis and neuromyelitis optica: A control quantitative study by 
3D-enhanced susceptibility-weighted angiography (ESWAN). European 
journal of radiology, 81(4), pp.e633–e639. 
Ciccarelli, O. et al., 2012. MS cortical lesions on double inversion recovery 
MRI: Few but true. Neurology, 78(5), pp.296–297. 
Cifelli, A. et al., 2002. Thalamic neurodegeneration in multiple sclerosis. 
Annals of neurology, 52(5), pp.650–653. 
Cikes, N. et al., 2008. Non-MS autoimmune demyelination. Clinical neurology 
and neurosurgery, 110(9), pp.905–912. 
Colombo, B. et al., 2011. Brain white matter lesions in migraine: what's the 
meaning? Neurological Sciences, 32 Suppl 1, pp.S37–40. 
Compston, A., 1999. The pathological anatomy of the lesion in multiple 
sclerosis. Brain research bulletin, 50(5-6), pp.463–464. 
201 
 
Compston, A. et al., 2006. McAlpines's Multiple Sclerosis Fourth edition, 
Churchill Livingstone Elsevier, Section 4, pp.447-669. 
Confavreux, C. et al., 2014. The clinical course of multiple sclerosis. 
Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn, 
122, pp.343–369. 
Crawford, M.P. et al., 2004. High prevalence of autoreactive, neuroantigen-
specific CD8+ T cells in multiple sclerosis revealed by novel flow 
cytometric assay. Blood, 103(11), pp.4222–4231. 
Cutter, G.R. et al., 1999. Development of a multiple sclerosis functional 
composite as a clinical trial outcome measure. Brain : a journal of 
neurology, 122 ( Pt 5), pp.871–882. 
Davies, G.R. et al., 2004. Evidence for grey matter MTR abnormality in 
minimally disabled patients with early relapsing-remitting multiple 
sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 75(7), 
pp.998–1002. 
Dawson, J., 1916. The histology of disseminated sclerosis. Trans. R. Soc. 
Edinburgh, 50, pp.517–740. 
de Graaf, W.L. et al., 2012. Lesion detection at seven Tesla in multiple 
sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR. European 
Radiology, 22(1), pp.221–231. 
DeLuca, G.C. et al., 2006. The contribution of demyelination to axonal loss in 
multiple sclerosis. Brain : a journal of neurology, 129(Pt 6), pp.1507–1516. 
Deshmukh, V.A. et al., 2013. A regenerative approach to the treatment of 
multiple sclerosis. Nature, 502(7471), pp.327–332. 
deVeber, G.A. et al., 1992. Fabry disease: immunocytochemical 
characterization of neuronal involvement. Annals of neurology, 31(4), 
pp.409–415. 
Disanto, G. et al., 2012. Multiple sclerosis: risk factors and their interactions. 
CNS & neurological disorders drug targets, 11(5), pp.545–555. 
Dusankova, J.B. et al., 2012. Cross cultural validation of the Minimal 
Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and 
the Brief International Cognitive Assessment for Multiple Sclerosis 
(BICAMS). The Clinical neuropsychologist, 26(7), pp.1186–1200. 
Ebers, G.C. et al., 2008. Natural history of MS. European journal of neurology 
: the official journal of the European Federation of Neurological Societies, 
15(9), pp.881–882. 
Elleder, M. et al., 1994. Leptomeningeal lipid storage patterns in Fabry 
disease. Acta neuropathologica, 88(6), pp.579–582. 
202 
 
Ellwardt, E. et al., 2014. Molecular mechanims linking neuroinflammation and 
neurodegeneration in MS. Experimental neurology, pp.1–30. 
Fels, C. et al., 2004. Neurosarcoidosis: findings in MRI. Clinical imaging, 
28(3), pp.166–169. 
Fernandes de Abreu, D.A.,= et al., 2011. Seasonal, gestational and postnatal 
influences on multiple sclerosis: the beneficial role of a vitamin D 
supplementation during early life. Journal of the neurological sciences, 
311(1-2), pp.64–68. 
Filippi, M. et al., 2010. MR Imaging of Gray Matter Involvement in Multiple 
Sclerosis: Implications for Understanding Disease Pathophysiology and 
Monitoring Treatment Efficacy. American Journal of Neuroradiology, 
31(7), pp.1171–1177. 
Filippi, M. et al., 2010a. The contribution of MRI in assessing cognitive 
impairment in multiple sclerosis. Neurology, 75(23), pp.2121–2128. 
Filippi, M. et al., 2010b. Intracortical lesions: Relevance for new MRI 
diagnostic criteria for multiple sclerosis. Neurology, 75(22), pp.1988–1994. 
Filippi, M. et al., 2011. Magnetic resonance techniques in multiple sclerosis: 
the present and the future. Archives of neurology, 68(12), pp.1514–1520. 
Filippi, M. et al., 2012. Association between pathological and MRI findings in 
multiple sclerosis. The Lancet Neurology, 11(4), pp.349–360. 
Filippi, M. et al., 2013. Ultra-high-field MR imaging in multiple sclerosis. 
Journal of Neurology, Neurosurgery & Psychiatry, 85(1), pp.60-66. 
 Fischer, J.S. et al., 1999. The Multiple Sclerosis Functional Composite 
measure (MSFC): an integrated approach to MS clinical outcome 
assessment. Multiple Sclerosis, 5(4), pp.244–250. 
Fisniku, L.K. et al., 2008. Disability and T2 MRI lesions: a 20-year follow-up of 
patients with relapse onset of multiple sclerosis. Brain : a journal of 
neurology, 131(3), pp.808–817. 
Fox, R.J. et al., 2005. Brain atrophy and magnetisation transfer ratio following 
methylprednisolone in multiple sclerosis: short-term changes and long-
term implications. Multiple sclerosis (Houndmills, Basingstoke, England), 
11(2), pp.140–145. 
Frischer, J.M. et al., 2009. The relation between inflammation and 
neurodegeneration in multiple sclerosis brains. Brain : a journal of 
neurology, 132(5), pp.1175–1189. 
Frohman, E. et al., 2006. Multiple Sclerosis - The plaque and its 
pathogenesis. New England Journal of Medicine, 354(9), pp.942-955. 
Fuse, A. et al., 2013. Reversible focal cerebral cortical lesions in a patient with 
203 
 
heat stroke. Internal medicine (Tokyo, Japan), 52(3), pp.377–380. 
Gaitan, M.I. et al., 2012. Initial investigation of the blood-brain barrier in MS 
lesions at 7 tesla. Multiple sclerosis,19(8), pp.1068-1073. 
Gandhi, R. et al., 2012. Chapter 1: Disease Pathogenesis. In Multiple 
Sclerosis: Diagnosis and Therapy. John Wiley & Sons, Ltd. pp 3 - 26. 
Garach, R.M. et al., 2004. Robust phase sensitive inversion recovery imaging 
using a Markov random field model. Conference proceedings: Annual 
International Conference of the IEEE Engineering in Medicine and Biology 
Society. IEEE Engineering in Medicine and Biology Society. Conference, 
2, pp.1569–1572. 
Gelineau-Morel, R. et al., 2011. The effect of hypointense white matter lesions 
on automated gray matter segmentation in multiple sclerosis. Human 
brain mapping, 33(12), pp.2802-2814. 
Geurts, J.J.G. et al., 2005a. Cortical Lesions in Multiple Sclerosis: Combined 
Postmortem MR Imaging and Histopathology. American journal of 
Neuroradiology, 26(3), pp. 572 -577. 
Geurts, J.J.G. et al., 2005b. Intracortical Lesions in Multiple Sclerosis: 
Improved Detection with 3D Double Inversion-Recovery MR Imaging. 
Radiology, 236(1), pp.254–260. 
Geurts, J.J.G. et al., 2008. Grey matter pathology in multiple sclerosis. The 
Lancet Neurology, 7(9), pp.841–851. 
Geurts, J.J.G. et al., 2008a. Does high-field MR imaging improve cortical 
lesion detection in multiple sclerosis? Journal of neurology, 255(2), 
pp.183–191. 
Geurts, J.J.G. et al., 2011. Consensus recommendations for MS cortical 
lesion scoring using double inversion recovery MRI. Neurology, 76(5), 
pp.418–424. 
Gilmore C.P. et al. 2009 Regional variations in the extent and pattern of grey 
matter demyelination in multiple sclerosis : a comparison between the 
cerebral cortex , cerebellar cortex , deep grey matter nuclei and the spinal 
cord. Journal of Neurology , Neurosurgery and Psychiatry 80(2) pp182-
187. 
Ginsberg, L. et al., 2007. Magnetic resonance imaging changes in Fabry 
disease. Acta Paediatrica, 95, pp.57–62. 
Giorgio, A. et al., 2010. Cognition in multiple sclerosis: relevance of lesions, 
brain atrophy and proton MR spectroscopy. Neurological Sciences, 
31(Suppl 2), pp.S245–8. 
Giorgio, A. et al., 2011. Cortical lesions in radiologically isolated syndrome. 
Neurology, 77(21), pp.1896–1899. 
204 
 
Gonzalez, C.F. et al., 1994. Distributional patterns of multiple sclerosis brain 
lesions. Magnetic resonance imaging--clinical correlation. Journal of 
neuroimaging : official journal of the American Society of Neuroimaging, 
4(4), pp.188–195. 
Goris, A., 2012. Comment: The HLA region in multiple sclerosis. Neurology, 
79(6) , pp.544-544 
Granberg, T. et al., 2012. Radiologically isolated syndrome - incidental 
magnetic resonance imaging findings suggestive of multiple sclerosis, a 
systematic review. Multiple sclerosis, 19(3), pp.271-280. 
Grant, I. et al., 1984. Deficient learning and memory in early and middle 
phases of multiple sclerosis. Journal of Neurology, Neurosurgery & 
Psychiatry, 47(3), pp.250–255. 
Graumann, U. et al., 2003. Molecular Changes in Normal Appearing White 
Matter in Multiple Sclerosis are Characteristic of Neuroprotective 
Mechanisms Against Hypoxic Insult. Brain Pathology, 13(4), pp.554–573. 
Griffin, C.M. et al., 2002. The relationship between lesion and normal 
appearing brain tissue abnormalities in early relapsing remitting multiple 
sclerosis. Journal of neurology, 249(2), pp.193–199. 
Guttmann, C.R. et al., 1995. The evolution of multiple sclerosis lesions on 
serial MR. AJNR. American journal of neuroradiology, 16(7), pp.1481–
1491. 
Guttmann, C.R.G. et al., 2006. Can MRI reveal phenotypes of multiple 
sclerosis? Magnetic resonance imaging, 24(4), pp.475–481. 
Hagemeier, J. et al., 2012. Iron deposition in multiple sclerosis lesions 
measured by susceptibility-weighted imaging filtered phase: A case 
control study. Journal of magnetic resonance imaging : JMRI, 36(1), 
pp.73–83. 
Haider, L. et al., 2014. Multiple sclerosis deep grey matter: the relation 
between demyelination, neurodegeneration, inflammation and iron. 
Journal of Neurology, Neurosurgery & Psychiatry, pii: jnnp-2014-307712, 
pp.1-10. 
Haller, S. et al., 2009. Magnetic resonance imaging techniques in white matter 
disease: potentials and limitations. Topics in magnetic resonance imaging: 
TMRI, 20(6), pp.301–312. 
Herskovits, E.H. et al., 2001. Accuracy for detection of simulated lesions: 
comparison of fluid-attenuated inversion-recovery, proton density--
weighted, and T2-weighted synthetic brain MR imaging. AJR. American 
journal of roentgenology, 176(5), pp.1313–1318. 
Hoffmann, B., 2009. Fabry disease: recent advances in pathology, diagnosis, 
treatment and monitoring. Orphanet Journal of  Rare Diseases, 4(1), pp. 
205 
 
1-9 
Hou, P. et al., 2005. Phase-Sensitive T1 Inversion Recovery Imaging: A Time-
Efficient Interleaved Technique for Improved Tissue Contrast in 
Neuroimaging. American journal of Neuroradiology, 26(6), pp.1432-1438. 
Hulst, H.E. et al., 2013. Cognitive impairment in MS: Impact of white matter 
integrity, gray matter volume, and lesions. Neurology, 80(11), pp.1025–
1032. 
IMSGC et al., 2007. Risk alleles for multiple sclerosis identified by a genome 
wide study. The New England journal of medicine, 357(9), pp.851–862. 
Johnson, G. et al., 1999. 2D multislice and 3D MRI sequences are often 
equally sensitive. Magnetic resonance in medicine : official journal of the 
Society of Magnetic Resonance in Medicine / Society of Magnetic 
Resonance in Medicine, 41(4), pp.824–828. 
Jongen, P.J. et al., 2012. Cognitive impairment in multiple sclerosis. Minerva 
medica, 103(2), pp.73–96. 
Kacar, K. et al., 2011. Overcoming the clinical-MR imaging paradox of 
multiple sclerosis: MR imaging data assessed with a random forest 
approach. American Journal of Neuroradiology, 32(11), pp.2098–2102. 
Kahn, P.,1973. Anderson-Fabry disease: a histopathological study of three 
cases with observations on the mechanism of production of pain. Journal 
of Neurology, Neurosurgery & Psychiatry, 36(6), pp.1053–1062. 
Kakita, A., 2013. Surgical pathologic features of cerebral cortical lesions taken 
from 600 patients with intractable epilepsy. Brain & development, 35(8), 
pp.793–801. 
Kampman, M.T. et al., 2012. Effect of vitamin D3 supplementation on 
relapses, disease progression, and measures of function in persons with 
multiple sclerosis: exploratory outcomes from a double-blind randomised 
controlled trial. Multiple sclerosis (Houndmills, Basingstoke, England), 
18(8), pp.1144–1151. 
Kapoor, R. et al., 2010. Lamotrigine for neuroprotection in secondary 
progressive multiple sclerosis: a randomised, double-blind, placebo-
controlled, parallel-group trial. Lancet neurology, 9(7), pp.681–688. 
Kaur, C. et al., 2008. Blood Brain Barrier in Hypoxic-Ischemic Conditions. 
Current Neurovascular Research, 5(1), pp.71–81. 
Kemppinen, A. et al., 2011. Genome-wide association studies in multiple 
sclerosis: lessons and future prospects. Briefings in functional genomics, 
10(2), pp.61–70. 
Kidd, D. et al., 1999. Cortical lesions in multiple sclerosis. Brain : a journal of 
neurology, 122(1), pp.17–26. 
206 
 
Kilsdonk, I.D. et al., 2013. Multicontrast MR Imaging at 7T in Multiple 
Sclerosis: Highest Lesion Detection in Cortical Gray Matter with 3D-
FLAIR. American Journal of Neuroradiology, 34(4), pp.791–796. 
Kilsdonk, I.D. et al., 2011. 2010 revisions to McDonald criteria for diagnosis of 
multiple sclerosis: impact of 3-Tesla magnetic resonance imaging. Annals 
of neurology, 70(1), pp.182–183. 
Kint, J.A., 1970. Fabry's disease: alpha-galactosidase deficiency. Science, 
167(3922), pp.1268-1269. 
Kleinschmidt-Demasters, B.K. et al., 2012. Update on PML and PML-IRIS 
Occurring in Multiple Sclerosis Patients Treated With Natalizumab. 
Journal of neuropathology and experimental neurology, 71(7), pp.604–
617. 
Kurtzke, J.F., 1983. Rating neurologic impairment in multiple sclerosis: an 
expanded disability status scale (EDSS). Neurology, 33(11), pp.1444–
1452. 
Kutzelnigg, A. et al., 2005a. Cortical demyelination and diffuse white matter 
injury in multiple sclerosis. Brain : a journal of neurology, 128(Pt 11), 
pp.2705–2712. 
Kutzelnigg, A. et al., 2005b. Cortical lesions and brain atrophy in MS. Journal 
of the neurological sciences, 233(1-2), pp.55–59. 
Kutzelnigg, A. et al., 2006. Cortical demyelination in multiple sclerosis: a 
substrate for cognitive deficits? Journal of the neurological sciences, 
245(1-2), pp.123–126. 
Kutzelnigg, A. et al., 2007. Widespread demyelination in the cerebellar cortex 
in multiple sclerosis. Brain pathology (Zurich, Switzerland), 17(1), pp.38–44. 
Lassmann, H. et al., 2007. The Immunopathology of Multiple Sclerosis: An 
Overview. Brain Pathology, 17(2), pp.210–218. 
Lassmann, H. et al., 2008. Cortical demyelination in CNS inflammatory 
demyelinating diseases. Neurology, 70(5), pp.332–333. 
Lassmann, H., 2008a. Mechanisms of inflammation induced tissue injury in 
multiple sclerosis. Journal of the neurological sciences, 274(1-2), pp.45–
47. 
Lassmann, H., 2008b. The Pathologic Substrate of Magnetic Resonance 
Alterations in Multiple Sclerosis. Neuroimaging Clinics of North America, 
18(4), pp.563–576. 
Lassmann, H., et al., 2012. Progressive multiple sclerosis: pathology and 
pathogenesis. Nature Publishing Group, 8(11), pp.647–656. 
Lassmann, H., 2014. Mechanisms of white matter damage in multiple 
207 
 
sclerosis. Glia, 62(11), pp 1816-1830. 
Lauer, K., 1995. Environmental associations with the risk of multiple sclerosis: 
the contribution of ecological studies. Acta neurologica Scandinavica. 
Supplementum, 161, pp.77–88. 
Lazeron, R.H. et al., 2000. Neuropsychological impairment in multiple 
sclerosis patients: the role of (juxta)cortical lesion on FLAIR. Multiple 
Sclerosis, 6(4), pp.280–285. 
Leary, S., et al., 2009. Queen Square Textbook of Neurology, John Wiley & 
Sons, Ltd. Chapter 10, pp. 412-447. 
Lezak, M.D. et al., 2012. Neuropsychological Assessment 5 ed., Oxford 
University Press. 
Li, Q. et al., 2011. Double inversion recovery magnetic resonance imaging at 
3 T: diagnostic value in hippocampal sclerosis. Journal of computer 
assisted tomography, 35(2), pp.290–293. 
Lidove, O. et al., 2009. Aseptic meningitis and ischaemic stroke in Fabry 
disease. International journal of clinical practice, 63(11), pp.1663–1667. 
Mehta A.  et al., 2004. Fabry disease defined: baseline clinical manifestations 
of 366 patients in the Fabry Outcome Survey. Europiean journal of clinical 
investigation, 34 (3), pp.236-242. 
Lublin, F.D. et al.,1996. Defining the clinical course of multiple sclerosis: 
results of an international survey. National Multiple Sclerosis Society 
(USA) Advisory Committee on Clinical Trials of New Agents in Multiple 
Sclerosis. Neurology, 46(4), pp.907–911. 
Lucchinetti, C.F. et al., 1996. Distinct patterns of multiple sclerosis pathology 
indicates heterogeneity on pathogenesis. Brain pathology (Zurich, 
Switzerland), 6(3), pp.259–274. 
Lucchinetti, C. et al., 2000. Heterogeneity of multiple sclerosis lesions: 
implications for the pathogenesis of demyelination. Annals of Neurology, 
47(6), pp.707-717. 
Lucchinetti, C. et al., 2004. The pathology of primary progressive multiple 
sclerosis. Multiple Sclerosis, 10 Suppl 1, pp.S23–30. 
Lucchinetti, C.F. et al., 2011. Inflammatory Cortical Demyelination in Early 
Multiple Sclerosis. The New England journal of medicine, 365(23), 
pp.2188–2197. 
Lumsden, C.E., 1970. The neuropahtology of multiple sclerosis. In Handbook 
of Clinical Neurology, Vol 9, pp. 217-309.  
Lynch, S.G. et al., 2010. Evaluating processing speed in multiple sclerosis: a 
comparison of two rapid serial processing measures. The Clinical 
208 
 
neuropsychologist, 24(6), pp.963–976. 
Ma, J., 2005. Multislice and multicoil phase-sensitive inversion-recovery 
imaging. Magnetic resonance in medicine : official journal of the Society of 
Magnetic Resonance in Medicine / Society of Magnetic Resonance in 
Medicine, 53(4), pp.904–910. 
Mackenzie, I.S. et al., 2014. Incidence and prevalence of multiple sclerosis in 
the UK 1990-2010: a descriptive study in the General Practice Research 
Database. Journal of Neurology, Neurosurgery & Psychiatry, 85(1), 
pp.76–84. 
Magliozzi, R. et al., 2006. Meningeal B-cell follicles in secondary progressive 
multiple sclerosis associate with early onset of disease and severe cortical 
pathology. Brain : a journal of neurology, 130(4), pp.1089–1104. 
Magliozzi, R. et al., 2007. Meningeal B-cell follicles in secondary progressive 
multiple sclerosis associate with early onset of disease and severe cortical 
pathology. Brain : a journal of neurology, 130(Pt 4), pp.1089–1104. 
Magliozzi, R. et al., 2010. A Gradient of neuronal loss and meningeal 
inflammation in multiple sclerosis. Annals of neurology, 68(4), pp.477–
493. 
Mainero, C. et al., 2009. In vivo imaging of cortical pathology in multiple 
sclerosis using ultra-high field MRI. Neurology ,73(9), pp.41-48. 
Maldjian, J.A. et al., 2003. An automated method for neuroanatomic and 
cytoarchitectonic atlas-based interrogation of fMRI data sets. NeuroImage, 
19(3), pp.1233–1239. 
Martinelli, V. et al., 2014. Vitamin D levels and risk of multiple sclerosis in 
patients with clinically isolated syndromes. Multiple Sclerosis Journal, 
20(2), pp.147–155. 
McDonald, W.I. et al., 2001. Recommended diagnostic criteria for multiple 
sclerosis: guidelines from the International Panel on the diagnosis of 
multiple sclerosis. Annals of neurology, 50(1), pp.121–127. 
McRobbie, D.W. et al., 2003. MRI From Picture to Proton, Cambridge 
University Press, 2nd Edition, Part A, pp.30-167. 
McVeigh, E.R. et al. , 1986. Phase and Sensitivity of Receiver Coils in 
Magnetic-Resonance-Imaging. Medical physics, 13(6), pp.806–814. 
Mike, A. et al., 2011. Identification and Clinical Impact of Multiple Sclerosis 
Cortical Lesions as Assessed by Routine 3T MR Imaging. American 
Journal of Neuroradiology, 32(3), pp.515–521. 
 
Miki, Y. et al., 1998. Isolated U-fiber involvement in MS: preliminary 
209 
 
observations. Neurology, 50(5), pp.1301–1306. 
Miller, D.H. et al., 2002. Measurement of atrophy in multiple sclerosis: 
pathological basis, methodological aspects and clinical relevance. Brain : 
a journal of neurology, 125(Pt 8), pp.1676–1695. 
Miller, D. et al., 2005. Clinically isolated syndromes suggestive of multiple 
sclerosis, part 2: non-conventional MRI, recovery processes, and 
management. Lancet neurology, 4(6), pp.341–348. 
Miller, D.H. et al., 2012. Clinically isolated syndromes. Lancet neurology, 
11(2), pp.157–169. 
Mistry, N. et al., 2011. Focal multiple sclerosis lesions abound in 'normal 
appearing white matter'. Multiple sclerosis (Houndmills, Basingstoke, 
England), 17(11), pp.1313–1323. 
Modat, M. et al., 2010. Fast free-form deformation using graphics processing 
units. Computer methods and programs in biomedicine, 98(3), pp.278–
284. 
Montalban, X. et al., 2009. Primary progressive multiple sclerosis diagnostic 
criteria: a reappraisal. Multiple sclerosis (Houndmills, Basingstoke, 
England), 15(12), pp.1459–1465. 
Montalban, X. et al., 2010. MRI criteria for MS in patients with clinically 
isolated syndromes. Neurology, 74(5), pp.427–434. 
Mueller, S.G. et al., 2010. Influences of lobar gray matter and white matter 
lesion load on cognition and mood. Psychiatry Research: Neuroimaging, 
181(2), pp.90–96. 
Muhlert, N. et al., 2013. The grey matter correlates of impaired decision-
making in multiple sclerosis. Journal of neurology, neurosurgery and 
neuropsychiatry, p.jnnp-2014-308169, pp.1-7. 
Møller, A.T. et al., 2007. Neurological manifestations in Fabry's disease. 
Nature Clinical Practice Neurology, 3(2), pp.95–106. 
Myhr, K.M. et al., 2001. Disability and prognosis in multiple sclerosis: 
demographic and clinical variables important for the ability to walk and 
awarding of disability pension. Multiple Sclerosis, 7(1), pp.59–65. 
Narr, K.L. et al., 2005. Mapping Cortical Thickness and Gray Matter 
Concentration in First Episode Schizophrenia. Cerebral Cortex, 15(6), 
pp.708–719. 
Neema, M. et al., 2009. Deep Gray Matter Involvement on Brain MRI Scans Is 
Associated with Clinical Progression in Multiple Sclerosis. Journal of 
neuroimaging : official journal of the American Society of Neuroimaging, 
19(1), pp.3–8. 
210 
 
Nelson, F. et al., 2007a. Improved Identification of Intracortical Lesions in 
Multiple Sclerosis with Phase-Sensitive Inversion Recovery in 
Combination with Fast Double Inversion Recovery MR Imaging. American 
Journal of Neuroradiology, 28(9), pp.1645–1649.  
Nelson, F. et al., 2008. 3D MPRAGE improves classification of cortical lesions 
in multiple sclerosis. Multiple sclerosis, 14(9), pp.1214–1219. 
Nelson, F. et al., 2011. Intracortical lesions by 3T magnetic resonance 
imaging and correlation with cognitive impairment in multiple sclerosis. 
Multiple sclerosis, 17(9), pp.1122–1129. 
Nichtweiss, M. et al., 2012. White matter lesions and vascular cognitive 
impairment: part 1: typical and unusual causes. Clinical neuroradiology, 
22(3), pp.193–210. 
Nielsen, A.S. et al., 2013. Contribution of cortical lesion subtypes at 7T MRI to 
physical and cognitive performance in MS. Neurology, 81(7), pp.641-649. 
Nielsen, A.S. et al., 2011. Focal cortical lesion detection in multiple sclerosis: 
3 tesla DIR versus 7 tesla FLASH-T2*. Journal of magnetic resonance 
imaging : JMRI, 35(3), pp.537–542. 
Paavilainen, T. et al., 2013. Diffusion tensor imaging and brain volumetry in 
Fabry disease patients. Neuroradiology, 55(5), pp.551–558. 
Papadopoulou, A. et al., 2013. Contribution of cortical and white matter 
lesions to cognitive impairment in multiple sclerosis. Multiple sclerosis, 
19(10), pp.1290-1296. 
Patzold, U. et al., 1982. Course of multiple sclerosis. First results of a 
prospective study carried out of 102 MS patients from 1976-1980. Acta 
neurologica Scandinavica, 65(4), pp.248–266. 
Pelvig, D.P. et al., 2008. Neocortical glial cell numbers in human brains. 
Neurobiology of aging, 29(11), pp.1754–1762. 
Peterson, J.W. et al., 2001. Transected neurites, apoptotic neurons, and 
reduced inflammation in cortical multiple sclerosis lesions. Annals of 
neurology, 50(3), pp.389–400. 
Pirko, I. et al., 2007. Gray matter involvement in multiple sclerosis. Neurology, 
68(9), pp.634–642. 
Pitt, D. et al., 2010. Imaging Cortical Lesions in Multiple Sclerosis With Ultra–
High-Field Magnetic Resonance Imaging. Archives of neurology, 67(7), 
pp.812–818. 
Pol, H.E.H. et al., 2001. Focal Gray Matter Density Changes in Schizophrenia. 
Archives of General Psychiatry, 58(12), pp.1118–1125. 
Polman, C.H. et al., 2005. Diagnostic criteria for multiple sclerosis: 2005 
211 
 
revisions to the “McDonald Criteria.” Annals of neurology, 58(6), pp.840–
846. 
Polman, C.H. et al., 2010. The multiple sclerosis functional composite: a 
clinically meaningful measure of disability. Neurology, 74 Suppl 3, pp.S8–
15. 
Polman, C.H. et al., 2011. Diagnostic criteria for multiple sclerosis: 2010 
revisions to the McDonald criteria. Annals of neurology, 69(2), pp.292–
302. 
Popescu, B.F.G. et al., 2011. A case of multiple sclerosis presenting with 
inflammatory cortical demyelination. Neurology, 76(20), pp.1705–1710. 
Popescu, B.F.G. et al., 2012a. Meningeal and cortical grey matter pathology 
in multiple sclerosis. BMC neurology, 12(1), pp.1-8. 
Popescu, B.F.G. et al., 2012b. Pathology of demyelinating diseases. Annual 
review of pathology, 7(1), pp.185–217. 
Popescu, B.F.G. et al., 2013. Pathology of Multiple Sclerosis: Where Do We 
Stand? CONTINUUM: Lifelong Learning in Neurology, 19(4, Multiple 
Sclerosis), pp.901-921. 
Poser, C.M. et al., 1983. New diagnostic criteria for multiple sclerosis: 
Guidelines for research protocols. Annals of neurology, 13(3), pp.227–
231. 
Prineas, J.W. et al., 1993. Multiple sclerosis. Pathology of recurrent lesions. 
Brain : a journal of neurology, 116 ( Pt 3), pp.681–693. 
Prineas J.W. et al., 1997. Demyelinating diseases In:Greenfields 
neuropathology, 2 (1997); pp.471-550. 
Pucci, E. et al., 2011. Natalizumab for relapsing remitting multiple sclerosis 
(review). Cochrane Database of Systematic Reviews, Issue 10, pp 1-99. 
Raine, C.S., 1994. The Dale E. McFarlin Memorial Lecture: the immunology of 
the multiple sclerosis lesion. Annals of neurology, 36 Suppl, pp.S61–72. 
Rao, S.M. et al., 1991. Cognitive dysfunction in multiple sclerosis. I. 
Frequency, patterns, and prediction. Neurology, 41(5), pp.685–691. 
Reynolds, R. et al., 2011. The neuropathological basis of clinical progression 
in multiple sclerosis. Acta neuropathologica, 122(2), pp.155–170. 
Rinaldi, F. et al., 2010. Cortical lesions and cognitive impairment in multiple 
sclerosis. Neurological Sciences, 31(S2), pp.235–237. 
Rinaldi, F. et al., 2011. Natalizumab prevents the accumulation of cortical 
lesions in relapsing remitting multiple sclerosis: a preliminary report. 
Neurological Sciences, 31 Suppl 3(S3), pp.317–320. 
212 
 
Rinaldi, F. et al., 2012. Natalizumab strongly suppresses cortical pathology in 
relapsing-remitting multiple sclerosis. Multiple sclerosis, 18(12), pp.1760-
1767. 
Roosendaal, S. et al., 2009. Accumulation of cortical lesions in MS: relation 
with cognitive impairment. Multiple Sclerosis, 15(6), pp.708–714. 
Ropele, S. et al., 2011. MRI assessment of iron deposition in multiple 
sclerosis. Journal of magnetic resonance imaging : JMRI, 34(1), pp.13–
21. 
Rossato, G. et al., 2010. Cerebral distribution of white matter lesions in 
migraine with aura patients. Cephalalgia : an international journal of 
headache, 30(7), pp.855–859. 
Rovaris, M. et al., 2000. MRI correlates of cognitive dysfunction in multiple 
sclerosis patients. Journal of neurovirology, 6(S2), pp.S172-5.  
Rudick, R.A. et al., 2009. Gray-Matter Injury in Multiple Sclerosis. The New 
England journal of medicine, 361(15), pp.1505–1506. 
Runia, T.F. et al., 2012. Lower serum vitamin D levels are associated with a 
higher relapse risk in multiple sclerosis. Neurology, 79(3), pp.261–266. 
Sailer, M., 2003. Focal thinning of the cerebral cortex in multiple sclerosis. 
Brain : a journal of neurology, 126(8), pp.1734–1744. 
Saip, S. et al., 2007. Fabry disease mimicking multiple sclerosis. Clinical 
neurology and neurosurgery, 109(4), pp.361–363. 
Samson, R.S. et al., 2013. Sulcal and gyral crown cortical grey matter 
involvement in multiple sclerosis: A magnetisation transfer ratio study. 
Multiple Sclerosis and Related Disorders, 2, pp.204-212. 
Scalfari, A. et al., 2010. The natural history of multiple sclerosis: a 
geographically based study 10: relapses and long-term disability. Brain : a 
journal of neurology, 133(Pt 7), pp.1914–1929. 
Schedel, J. et al., 2010. Cerebral lesions in patients with connective tissue 
diseases and systemic vasculitides: are there specific patterns? Annals of 
the New York Academy of Sciences, 1193, pp.167–175. 
Schmierer, K et al., 2004. Magnetisation transfer ratio and myelin in 
postmortem multiple sclerosis. Annals of Neurology , 56(3), pp. 407 - 415. 
Schmierer, K. et al., 2010. High field (9.4 Tesla) magnetic resonance imaging 
of cortical grey matter lesions in multiple sclerosis. Brain : a journal of 
neurology, 133(3), pp.858–867. 
Schumacher, G.A. et al., 1965. Problems of experimental trials of therapy in 
Multiple Sclerosis: report by the panel on the evaluation of experimental 
trials of therapy in Multiple Sclerosis. Annals of the New York Academy of 
213 
 
Sciences, 122, pp.552–568. 
Seewann, A. et al., 2009. Translating pathology in multiple sclerosis: the 
combination of postmortem imaging, histopathology and clinical findings. 
Acta neurologica Scandinavica, 119(6), pp.349–355. 
Seewann, A. et al., 2011. Imaging the tip of the iceberg: visualization of 
cortical lesions in multiple sclerosis. Multiple sclerosis (Houndmills, 
Basingstoke, England), 17(10), pp.1202–1210. 
Seewann, A. et al., 2012. Postmortem verification of MS cortical lesion 
detection with 3D DIR. Neurology, 78(5), pp.302–308. 
Serafini, B. et al., 2004. Detection of ectopic B-cell follicles with germinal 
centers in the meninges of patients with secondary progressive multiple 
sclerosis. Brain pathology (Zurich, Switzerland), 14(2), pp.164–174. 
Sharma, R. et al., 2001. Grey matter abnormalities in multiple sclerosis: 
proton magnetic resonance spectroscopic imaging. Multiple Sclerosis, 
7(4), pp.221–226. 
Simon, B. et al., 2010. Improved in vivo detection of cortical lesions in multiple 
sclerosis using double inversion recovery MR imaging at 3 Tesla. 
European Radiology, 20(7), pp.1675–1683. 
Simon, J.H., 2006. Brain atrophy in multiple sclerosis: what we know and 
would like to know. Multiple Sclerosis, 12(6), pp.679–687. 
Simon, J.H, 2012. Very early MS -- insights from MRI. Multiple sclerosis 
(Houndmills, Basingstoke, England), 18(10), pp.1372–1376. 
Sinnecker, T. et al., 2012. Distinct lesion morphology at 7-T MRI differentiates 
neuromyelitis optica from multiple sclerosis. Neurology, 79(7), pp.708–
714. 
Smith, A., 1982. Symbol digit modalities test: Manual. Los Angeles: Western 
Psychological Services, Manual. 
Snell, R., 1997 Chapter 1: Introduction and Organisation of the Nervous 
System. In Clinical Neuroanatomy for Medical Students. Lipincott Raven, 
pp. 76-89. 
Snell, R., 1997a Chapter 15: Structure and Functional localisation of the 
Cerebral Cortex. In Clinical Neuroanatomy for Medical Students. Lipincott 
Raven, pp. 275–295. 
Sobel, R.A. et al., 2008. Chapter 20: Demyelinating diseases In: GGreenfields 
Neuropathology, 8th edition, pp.1513 -1594.  
Solomon, A.J.  et al., 2013. Misdiagnosis of multiple sclerosis: frequency, 
causes, effects, and prevention. Current Neurology and Neuroscience 
Reports, 13(12), p.403. 
214 
 
Sperling, R.A. et al., 2001. Regional magnetic resonance imaging lesion 
burden and cognitive function in multiple sclerosis: a longitudinal study. 
Archives of neurology, 58(1), pp.115–121. 
Stadelmann, C. et al., 2008. Cortical pathology in multiple sclerosis. Current 
opinion in neurology, 21(3), pp.229–234. 
Stankiewicz, J. et al., 2007. Iron in chronic brain disorders: imaging and 
neurotherapeutic implications. Neurotherapeutics : the journal of the 
American Society for Experimental NeuroTherapeutics, 4(3), pp.371–386. 
Steiner, G., 1952. Environmental studies in multiple sclerosis. Neurology, 
2(3), pp.260–262. 
Strober, L. et al., 2009. Sensitivity of conventional memory tests in multiple 
sclerosis: comparing the Rao Brief Repeatable Neuropsychological 
Battery and the Minimal Assessment of Cognitive Function in MS. Multiple 
Sclerosis, 15(9), pp.1077–1084. 
Stys, P.K, 2004. Axonal degeneration in multiple sclerosis : is it time for 
neuroprotective strategies? Ann Neuol 55 pp 601-603 
Summers, M. et al., 2008. Cognitive impairment in relapsing-remitting multiple 
sclerosis can be predicted by imaging performed several years earlier. 
Multiple sclerosis (Houndmills, Basingstoke, England), 14(2), pp.197–204. 
Sundström, P. et al., 2004. An altered immune response to Epstein-Barr virus 
in multiple sclerosis: A prospective study. Neurology, 62(12), pp.2277–
2282. 
Tallantyre, E.C. et al., 2009. A comparison of 3T and 7T in the detection of 
small parenchymal veins within MS lesions. Investigative radiology, 44(9), 
pp.491–494. 
Tallantyre, E.C. et al., 2010. 3 Tesla and 7 Tesla MRI of multiple sclerosis 
cortical lesions. Journal of magnetic resonance imaging : JMRI, 32(4), 
pp.971–977. 
Tedeschi, G. et al., 1999. Diffuse central neuronal involvement in Fabry 
disease: a proton MRS imaging study. Neurology, 52(8), pp.1663–1667. 
Thompson, A.J. et al., 1990. Patterns of disease activity in multiple sclerosis: 
clinical and magnetic resonance imaging study. BMJ : British Medical 
Journal, 300(6725), p.631-634. 
Tiemann, L. et al., 2009. Cognitive decline in multiple sclerosis: impact of 
topographic lesion distribution on differential cognitive deficit patterns. 
Multiple Sclerosis, 15(10), pp.1164-1174. 
Tintoré, M. et al., 2003. New diagnostic criteria for multiple sclerosis: 
application in first demyelinating episode. Neurology, 60(1), pp.27–30. 
215 
 
Traboulsee, A.L. et al., 2006. The role of MRI in the diagnosis of multiple 
sclerosis. Advances in neurology, 98, pp.125–146. 
Trapp, B.D. et al., 1998. Axonal Transection in the Lesions of Multiple 
Sclerosis. The New England journal of medicine, 338(5), pp.278–285. 
Trapp, B.D. et al., 1999. Neurodegeneration in Multiple Sclerosis: 
Relationship to Neurological Disability. The Neuroscientist, 5(1), pp.48-57. 
Trapp, B.D. et al., 2008. Multiple Sclerosis: An Immune or Neurodegenerative 
Disorder? Annual Review of Neuroscience, 31(1), pp.247–269. 
Trapp, B.D. et al., 2009. Virtual hypoxia and chronic necrosis of demyelinated 
axons in multiple sclerosis. Lancet neurology, 8(3), pp.280–291. 
Trip, S.A. et al., 2005. Imaging in multiple sclerosis.Journal of Neurology, 
Neurosurgery and Neuropsychiatry, 76(S3), pp.iii111-iii18. 
Tsunoda, I. et al., 2002. Inside-Out versus Outside-In models for virus 
induced demyelination: axonal damage triggering demyelination. Springer 
seminars in immunopathology, 24(2), pp.105–125. 
Tur, C. et al., 2011. Complementary roles of grey matter MTR and T2 lesions 
in predicting progression in early PPMS. Journal of Neurology, 
Neurosurgery & Psychiatry, 82(4), pp.423–428. 
Turetschek, K. et al., 1998. Double inversion recovery imaging of the brain: 
Initial experience and comparison with fluid attenuated inversion recovery 
imaging. Magnetic resonance imaging, 16(2), pp.127–135. 
Van der Elst, W. et al., 2006. The Stroop Color-Word Test: Influence of Age, 
Sex, and Education; and Normative Data for a Large Sample Across the 
Adult Age Range. Assessment, 13(1), pp.62–79. 
van Horssen, J. et al., 2007. The Blood-Brain Barrier in Cortical Multiple 
Sclerosis Lesions. Journal of neuropathology and experimental neurology, 
66(4), pp.321–328. 
van Veluw, S.J. et al., 2012. In vivo detection of cerebral cortical microinfarcts 
with high-resolution 7T MRI. Journal of cerebral blood flow and 
metabolism : official journal of the International Society of Cerebral Blood 
Flow and Metabolism, 33(3), pp.322–329. 
van Waesberghe, J.H. et al., 1998. Patterns of lesion development in multiple 
sclerosis: longitudinal observations with T1-weighted spin-echo and 
magnetisation transfer MR. AJNR. American journal of neuroradiology, 
19(4), pp.675–683. 
van Waesberghe, J.H. et al., 1999. Axonal loss in multiple sclerosis lesions: 
magnetic resonance imaging insights into substrates of disability. Annals 
of neurology, 46(5), pp.747–754. 
216 
 
van Walderveen, M.A. et al., 2001. Hypointense lesions on T1-weighted spin-
echo magnetic resonance imaging: relation to clinical characteristics in 
subgroups of patients with multiple sclerosis. Archives of neurology, 58(1), 
pp.76–81. 
Vercellino, M. et al., 2005. Grey matter pathology in multiple sclerosis. Journal 
of neuropathology and experimental neurology, 64(12), pp.1101–1107. 
Vercellino, M. et al., 2009. Demyelination, Inflammation, and 
Neurodegeneration in Multiple Sclerosis Deep Gray Matter. Journal of 
neuropathology and experimental neurology, 68(5), pp.489–502. 
Viglietta, V. et al., 2004. Loss of functional suppression by CD4+CD25+ 
regulatory T cells in patients with multiple sclerosis. The Journal of 
experimental medicine, 199(7), pp.971–979. 
Vrenken, H. et al., 2006a. Whole-Brain T1 Mapping in Multiple Sclerosis: 
Global Changes of Normal-appearing Gray and White Matter. Radiology, 
240(3), pp.811–820. 
Vrenken, H. et al., 2006b. Altered diffusion tensor in multiple sclerosis normal-
appearing brain tissue: cortical diffusion changes seem related to clinical 
deterioration. Journal of magnetic resonance imaging : JMRI, 23(5), 
pp.628–636. 
Wattjes, M.P. et al., 2007. Double Inversion Recovery Brain Imaging at 3T: 
Diagnostic Value in the Detection of Multiple Sclerosis Lesions. American 
Journal of Neuroradiology, 28(1), pp.54–59. 
Wattjes, M.P. et al., 2009. High field MRI in the diagnosis of multiple sclerosis: 
high field-high yield? Neuroradiology, 51(5), pp.279–292. 
Wegner, C. et al., 2003. A new view of the cortex, new insights into multiple 
sclerosis. Brain : a journal of neurology, 126(Pt 8), pp.1719–1721. 
Wegner, C. et al., 2006. Neocortical neuronal, synaptic, and glial loss in 
multiple sclerosis. Neurology, 67(6), pp.960–967. 
Wegner, C. et al., 2009. Gray matter pathology and multiple sclerosis. Current 
Neurology and Neuroscience Reports, 9(5), pp.399–404. 
Weinshenker, B.G. et al., 1989. The natural history of Multiple Sclerosis : A 
geographically based study Brain 112 ( Pt 6), pp.1419–1428.  
Westbrook, C., 2011. Chapter 1: Basic Principles. In MRI in Practice, 4th 
edition. pp. 8–10. 
Yousry, T.A. et al., 1997. Comparison of MR pulse sequences in the detection 
of multiple sclerosis lesions. AJNR. American journal of neuroradiology, 
18(5), pp.959–963. 
Zang, Y.C.Q. et al., 2004. Increased CD8+ cytotoxic T cell responses to 
217 
 
myelin basic protein in multiple sclerosis. Journal of immunology 
(Baltimore, Md. : 1950), 172(8), pp.5120–5127. 
Zeis, T. et al., 2008. Normal-appearing white matter in multiple sclerosis is in 
a subtle balance between inflammation and neuroprotection. Brain : a 
journal of neurology, 131(1), pp.288–303. 
Zhou, X.J., 2004. Basic Pulse Sequences. In M. A. Bernstein, K. F. King, & X. 
J. Zhou, eds. Handbook of MRI Pulse Sequences. Phase Sensitive 
Inversion Recovery. pp. 616–620. 
 
 
 
 
